Contact
searchSearch
HMP Global
Login
Dory Abelman, PhD, HBHSc
Conference Coverage
Ultra-Deep Whole Genome Sequencing of Cell-Free DNA Enhances MRD Detection and Risk Stratification in Multiple Myeloma
02/11/2026
Dory Abelman, PhD, HBHSc, presents a blood-based cell-free DNA approach that accurately detects minimal residual disease and predicts relapse in multiple myeloma up to 1 year earlier than clinical progression.
Dory Abelman, PhD, HBHSc, presents a blood-based cell-free DNA approach that accurately detects minimal residual disease and predicts relapse in multiple myeloma up to 1 year earlier than clinical progression.
Dory Abelman, PhD, HBHSc,...
02/11/2026
Oncology
Olalekan Oluwole, MD, MBBS
Conference Coverage
Evaluating Benefits of Outpatient vs Inpatient CAR T-Cell Therapy at Newly Authorized Treatment Centers
02/11/2026
Olalekan O. Oluwole
Olalekan Oluwole, MD, MBBS reported results from an observational analysis that outpatient treatment with CAR T-cell therapy was associated with lower healthcare utilization, fewer adverse events, and reduced medical costs compared with...
Olalekan Oluwole, MD, MBBS reported results from an observational analysis that outpatient treatment with CAR T-cell therapy was associated with lower healthcare utilization, fewer adverse events, and reduced medical costs compared with...
Olalekan Oluwole, MD, MBBS...
02/11/2026
Oncology
Luciano Costa, MD
Videos
Teclistamab Plus Daratumumab Demonstrates Significant Survival Benefit for R/R Multiple Myeloma: MajesTEC-3 Trial
01/30/2026
Luciano J. Costa
Luciano Costa, MD, reported results from the MajesTEC-3 trial which found teclistamab plus daratumumab delivered significant progression-free and overall survival benefits as early as a second line-therapy in multiple myeloma.
Luciano Costa, MD, reported results from the MajesTEC-3 trial which found teclistamab plus daratumumab delivered significant progression-free and overall survival benefits as early as a second line-therapy in multiple myeloma.
Luciano Costa, MD, reported...
01/30/2026
Oncology
Olalekan Oluwole, MD, MBBS
Conference Coverage
Time and Travel Impact of CAR T-Cell vs Bispecific Antibody Therapy for Patients With R/R DLBCL: Real-World Analysis
01/26/2026
Olalekan O. Oluwole
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS,...
01/26/2026
Oncology
Bilal Abid MD, MS, FACP, MRCP, FRCP
Conference Coverage
Evaluating Infection Patterns Among Patients With Multiple Myeloma Receiving BCMA-Targeting CAR T-Cell Therapy
01/26/2026
Bilal Abid, MD, MS, FACP, MRCP, FRCP
Bilal Abid MD, MS, FACP, MRCP, FRCP, shared results from a large real-world analysis of infection patterns and outcomes among patients with R/R MM treated with BCMA CAR T–cell therapy.
Bilal Abid MD, MS, FACP, MRCP, FRCP, shared results from a large real-world analysis of infection patterns and outcomes among patients with R/R MM treated with BCMA CAR T–cell therapy.
Bilal Abid MD, MS, FACP, MRCP,...
01/26/2026
Oncology
Matthew Connor, MD
Conference Coverage
Evolving Strategies for the Treatment of Acute Lymphoblastic Leukemia
01/22/2026
Matthew Connor, MD
Matthew Connor, MD, highlighted emerging ASH 2025 data showing earlier use of CAR T-cell therapy and novel antigen targets for acute lymphoblastic leukemia, along with ponatinib-based frontline strategies.
Matthew Connor, MD, highlighted emerging ASH 2025 data showing earlier use of CAR T-cell therapy and novel antigen targets for acute lymphoblastic leukemia, along with ponatinib-based frontline strategies.
Matthew Connor, MD, highlighted...
01/22/2026
Oncology
Ira Zackon, MD
Conference Coverage
Real-World Analysis Shows Rapid Uptake of Bispecific Antibodies in Community Settings for Multiple Myeloma Treatment
01/22/2026
Ira Zackon, MD
Ira Zackon, MD, shared results which found bispecific antibody use is rapidly increasing in US community oncology practices for heavily pretreated multiple myeloma, with overall survival outcomes comparable to clinical trials.
Ira Zackon, MD, shared results which found bispecific antibody use is rapidly increasing in US community oncology practices for heavily pretreated multiple myeloma, with overall survival outcomes comparable to clinical trials.
Ira Zackon, MD, shared results...
01/22/2026
Oncology
Saad Usmani, MD, MBA, FACP, FASCO
Conference Coverage
KTX1001 Monotherapy Shows Clinical Activity and Manageable Safety for R/R Myeloma
01/22/2026
Saad Usmani, MD, MBA, FACP, FASCO
Saad Usmani, MD, MBA, FACP, FASCO, shared that the oral NSD2 inhibitor, KTX1001, showed promising clinical activity with manageable safety for relapsed/refractory multiple myeloma, including high-risk t(4;14) disease.
Saad Usmani, MD, MBA, FACP, FASCO, shared that the oral NSD2 inhibitor, KTX1001, showed promising clinical activity with manageable safety for relapsed/refractory multiple myeloma, including high-risk t(4;14) disease.
Saad Usmani, MD, MBA, FACP,...
01/22/2026
Oncology
Ola Landgren, MD, PhD
Conference Coverage
Daratumumab Plus Teclistamab Demonstrates Favorable Safety and Efficacy for Smoldering Multiple Myeloma: REVIVE Study
01/22/2026
C. Ola Landgren, MD, PhD
Ola Landgren, MD, PhD, shared early results from the phase 2 REVIVE study which showed daratumumab plus teclistamab can be safely administered for high-risk smoldering myeloma.
Ola Landgren, MD, PhD, shared early results from the phase 2 REVIVE study which showed daratumumab plus teclistamab can be safely administered for high-risk smoldering myeloma.
Ola Landgren, MD, PhD, shared...
01/22/2026
Oncology
Jeff Sharman, MD
Conference Coverage
Mosunetuzumab Demonstrates Strong Efficacy for Elderly Patients With Diffuse Large B-Cell Lymphoma
01/22/2026
Jeff P. Sharman
Jeff Sharman, MD, reported phase 2 results that showed frontline mosunetuzumab therapy produced high response rates with minimal toxicity among elderly, treatment-naive patients with DLBCL who were unfit for standard chemotherapy.
Jeff Sharman, MD, reported phase 2 results that showed frontline mosunetuzumab therapy produced high response rates with minimal toxicity among elderly, treatment-naive patients with DLBCL who were unfit for standard chemotherapy.
Jeff Sharman, MD, reported phase...
01/22/2026
Oncology
Julia Han Noll, PhD
Conference Coverage
Mechanistic Insights Into Delayed Immune Toxicities Following BCMA CAR T-Cell Therapy
01/16/2026
Julia Han Noll, PhD
Julia Han Noll, PhD, University of Pennsylvania, Philadelphia, Pennsylvania, presented mechanistic data identifying a distinct spectrum of delayed toxicities associated with BCMA-directed CAR T-cell therapy at the 2025 ASH Annual Meeting &...
Julia Han Noll, PhD, University of Pennsylvania, Philadelphia, Pennsylvania, presented mechanistic data identifying a distinct spectrum of delayed toxicities associated with BCMA-directed CAR T-cell therapy at the 2025 ASH Annual Meeting &...
Julia Han Noll, PhD, University...
01/16/2026
Oncology
Matthew Connor, MD
Conference Coverage
IL18-Armored CAR T-Cell Therapy Produces Deep and Sustained Responses for Heavily Pretreated B-Cell Acute Lymphoblastic Leukemia
01/16/2026
Matthew Connor, MD
Matthew Connor, MD, reported that IL18-armored CD19 CAR T-cells produced deep, durable remissions with manageable toxicity among heavily pretreated adults with relapsed/refractory B-cell acute lymphoblastic leukemia in a phase 1 trial.
Matthew Connor, MD, reported that IL18-armored CD19 CAR T-cells produced deep, durable remissions with manageable toxicity among heavily pretreated adults with relapsed/refractory B-cell acute lymphoblastic leukemia in a phase 1 trial.
Matthew Connor, MD, reported...
01/16/2026
Oncology
Krish Patel, MD
Conference Coverage
Analyzing Patient Preferences on Follicular Lymphoma Treatment Delivery Options
01/16/2026
Krish Patel, MD
Krish Patel, MD, shared results from a patient preference study for relapsed/refractory follicular lymphoma at the 2025 ASH Annual Meeting & Exposition.
Krish Patel, MD, shared results from a patient preference study for relapsed/refractory follicular lymphoma at the 2025 ASH Annual Meeting & Exposition.
Krish Patel, MD, shared results...
01/16/2026
Oncology
Ciro Rinaldi, MD, PhD
Conference Coverage
Elritercept Plus Ruxolitinib Demonstrates Favorable Safety and Strong Efficacy for Patients With Myelofibrosis and Anemia: RESTORE Trial
01/14/2026
Ciro Rinaldi, MD, PhD
Ciro Rinaldi, MD, PhD, shared results from the phase 2 RESTORE trial, which evaluated the combination of elritercept and ruxolitinib among patients with myelofibrosis and anemia who were resistant or intolerant to ruxolitinib alone.
Ciro Rinaldi, MD, PhD, shared results from the phase 2 RESTORE trial, which evaluated the combination of elritercept and ruxolitinib among patients with myelofibrosis and anemia who were resistant or intolerant to ruxolitinib alone.
Ciro Rinaldi, MD, PhD, shared...
01/14/2026
Oncology
Ibrahim Aldoss, MD
Videos
Azacitidine Plus Venetoclax Shows Superior Efficacy Compared With Intensive Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia
01/12/2026
Ibrahim Aldoss, MD
Ibrahim Aldoss, MD, shared results from the phase 2 PARADIGM trial which showed frontline azacitidine plus venetoclax significantly improved survival, response rates, and quality of life compared with intensive chemotherapy for AML.
Ibrahim Aldoss, MD, shared results from the phase 2 PARADIGM trial which showed frontline azacitidine plus venetoclax significantly improved survival, response rates, and quality of life compared with intensive chemotherapy for AML.
Ibrahim Aldoss, MD, shared...
01/12/2026
Oncology
Saad Usmani, MD, MBA, FACP, FASCO
Videos
Teclistamab Plus Talquetamab Shows Deep and Durable Responses for Extramedullary Multiple Myeloma: RedirecTT-1
01/08/2026
Saad Usmani, MD, MBA, FACP, FASCO
Saad Usmani, MD, MBA, FACP, FASCO, presented updated results from the phase 2 RedirecTT-1 trial which evaluated teclistamab plus talquetamab for relapsed/refractory multiple myeloma with extramedullary disease.
Saad Usmani, MD, MBA, FACP, FASCO, presented updated results from the phase 2 RedirecTT-1 trial which evaluated teclistamab plus talquetamab for relapsed/refractory multiple myeloma with extramedullary disease.
Saad Usmani, MD, MBA, FACP,...
01/08/2026
Oncology
John Burke, MD
Videos
Subcutaneous Mosunetuzumab Demonstrates Deep, Early Responses for Treatment-Naïve Follicular Lymphoma: Phase 2 MorningSun Trial
01/08/2026
John Burke, MD
John Burke, MD, reported that subcutaneous mosunetuzumab achieved high response rates and durable remissions with manageable toxicity for treatment-naïve, high-tumor burden follicular lymphoma.
John Burke, MD, reported that subcutaneous mosunetuzumab achieved high response rates and durable remissions with manageable toxicity for treatment-naïve, high-tumor burden follicular lymphoma.
John Burke, MD, reported that...
01/08/2026
Oncology
Stephen Schuster, MD
Videos
5-Year Data Show Durable Remissions With Tisagenlecleucel for R/R Follicular Lymphoma: ELARA Trial
01/08/2026
Stephen Schuster, MD
Stephen Schuster presented updated results from the phase 2 ELARA study which evaluated tisagenlecleucel among patients with relapsed/refractory follicular lymphoma.
Stephen Schuster presented updated results from the phase 2 ELARA study which evaluated tisagenlecleucel among patients with relapsed/refractory follicular lymphoma.
Stephen Schuster presented...
01/08/2026
Oncology
David Andorsky, MD
Videos
Novel Allosteric BCR::ABL1 Inhibitor TERN-701 Demonstrates Encouraging Efficacy for Chronic Myeloid Leukemia: CARDINAL Study
01/05/2026
David Andorsky, MD
David Andorsky, MD, presented early results from the phase 1/2 CARDINAL study which evaluated TERN-701 for patients with heavily pretreated chronic myeloid leukemia, at the 2025 ASH Annual Meeting & Exposition.
David Andorsky, MD, presented early results from the phase 1/2 CARDINAL study which evaluated TERN-701 for patients with heavily pretreated chronic myeloid leukemia, at the 2025 ASH Annual Meeting & Exposition.
David Andorsky, MD, presented...
01/05/2026
Oncology
Conference Coverage
Tabelecleucel Shows Activity and Favorable Safety for Pediatric Patients With R/R EBV-Positive Post-Transplant Lymphoproliferative Disease: ALLELE Trial
12/29/2025
Emily Estrada
Tabelecleucel demonstrated durable responses and favorable safety among pediatric patients with relapsed/refractory Epstein–Barr virus-positive PTLD, according to results presented at the 2025 ASH Annual Meeting & Exposition.
Tabelecleucel demonstrated durable responses and favorable safety among pediatric patients with relapsed/refractory Epstein–Barr virus-positive PTLD, according to results presented at the 2025 ASH Annual Meeting & Exposition.
Tabelecleucel demonstrated...
12/29/2025
Oncology
Chan Cheah, MBBS
Conference Coverage
Epcoritamab Plus R-Mini-CHOP Demonstrates Durable Efficacy and Manageable Safety for Elderly Patients With DLBCL: 2-Year Results From EPCORE NHL-2
12/23/2025
Chan Cheah, MBBS
Epcoritamab plus R-mini-CHOP achieved high and durable response rates with manageable toxicity among elderly, treatment-naïve patients with DLBCL, according to results presented at the 2025 ASH Annual Meeting & Exposition.
Epcoritamab plus R-mini-CHOP achieved high and durable response rates with manageable toxicity among elderly, treatment-naïve patients with DLBCL, according to results presented at the 2025 ASH Annual Meeting & Exposition.
Epcoritamab plus R-mini-CHOP...
12/23/2025
Oncology
Andrew Kuykendall, MD
Conference Coverage
Rusfertide Demonstrates Durable Hematocrit Control and Symptom Improvement for Polycythemia Vera: VERIFY Trial
12/17/2025
Andrew Kuykendall
At the 2025 ASH Annual Meeting & Exposition, Andrew Kuykendall, MD, discussed updated results from the phase 3 VERIFY trial which evaluated rusfertide among patients with polycythemia vera.
At the 2025 ASH Annual Meeting & Exposition, Andrew Kuykendall, MD, discussed updated results from the phase 3 VERIFY trial which evaluated rusfertide among patients with polycythemia vera.
At the 2025 ASH Annual Meeting &...
12/17/2025
Oncology
Krish Patel, MD
Conference Coverage
Quality Improvement Project Identifies Knowledge Gaps and Barriers to Bispecific Antibody Use in Community Oncology Practices
12/17/2025
Krish Patel, MD
At the 2025 ASH Annual Meeting & Exposition, Krish Patel, MD, shared insights into the development of a quality improvement initiative aimed to identify barriers of bispecific antibody use in community oncology practices.
At the 2025 ASH Annual Meeting & Exposition, Krish Patel, MD, shared insights into the development of a quality improvement initiative aimed to identify barriers of bispecific antibody use in community oncology practices.
At the 2025 ASH Annual Meeting &...
12/17/2025
Oncology
Robert Orlowski, MD, PhD
Conference Coverage
Linvoseltamab Demonstrates Deep, Durable Responses as Frontline Myeloma Therapy: LINKER-MM4 Trial
12/17/2025
Robert Orlowski, MD, PhD
At the 2025 ASH Annual Meeting & Exposition, Robert Orlowski, MD, PhD, shares results from the LINKER-MM4 trial which evaluated linvoseltamab for newly diagnosed multiple myeloma.
At the 2025 ASH Annual Meeting & Exposition, Robert Orlowski, MD, PhD, shares results from the LINKER-MM4 trial which evaluated linvoseltamab for newly diagnosed multiple myeloma.
At the 2025 ASH Annual Meeting &...
12/17/2025
Oncology
Wojciech Jurczak, MD, PhD
Conference Coverage
Frontline Pirtobrutinib Shows Superior PFS vs Bendamustine-Rituximab for CLL/SLL: BRUIN CLL-313 Trial
12/15/2025
Wojciech Jurczak, MD, PhD
According to first results from a phase 3 trial presented by Wojciech Jurczak, MD, PhD, at the 2025 ASH Annual Meeting, pirtobrutinib showed superior PFS and tolerability for treatment-naïve chronic lymphocytic leukemia/small lymphocytic...
According to first results from a phase 3 trial presented by Wojciech Jurczak, MD, PhD, at the 2025 ASH Annual Meeting, pirtobrutinib showed superior PFS and tolerability for treatment-naïve chronic lymphocytic leukemia/small lymphocytic...
According to first results from...
12/15/2025
Oncology
Hanny Al-Samkari, MD
Conference Coverage
Ianalumab Plus Eltrombopag for Patients With Primary Immune Thrombocytopenia After Frontline Corticosteroid Therapy: VAYHIT2 Trial
12/15/2025
Hanny Al-Samkari, MD
At the ASH 2025 Annual Meeting & Exposition, Hanny Al-Samkari, MD, presented phase 3 data on ianalumab vs placebo plus eltrombopag as second-line treatment for patients with ITP.
At the ASH 2025 Annual Meeting & Exposition, Hanny Al-Samkari, MD, presented phase 3 data on ianalumab vs placebo plus eltrombopag as second-line treatment for patients with ITP.
At the ASH 2025 Annual Meeting &...
12/15/2025
Oncology
Conference Coverage
Real-World ctDNA Monitoring Shows MRD Clearance Predicts Relapse Risk and Survival Outcomes for DLBCL: HOVON-902 Analysis
12/11/2025
Emily Estrada
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring...
12/11/2025
Oncology
Conference Coverage
Circulating Tumor DNA Utility for Predicting Outcomes for Patients With Aggressive and Indolent Lymphomas: Real-World Analysis
12/11/2025
Gina Tomaine
At the ASH 2025 Annual Meeting & Exposition, real-world data data was presented on the strong prognostic utility of ctDNA as a biomarker to inform treatment across indolent and aggressive subtypes of lymphoma.
At the ASH 2025 Annual Meeting & Exposition, real-world data data was presented on the strong prognostic utility of ctDNA as a biomarker to inform treatment across indolent and aggressive subtypes of lymphoma.
At the ASH 2025 Annual Meeting &...
12/11/2025
Oncology
Bilal Abid MD, MS, FACP, MRCP, FRCP
Conference Coverage
Germinal Center B-Cell Subtype DLBCL Associated With Superior Outcomes After CAR T-Cell Therapy
12/09/2025
Bilal Abid, MD, MS, FACP, MRCP, FRCP
According to results presented by Bilal Abid, MD, at the 2025 ASH Annual Meeting, patients with GCB subtype R/R diffuse large B-cell lymphoma experienced significantly better survival after CAR T-cell therapy than those with non-GCB disease.
According to results presented by Bilal Abid, MD, at the 2025 ASH Annual Meeting, patients with GCB subtype R/R diffuse large B-cell lymphoma experienced significantly better survival after CAR T-cell therapy than those with non-GCB disease.
According to results presented...
12/09/2025
Oncology
Olalekan Oluwole, MD, MBBS
Conference Coverage
Healthcare Resource Utilization for Patients With DLBCL and MM Comparable Between New and Established CAR T-Cell Therapy Centers
12/09/2025
Olalekan O. Oluwole
Newly authorized US CAR T-cell therapy centers deliver healthcare resources for DLBCL and MM comparable to established programs, according to a real-world analysis presented by Olalekan Oluwole, MD, MBBS, at the 2025 ASH Annual Meeting.
Newly authorized US CAR T-cell therapy centers deliver healthcare resources for DLBCL and MM comparable to established programs, according to a real-world analysis presented by Olalekan Oluwole, MD, MBBS, at the 2025 ASH Annual Meeting.
Newly authorized US CAR T-cell...
12/09/2025
Oncology
Veronika Bachanova, MD, PhD
Conference Coverage
Emergence of Novel Composite End Points Toxicity/PFS and Toxicity-Free CR to Benchmark Safety and Efficacy of CAR-T Cell Therapy for DLBCL
12/08/2025
Veronika Bachanova, MD, PhD
At the ASH 2025 Annual Meeting, Veronika Bachanova, MD, PhD, explains data on the value of novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) for evaluating cell therapies for...
At the ASH 2025 Annual Meeting, Veronika Bachanova, MD, PhD, explains data on the value of novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) for evaluating cell therapies for...
At the ASH 2025 Annual Meeting,...
12/08/2025
Oncology
Ran Reshef, MD, MSc
Conference Coverage
Relationship of Cilta-Cel Dose to PFS Outcomes for Patients With R/R Multiple Myeloma: Real-World Analysis
12/08/2025
Ran Reshef, MD, MSc
Higher cell doses of ciltacabtagene autoleucel were associated with improved progression-free survival without added toxicity, according to results from a real-world analysis presented by Ran Reshef, MD, MSc, at the 2025 ASH Annual Meeting &...
Higher cell doses of ciltacabtagene autoleucel were associated with improved progression-free survival without added toxicity, according to results from a real-world analysis presented by Ran Reshef, MD, MSc, at the 2025 ASH Annual Meeting &...
Higher cell doses of...
12/08/2025
Oncology
Adam Cohen, MD
Conference Coverage
Cevostamab Consolidation After BCMA CAR T-Cell Therapy for Patients With R/R Multiple Myeloma: "STEM" Trial
12/08/2025
Adam Cohen, MD
At the ASH 2025 Annual Meeting, Adam Cohen, MD, shares data from the “STEM” (Sequential T Cell-Engagement for Myeloma) phase 2 trial on cevostamab consolidation following BCMA CAR T-cell therapy for R/R MM.
At the ASH 2025 Annual Meeting, Adam Cohen, MD, shares data from the “STEM” (Sequential T Cell-Engagement for Myeloma) phase 2 trial on cevostamab consolidation following BCMA CAR T-cell therapy for R/R MM.
At the ASH 2025 Annual Meeting,...
12/08/2025
Oncology
Jean-Marie Michot, MD
Conference Coverage
OLYMPIA-3 Trial: Odronextamab With CHOP Demonstrates Strong Efficacy and Manageable Safety for Patients With Newly Diagnosed DLBCL
12/07/2025
Jean-Marie Michot, MD
Odronextamab combined with CHOP therapy demonstrated high response rates and manageable toxicity among patients with previously untreated diffuse large B-cell lymphoma, according to results presented at the 2025 ASH Annual Meeting.
Odronextamab combined with CHOP therapy demonstrated high response rates and manageable toxicity among patients with previously untreated diffuse large B-cell lymphoma, according to results presented at the 2025 ASH Annual Meeting.
Odronextamab combined with CHOP...
12/07/2025
Oncology
Sairah Ahmed, MD
Conference Coverage
Lisocabtagene Maraleucel Achieves High Responses and Durable 3-Year Remissions for R/R Follicular Lymphoma: TRANSCEND FL
12/07/2025
Sairah Ahmed, MD
For patients with at least 3 prior lines of therapy, lisocabtagene maraleucel produced durable, high response rates among patients with R/R follicular lymphoma, according to a 3-year update presented at the 2025 ASH Annual Meeting.
For patients with at least 3 prior lines of therapy, lisocabtagene maraleucel produced durable, high response rates among patients with R/R follicular lymphoma, according to a 3-year update presented at the 2025 ASH Annual Meeting.
For patients with at least 3...
12/07/2025
Oncology
Elizabeth Budde, MD, PhD
Conference Coverage
BAFFR CAR T-Cell Therapy Shows Durable Responses, Manageable Toxicity for Patients With B-Cell Lymphomas Relapsing After or Ineligible for CD19-Targeted Treatments
12/07/2025
Elizabeth Budde, MD, PhD
Elizabeth Budde, MD, PhD, shares data on PMB-CT01, a novel autologous CAR-T cell therapy developed against B-cell activating factor for patients with B-cell lymphomas relapsing after or ineligible for CD-19 targeted treatments at the 2025 ASH...
Elizabeth Budde, MD, PhD, shares data on PMB-CT01, a novel autologous CAR-T cell therapy developed against B-cell activating factor for patients with B-cell lymphomas relapsing after or ineligible for CD-19 targeted treatments at the 2025 ASH...
Elizabeth Budde, MD, PhD, shares...
12/07/2025
Oncology
Mitul Gandhi, MD
Conference Coverage
Daratumumab Added to Lenalidomide Maintenance Therapy Following Transplant Improves Depth and Durability of MRD Response for MM: AURIGA Study
12/07/2025
Mitul Gandhi, MD
Daratumumab plus lenalidomide maintenance therapy following ASCT improved MRD-negative conversion and durability among newly diagnosed multiple myeloma patients, according to data presented at 2025 ASH Annual Meeting & Exposition.
Daratumumab plus lenalidomide maintenance therapy following ASCT improved MRD-negative conversion and durability among newly diagnosed multiple myeloma patients, according to data presented at 2025 ASH Annual Meeting & Exposition.
Daratumumab plus lenalidomide...
12/07/2025
Oncology
Jorge Cortes, MD
Conference Coverage
Asciminib Shows Improved Patient Outcomes vs Investigator-Selected Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: ASC4FIRST Trial
12/07/2025
Jorge Cortes, MD
Jorge Cortes, MD, shares patient-reported outcomes from the ASC4FIRST trial, which compared asciminib with standard frontline tyrosine kinase inhibitors for CML at the 2025 ASH Annual Meeting & Exposition.
Jorge Cortes, MD, shares patient-reported outcomes from the ASC4FIRST trial, which compared asciminib with standard frontline tyrosine kinase inhibitors for CML at the 2025 ASH Annual Meeting & Exposition.
Jorge Cortes, MD, shares...
12/07/2025
Oncology
Conference Coverage
Belantamab Mafodotin Triplet for R/R MM Shows Sustained Superiority vs Pomalidomide, Bortezomib, and Dexamethasone: DREAMM-8 Long-Term Follow-Up
12/07/2025
Gina Tomaine
Deep responses and durable outcomes were demonstrated among patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study presented at the 2025 ASH Annual Meeting.
Deep responses and durable outcomes were demonstrated among patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study presented at the 2025 ASH Annual Meeting.
Deep responses and durable...
12/07/2025
Oncology
Conference Coverage
Outcomes of Cilta-Cel Manufacturing for Lenalidomide-Refractory Multiple Myeloma Strongly Influenced by Prior Lines of Therapy
12/06/2025
Emily Estrada
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene...
12/06/2025
Oncology
Conference Coverage
Talquetamab Plus Teclistamab Demonstrates Durable Efficacy for Patients With R/R MM and Extramedullary Disease: Updated Results from RedirecTT-1 Study
12/06/2025
Emily Estrada
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
Talquetamab plus teclistamab...
12/06/2025
Oncology
Conference Coverage
Identifying Key Predictors of Early Relapse After Treatment With Ciltacabtagene Autoleucel to Inform Risk-Adapted Strategies for Patients With R/R MM
12/06/2025
Emily Estrada
A multicenter analysis presented at the 2025 ASH Annual Meeting identified key predictors of relapse within 18 months of ciltacabtagene autoleucel infusion to improve treatment strategy for patients with high-risk relapsed/refractory multiple...
A multicenter analysis presented at the 2025 ASH Annual Meeting identified key predictors of relapse within 18 months of ciltacabtagene autoleucel infusion to improve treatment strategy for patients with high-risk relapsed/refractory multiple...
A multicenter analysis presented...
12/06/2025
Oncology
Conference Coverage
Cilta-Cel Demonstrates Deep and Durable Responses for Standard-Risk Relapsed/Refractory Myeloma: CARTITUDE-4 Subgroup Analysis
12/06/2025
Emily Estrada
Based on results from the CARTITUDE-4 study presented at the 2025 ASH Annual Meeting, a ciltacabtagene autoleucel infusion achieved durable responses and promising survival outcomes for standard-risk relapsed/refractory multiple myeloma.
Based on results from the CARTITUDE-4 study presented at the 2025 ASH Annual Meeting, a ciltacabtagene autoleucel infusion achieved durable responses and promising survival outcomes for standard-risk relapsed/refractory multiple myeloma.
Based on results from the...
12/06/2025
Oncology
Conference Coverage
Odronextamab Plus CHOP Demonstrates High Response Rates and Manageable Safety for Previously Untreated DLBCL: First Results From OLYMPIA-3 Trial
12/03/2025
Emily Estrada
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP...
12/03/2025
Oncology
Conference Coverage
Epcoritamab Monotherapy Demonstrates High Response Rates and Durable MRD Negativity in Elderly, Chemotherapy-Ineligible 1L DLBCL Patients: Interim Results from EPCORE DLBCL-3
12/03/2025
Emily Estrada
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous...
12/03/2025
Oncology
Conference Coverage
Zanubrutinib Plus R-CHOP Therapy Shows Promising Efficacy, Acceptable Safety Among Patients With DLBCL Harboring Specific Gene Subtypes
12/02/2025
Emily Estrada
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy...
12/02/2025
Oncology
Conference Coverage
Subcutaneous Mosunetuzumab Shows Efficacy and Safety Among Elderly, Chemotherapy-Ineligible Patients With DLBCL: MorningSun Trial
12/02/2025
Emily Estrada
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at...
12/02/2025
Oncology
Lucía Pérez-Lamas, MD
Videos
Momelotinib Demonstrates Real-World Efficacy, Improved Anemia Symptoms Among Patients With Myelofibrosis
02/07/2025
Momelotinib for the treatment of myelofibrosis and anemia demonstrated improved real-world patient outcomes and a favorable safety profile, according to research presented at the 66th ASH Annual Meeting.
Momelotinib for the treatment of myelofibrosis and anemia demonstrated improved real-world patient outcomes and a favorable safety profile, according to research presented at the 66th ASH Annual Meeting.
Momelotinib for the treatment of...
02/07/2025
Oncology
Jean-Sébastien Claveau, MD
Conference Coverage
Eliminating Necessity for Sequential Assessment for Progressive Disease Among Patients With Relapsed Multiple Myeloma
01/31/2025
Additional confirmatory tests for progressive disease are not needed to determine progression among patients with MM after 2 biomarkers have met the criteria of progression at the same time, according to a retrospective study.
Additional confirmatory tests for progressive disease are not needed to determine progression among patients with MM after 2 biomarkers have met the criteria of progression at the same time, according to a retrospective study.
Additional confirmatory tests...
01/31/2025
Oncology
John Mascarenhas, MD
Videos
Latest Updates in Navtemadlin Therapy for Patients With Myelofibrosis
01/29/2025
John Mascarenhas, MD
Navtemadlin therapy demonstrated efficacy and safety for patients with JAK inhibitor relapsed/refractory myelofibrosis, as well as improved biomarkers of disease burden, according to data presented by John Mascarenhas, MD.
Navtemadlin therapy demonstrated efficacy and safety for patients with JAK inhibitor relapsed/refractory myelofibrosis, as well as improved biomarkers of disease burden, according to data presented by John Mascarenhas, MD.
Navtemadlin therapy demonstrated...
01/29/2025
Oncology
Jorge Cortes, MD
Videos
Asciminib Demonstrates Favorable Safety and Tolerability for Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Compared With Tyrosine Kinase Inhibitor Therapy
01/29/2025
Jorge Cortes, MD
Compared with standard tyrosine kinase inhibitors, asciminib demonstrated improved safety and tolerability for the treatment of chronic myeloid leukemia, according to phase 3 data presented at the 66th ASH annual meeting.
Compared with standard tyrosine kinase inhibitors, asciminib demonstrated improved safety and tolerability for the treatment of chronic myeloid leukemia, according to phase 3 data presented at the 66th ASH annual meeting.
Compared with standard tyrosine...
01/29/2025
Oncology
Lucia Masarova, MD
Videos
Pegylated Interferon Therapy Demonstrates Efficacy and Durability for Treatment of PV and Essential Thrombocythemia
01/20/2025
Pegylated interferon demonstrates feasibility and durability for the treatment of polycythemia vera and essential thrombocythemia, according to a phase 2 study presented by Lucia Masarova, MD, at the 66th ASH annual meeting.
Pegylated interferon demonstrates feasibility and durability for the treatment of polycythemia vera and essential thrombocythemia, according to a phase 2 study presented by Lucia Masarova, MD, at the 66th ASH annual meeting.
Pegylated interferon...
01/20/2025
Oncology
Efstathios Kastritis, MD
Videos
Daratumumab Added to Standard Frontline AL Amyloidosis Treatment Demonstrates Improved Clinical Outcomes
01/15/2025
Efstathios Kastritis
In the final analysis of the ANDROMEDA study, daratumumab added to standard bortezomib, cyclophosphamide, and dexamethasone therapy demonstrated better hematological responses and clinical improvement for the treatment of AL amyloidosis.
In the final analysis of the ANDROMEDA study, daratumumab added to standard bortezomib, cyclophosphamide, and dexamethasone therapy demonstrated better hematological responses and clinical improvement for the treatment of AL amyloidosis.
In the final analysis of the...
01/15/2025
Oncology
Christina Poh, MD
Videos
Tafasitamab Added to Lenalidomide and Ritixumab Shows Benefit for Patients With R/R FL
01/15/2025
The addition of tafasitamab to lenalidomide and rituximab therapy demonstrates safety and efficacy for patients with relapsed/refractory follicular lymphoma, according to results from a phase 3 trial presented at the 66th ASH Annual Meeting.
The addition of tafasitamab to lenalidomide and rituximab therapy demonstrates safety and efficacy for patients with relapsed/refractory follicular lymphoma, according to results from a phase 3 trial presented at the 66th ASH Annual Meeting.
The addition of tafasitamab to...
01/15/2025
Oncology
Benjamin Rolles, MD
Conference Coverage
Impact of Treatment Response to Hypomethylating Agents and Time-to-Transplant Status on Outcomes Among Patients With MDS
01/13/2025
Time to alloHCT may be more impactful than treatment response to hypomethylating agent-based therapy on outcomes for patients with myelodysplastic syndromes, according to research presented by Benjamin Rolles at the 66th ASH Annual Meeting.
Time to alloHCT may be more impactful than treatment response to hypomethylating agent-based therapy on outcomes for patients with myelodysplastic syndromes, according to research presented by Benjamin Rolles at the 66th ASH Annual Meeting.
Time to alloHCT may be more...
01/13/2025
Oncology
Gilles Salles, MD, PhD
Videos
Long-Term Follow-up of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients With Intermediate- or High-Risk DLBCL
01/07/2025
Gilles Salles, MD, PhD
According to a prolonged follow-up of the POLARIX trial, treatment with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone showed durable and significant PFS benefit vs R-CHOP among patients with intermediate-...
According to a prolonged follow-up of the POLARIX trial, treatment with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone showed durable and significant PFS benefit vs R-CHOP among patients with intermediate-...
According to a prolonged...
01/07/2025
Oncology
Hang Quach, MD, FRACP, FRCPA, MBBS
Videos
Trispecific Antibody Therapy Well-Tolerated Among Patients With Relapsed/Refractory Multiple Myeloma
01/06/2025
According to a phase 1 dose escalation study among patients with relapsed/refractory multiple myeloma, treatment with novel BCMA-CD38-CD3-targeting trispecific antibody ISB 2001 was well-tolerated.
According to a phase 1 dose escalation study among patients with relapsed/refractory multiple myeloma, treatment with novel BCMA-CD38-CD3-targeting trispecific antibody ISB 2001 was well-tolerated.
According to a phase 1 dose...
01/06/2025
Oncology
Adam Olszewski, MD
Videos
Mosunetuzumab Plus Polatuzumab Vedotin Shows Improved Outcomes vs Rituximab Plus Polatuzumab Vedotin Among Patients With R/R Large B-Cell Lymphoma
01/06/2025
Subcutaenous mosunetuzumab plus polatuzumab vedotin demonstrates improved efficacy and response rates compared with rituximab plus polatuzumab vedotin for patients with relapsed/refractory (R/R) LBCL, according to phase 2 study results...
Subcutaenous mosunetuzumab plus polatuzumab vedotin demonstrates improved efficacy and response rates compared with rituximab plus polatuzumab vedotin for patients with relapsed/refractory (R/R) LBCL, according to phase 2 study results...
Subcutaenous mosunetuzumab plus...
01/06/2025
Oncology
Conference Coverage
Bromodomain and BET Inhibitor INCB057643 Shows Benefit for Patients With Myelofibrosis  
12/19/2024
Gina Tomaine
According to research presented by Justin Watts, MD, at the 2024 ASH Annual Meeting & Exposition in San Diego, California, INCB057643 may improve patient outcomes in the treatment of hematologic malignancies including myelofibrosis.
According to research presented by Justin Watts, MD, at the 2024 ASH Annual Meeting & Exposition in San Diego, California, INCB057643 may improve patient outcomes in the treatment of hematologic malignancies including myelofibrosis.
According to research presented...
12/19/2024
Oncology
Firas El Chaer, MD
Conference Coverage
Nuvisertib Demonstrates Durable Clinical Activity for Patients With R/R Myelofibrosis
12/19/2024
According to data presented at the 66th ASH Annual Meeting by Firas El Chaer, MD, oral investigational highly selective PIM1 kinase inhibitor nuvisertib was well-tolerated and demonstrated clinical activity among patients with MF.
According to data presented at the 66th ASH Annual Meeting by Firas El Chaer, MD, oral investigational highly selective PIM1 kinase inhibitor nuvisertib was well-tolerated and demonstrated clinical activity among patients with MF.
According to data presented at...
12/19/2024
Oncology
Lucia Masarova, MD
Conference Coverage
Exploring Add-on Therapy With CK0804 for Patients With Myelofibrosis With Suboptimal Response to Ruxolitinib
12/19/2024
According to data presented at the 66th ASH Annual Meeting by Lucia Masarova, MD, CXCR4-enriched T regulatory cell therapy (CK0804) as an addition to ruxolitinib treatment demonstrated initial safety and promising clinical activity for...
According to data presented at the 66th ASH Annual Meeting by Lucia Masarova, MD, CXCR4-enriched T regulatory cell therapy (CK0804) as an addition to ruxolitinib treatment demonstrated initial safety and promising clinical activity for...
According to data presented at...
12/19/2024
Oncology
Elizabeth Brem, MD, University of California, Irvine
Videos
Odronextamab Monotherapy vs Standard of Care Therapy for Follicular Lymphoma: OLYMPIA-1 Trial
12/16/2024
Elizabeth Brem, MD, discusses safety and preliminary efficacy results from the phase 3 OLYMPIA-1 trial exploring odronextamab monotherapy for patients with high-risk follicular lymphoma.
Elizabeth Brem, MD, discusses safety and preliminary efficacy results from the phase 3 OLYMPIA-1 trial exploring odronextamab monotherapy for patients with high-risk follicular lymphoma.
Elizabeth Brem, MD, discusses...
12/16/2024
Oncology
John Burke, MD
Conference Coverage
First-Line Subcutaneous Mosunetuzumab Shows Encouraging Efficacy, Manageable Safety for Patients With Low Tumor Burden Follicular Lymphoma
12/13/2024
John M. Burke, MD
According to updated results presented by John Burke, MD, at the 66th ASH Annual Meeting, frontline subcutaneous treatment with fixed-duration mosunetuzumab among patients with low-tumor burden FL demonstrated efficacy and safety.
According to updated results presented by John Burke, MD, at the 66th ASH Annual Meeting, frontline subcutaneous treatment with fixed-duration mosunetuzumab among patients with low-tumor burden FL demonstrated efficacy and safety.
According to updated results...
12/13/2024
Oncology
Matthew Matasar, MD, MS
Videos
Odronextamab Monotherapy Shows Encouraging Efficacy, Manageable Safety for DLBCL Progressing After CAR-T Therapy
12/10/2024
Matthew Matasar, MD
Matthew Matasar, MD, discusses results from a primary analysis of the ELM-1 study that showed the encouraging efficacy and manageable safety of CD20-CD3 bispecific antibody odronextamab for relapsed/refractory DLBCL progressing after CAR...
Matthew Matasar, MD, discusses results from a primary analysis of the ELM-1 study that showed the encouraging efficacy and manageable safety of CD20-CD3 bispecific antibody odronextamab for relapsed/refractory DLBCL progressing after CAR...
Matthew Matasar, MD, discusses...
12/10/2024
Oncology
Nirav Shah, MD
Videos
Tandem CD20-CD19-Directed CAR T-Cell Therapy for Relapsed/Refractory DLBCL: Zamtocabtagene Autoleucel
12/08/2024
Nirav Shah, MD, discusses findings from an interim analysis of the phase 2 DALY II trial, which is the first pivotal trial evaluating tandem CD20-CD19 directed CAR T-cell product, zamtocabtagene autoleucel, for patients with...
Nirav Shah, MD, discusses findings from an interim analysis of the phase 2 DALY II trial, which is the first pivotal trial evaluating tandem CD20-CD19 directed CAR T-cell product, zamtocabtagene autoleucel, for patients with...
Nirav Shah, MD, discusses...
12/08/2024
Oncology
Meletios-Athanasios Dimopoulos, MD
Videos
Daratumumab Monotherapy Shows Benefit vs Active Monitoring for Patients With High-Risk Smoldering Multiple Myeloma
12/08/2024
Meletios-Athanasios Dimopoulos, MD, discusses findings from the phase 3 Aquila study which demonstrated the benefit of daratumumab monotherapy compared to active monitoring for patients with high-risk smoldering multiple myeloma.
Meletios-Athanasios Dimopoulos, MD, discusses findings from the phase 3 Aquila study which demonstrated the benefit of daratumumab monotherapy compared to active monitoring for patients with high-risk smoldering multiple myeloma.
Meletios-Athanasios Dimopoulos,...
12/08/2024
Oncology
Alaa Ali, MD, Lombardi Comprehensive Cancer Center
Videos
Fludarabine- vs Bendamustine-Based Lymphodepletion Prior to CAR-T Therapy for Relapsed/Refractory DLBCL
12/08/2024
At the 66th ASH Annual Meeting, Alaa Ali, MD, discusses findings from a real-world study that compared fludarabine- and bendamustine-based lymphodepletion prior to CAR-T therapy for the treatment of relapsed/refractory DLBCL.
At the 66th ASH Annual Meeting, Alaa Ali, MD, discusses findings from a real-world study that compared fludarabine- and bendamustine-based lymphodepletion prior to CAR-T therapy for the treatment of relapsed/refractory DLBCL.
At the 66th ASH Annual Meeting,...
12/08/2024
Oncology
Jean-Nicolas Champagne, MD, BC Cancer Vancouver
Videos
Retreatment With R-CHOP-Like Therapy Yields Durable Remission in Late-Relapse DLBCL
12/08/2024
Jean-Nicolas Champagne, MD, discusses results from a retrospective study that showed retreatment with R-CHOP-like therapy was a reasonable option for late-relapse DLBCL and resulted in durable remission in a high proportion of patients.
Jean-Nicolas Champagne, MD, discusses results from a retrospective study that showed retreatment with R-CHOP-like therapy was a reasonable option for late-relapse DLBCL and resulted in durable remission in a high proportion of patients.
Jean-Nicolas Champagne, MD,...
12/08/2024
Oncology
Anne Marijn Kramer, MD, PhD
Videos
CD22-Directed CAR-T Therapy Demonstrates Durable Remissions for Patients With Large B-Cell Lymphomas Relapsing After CD19-Directed CAR-T Therapy
12/08/2024
Anne Marijn Kramer, MD, PhD, discusses follow-up data from a phase 1 trial showing that CD22-directed CAR-T therapy provides durable remissions and long-term survival after 3 years for patients with large B-cell lymphomas progressing after...
Anne Marijn Kramer, MD, PhD, discusses follow-up data from a phase 1 trial showing that CD22-directed CAR-T therapy provides durable remissions and long-term survival after 3 years for patients with large B-cell lymphomas progressing after...
Anne Marijn Kramer, MD, PhD,...
12/08/2024
Oncology
Conference Coverage
Retreatment With R-CHOP-Like Therapy Effective in Late-Relapse DLBCL
12/07/2024
Meagan Thistle
In patients with late-relapse DLBCL, a retreatment strategy with R-CHOP-like therapy is a reasonable option and results in durable remission in a high proportion of patients, according to a retrospective study.
In patients with late-relapse DLBCL, a retreatment strategy with R-CHOP-like therapy is a reasonable option and results in durable remission in a high proportion of patients, according to a retrospective study.
In patients with late-relapse...
12/07/2024
Oncology
Conference Coverage
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Myelofibrosis
12/07/2024
Gina Tomaine
According to data presented at the 2024 ASH Annual Meeting, assessed outcomes after allogeneic HCT were found to be acceptable among older patients with myelofibrosis.
According to data presented at the 2024 ASH Annual Meeting, assessed outcomes after allogeneic HCT were found to be acceptable among older patients with myelofibrosis.
According to data presented at...
12/07/2024
Oncology
Conference Coverage
Novel JAK2 Inhibitor OB756 Treatment Well-Tolerated Among Patients With Myelofibrosis
12/07/2024
Gina Tomaine
According to results from a multicenter phase 1/2 trial, novel small molecule Janus kinase 2 (JAK2) inhibitor OB756 was found to be well-tolerated and demonstrated meaningful clinical activity among patients with MF.
According to results from a multicenter phase 1/2 trial, novel small molecule Janus kinase 2 (JAK2) inhibitor OB756 was found to be well-tolerated and demonstrated meaningful clinical activity among patients with MF.
According to results from a...
12/07/2024
Oncology
Conference Coverage
Bomedemstat Combined With Ruxolitinib Demonstrates Benefit Among Patients With Myelofibrosis
12/06/2024
Gina Tomaine
According to results from a phase 2 study, the addition of bomedemstat to a ruxolitinib regimen was well-tolerated, improved splenomegaly and symptom scores, and stabilized hemoglobin both in the frontline and second-line setting for patients...
According to results from a phase 2 study, the addition of bomedemstat to a ruxolitinib regimen was well-tolerated, improved splenomegaly and symptom scores, and stabilized hemoglobin both in the frontline and second-line setting for patients...
According to results from a...
12/06/2024
Oncology
Conference Coverage
Real-World Efficacy of Bispecific Antibodies for Patients With Relapsed or Refractory Large B-Cell Lymphomas
12/05/2024
Stephanie Holland
According to results from a retrospective study, the bispecific antibodies epcoritamab and glofitamab demonstrated worse outcomes among patients with relapsed or refractory large b-cell lymphomas in the real-world setting, compared with trial...
According to results from a retrospective study, the bispecific antibodies epcoritamab and glofitamab demonstrated worse outcomes among patients with relapsed or refractory large b-cell lymphomas in the real-world setting, compared with trial...
According to results from a...
12/05/2024
Oncology
Conference Coverage
Second-Line Fedratinib Shows Promise for Patients With Myelofibrosis With Low Baseline Platelet Counts
12/05/2024
Gina Tomaine
According to the phase 3 randomized FREEDOM2 Trial, fedratinib demonstrated spleen volume reduction and symptom reduction versus best available therapy among patients with myelofibrosis previously treated with ruxolitinib.
According to the phase 3 randomized FREEDOM2 Trial, fedratinib demonstrated spleen volume reduction and symptom reduction versus best available therapy among patients with myelofibrosis previously treated with ruxolitinib.
According to the phase 3...
12/05/2024
Oncology
Conference Coverage
Time of CAR-T Cell Therapy Failure May Predict Outcomes of Bispecific Antibody Therapy Among Patients With Relapsed or Refractory Large B-Cell Lymphoma
12/05/2024
Allison Casey
According to a retrospective, real-world study presented at the 2024 ASH Annual Meeting & Exposition, the timing of CAR-T cell therapy failure may predict the outcomes for bispecific antibody therapies for patients with relapsed/refractory...
According to a retrospective, real-world study presented at the 2024 ASH Annual Meeting & Exposition, the timing of CAR-T cell therapy failure may predict the outcomes for bispecific antibody therapies for patients with relapsed/refractory...
According to a retrospective,...
12/05/2024
Oncology
Conference Coverage
CD22-Directed CAR-T Therapy Provides Durable Remission and Long-Term Survival in Large B-Cell Lymphoma
12/05/2024
Among patients with large B-cell lymphoma progressing after CD19-directed CAR T-cell therapy, treatment with CD22-Directed CAR T-cells provided durable remissions and long-term survival after 3 years, according to follow-up data presented at...
Among patients with large B-cell lymphoma progressing after CD19-directed CAR T-cell therapy, treatment with CD22-Directed CAR T-cells provided durable remissions and long-term survival after 3 years, according to follow-up data presented at...
Among patients with large B-cell...
12/05/2024
Oncology
Moritz Furstenau, MD
Conference Coverage
Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL
06/26/2024
Moritz Furstenau, MD
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting,...
06/26/2024
Oncology
Eliza A Hawkes, MD
Conference Coverage
Assessing Efficacy of Acalabrutinib-Rituximab Followed by Chemo and ASCT for Patients With Treatment-Naive MCL
02/13/2024
Eliza A. Hawkes, MD
Eliza A Hawkes, MD, shares findings from the phase 2 WAMM trial, which assessed the use of acalabrutinib-rituximab followed by chemotherapy and autologous stem cell transplantation among young and fit patients with treatment-naive MCL.
Eliza A Hawkes, MD, shares findings from the phase 2 WAMM trial, which assessed the use of acalabrutinib-rituximab followed by chemotherapy and autologous stem cell transplantation among young and fit patients with treatment-naive MCL.
Eliza A Hawkes, MD, shares...
02/13/2024
Oncology
Carlyn Rose Tan, MD, Memorial Sloan Kettering Cancer Center
Conference Coverage
Prior Exposure to TCRT Associated With Lower CRS Incidence During Teclistamab Step-Up Dosing Phase Among Patients With R/R MM
01/22/2024
Carlyn Rose Tan, MD
At the 65th ASH Annual Meeting, Carlyn Rose Tan, MD, presented data that for patients with R/R multiple myeloma, exposure to a T-cell redirection therapy correlated with a lower incidence of cytokine release syndrome during the teclistamab...
At the 65th ASH Annual Meeting, Carlyn Rose Tan, MD, presented data that for patients with R/R multiple myeloma, exposure to a T-cell redirection therapy correlated with a lower incidence of cytokine release syndrome during the teclistamab...
At the 65th ASH Annual Meeting,...
01/22/2024
Oncology
Lorenzo Falchi, MD
Conference Coverage
Subcutaneous Mosunetuzumab Demonstrates Encouraging Efficacy, Manageable Safety as Frontline Therapy for High-Tumor Burden Follicular Lymphoma
01/12/2024
Lorenzo Falchi
At the 65th ASH Annual Meeting, Lorenzo Falchi, MD, shares results which indicated that subcutaneous mosunetuzumab as first-line therapy demonstrated efficacious outcomes and manageable safety among patients with high-tumor burden FL.
At the 65th ASH Annual Meeting, Lorenzo Falchi, MD, shares results which indicated that subcutaneous mosunetuzumab as first-line therapy demonstrated efficacious outcomes and manageable safety among patients with high-tumor burden FL.
At the 65th ASH Annual Meeting,...
01/12/2024
Oncology
Adrian Wiestner, MD
Conference Coverage
Exploring Possibilities for the Future of Chronic Lymphocytic Leukemia Treatment
01/12/2024
Adrian Wiestner, MD
At the 65th ASH Annual Meeting, Adrian Wiestner, MD, discusses exciting possibilities for the future of chronic lymphocytic leukemia treatment, including the prospect of time-limited treatment periods and T-cell-engaging bispecific antibodies.
At the 65th ASH Annual Meeting, Adrian Wiestner, MD, discusses exciting possibilities for the future of chronic lymphocytic leukemia treatment, including the prospect of time-limited treatment periods and T-cell-engaging bispecific antibodies.
At the 65th ASH Annual Meeting,...
01/12/2024
Oncology
Jeffrey Matous, MD, Sarah Cannon Research Institute
Conference Coverage
Talquetamab Plus Pomalidomide Shows Promising Efficacy, Manageable Safety for Patients With MM
01/11/2024
Jeffrey Matous, MD
At the 65th ASH Annual Meeting, Jeffrey Matous, MD, shared initial trial results that talquetamab plus pomalidomide demonstrated rapid, deep responses among patients with R/R multiple myeloma and ≥2 prior lines of therapy.
At the 65th ASH Annual Meeting, Jeffrey Matous, MD, shared initial trial results that talquetamab plus pomalidomide demonstrated rapid, deep responses among patients with R/R multiple myeloma and ≥2 prior lines of therapy.
At the 65th ASH Annual Meeting,...
01/11/2024
Oncology
Alina Markova, MD, Memorial Sloan Kettering
Conference Coverage
Topical Ruxolitinib Shows Promise for Treatment of Patients With Chronic Cutaneous GVHD
01/11/2024
Alina Markova, MD
At the 65th ASH Annual Meeting in San Diego, California, Alina Markova, MD, shared study results that demonstrated ruxolitinib 1.5% cream was safe and effective compared to placebo in treating cutaneous nonsclerotic and superficially...
At the 65th ASH Annual Meeting in San Diego, California, Alina Markova, MD, shared study results that demonstrated ruxolitinib 1.5% cream was safe and effective compared to placebo in treating cutaneous nonsclerotic and superficially...
At the 65th ASH Annual Meeting...
01/11/2024
Oncology
David Andorsky, MD
Conference Coverage
Updated Findings on Efficacy and Safety of Tazemetostat Plus Lenalidomide and Rituximab for Patients With R/R FL
01/10/2024
David J. Andorsky
At the 65th ASH Annual Meeting, David Andorsky, MD, discussed updated findings from the Symphony-1 trial after a 22.5-month follow-up.
At the 65th ASH Annual Meeting, David Andorsky, MD, discussed updated findings from the Symphony-1 trial after a 22.5-month follow-up.
At the 65th ASH Annual Meeting,...
01/10/2024
Oncology
Alexey Danilov, MD
Conference Coverage
Prognostic Value of Undetectable MRD Status Among Patients With Follicular Lymphoma Post-Initial Treatment
01/10/2024
Alexey Danilov, MD
At the 65th ASH Annual Meeting, Alexey Danilov, MD, analyzes the prognostic value of undetectable MRD among patients with follicular lymphoma initially treated with chemotherapy.
At the 65th ASH Annual Meeting, Alexey Danilov, MD, analyzes the prognostic value of undetectable MRD among patients with follicular lymphoma initially treated with chemotherapy.
At the 65th ASH Annual Meeting,...
01/10/2024
Oncology
David Andorsky, MD
Conference Coverage
Asciminib Continues to Demonstrate Efficacy and Tolerability Among Patients With CML in Chronic Phase
01/10/2024
David J. Andorsky
At the 65th ASH Annual Meeting, David Andorsky, MD, discussed an interim analysis of the AIM4CML trial, which indicated that asciminib treatment continued to demonstrate efficacy and tolerability among patients with CML chronic phase.
At the 65th ASH Annual Meeting, David Andorsky, MD, discussed an interim analysis of the AIM4CML trial, which indicated that asciminib treatment continued to demonstrate efficacy and tolerability among patients with CML chronic phase.
At the 65th ASH Annual Meeting,...
01/10/2024
Oncology
Yucai Wang, MD, PhD
Conference Coverage
Examining Efficacy of Frontline Bendamustine-Rituximab and Second-Line BTK Inhibitor Therapy Among Patients With MCL
01/10/2024
Yucai Wang, MD, PhD
At the 65th ASH Annual Meeting, Yucai Wang, MD, PhD, discusses trial findings that first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy yielded efficacious outcomes among patients with mantle cell...
At the 65th ASH Annual Meeting, Yucai Wang, MD, PhD, discusses trial findings that first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy yielded efficacious outcomes among patients with mantle cell...
At the 65th ASH Annual Meeting,...
01/10/2024
Oncology
Bijal Shah, MD
Conference Coverage
Recent Breakthroughs in the Mantle Cell Lymphoma Treatment Landscape
01/08/2024
Bijal D. Shah, MD
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the...
01/08/2024
Oncology
Robert Rifkin, MD, Rocky Mountain Cancer Centers
Conference Coverage
Analyzing Outpatient Administration and Step-Up Dosing of Teclistamab Among Patients With Multiple Myeloma
01/05/2024
Robert M. Rifkin, MD, FACP
At the 65th American Society of Hematology Annual Meeting in San Diego, California, Robert M Rifkin, MD, discusses a study analyzing the outpatient administration of step-up doses of BCMA-targeting bispecific antibody teclistamab.
At the 65th American Society of Hematology Annual Meeting in San Diego, California, Robert M Rifkin, MD, discusses a study analyzing the outpatient administration of step-up doses of BCMA-targeting bispecific antibody teclistamab.
At the 65th American Society of...
01/05/2024
Oncology
Douglas Tremblay, MD
Conference Coverage
Examining Predictors of Emergent Thrombocytopenia After Ruxolitinib Treatment Among Patients With Myelofibrosis
01/03/2024
Douglas Tremblay, MD
At the ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.
At the ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.
At the ASH Annual Meeting,...
01/03/2024
Oncology
Talha Badar, MD
Conference Coverage
Hypomethylating Agent Monotherapy Compared With Hypomethylating Agent Plus Venetoclax Regimen Among Patients With Untreated TP53-Mutated AML
01/03/2024
Talha Badar, MD
At the 65th ASH Annual Meeting, Talha Badar, MD, discusses a retrospective study on the efficacy of venetoclax combined with hypomethylating agent (HMA) therapy vs HMA monotherapy for patients with TP53-mutated acute myeloid leukemia.
At the 65th ASH Annual Meeting, Talha Badar, MD, discusses a retrospective study on the efficacy of venetoclax combined with hypomethylating agent (HMA) therapy vs HMA monotherapy for patients with TP53-mutated acute myeloid leukemia.
At the 65th ASH Annual Meeting,...
01/03/2024
Oncology
Shernan G Holtan, MD, University of Minnesota
Conference Coverage
Selective Oral AURKA Inhibitor for Graft-Versus-Host Disease and Relapse Prophylaxis Following Allogeneic HCT
12/21/2023
Shernan Holtan, MD
At the 2023 ASH Annual Meeting, Shernan G Holtan, MD, shares data from a trial of post-transplant cyclophosphamide plus sirolimus combined with VIC-1911, a selective oral AURKA inhibitor, for patients with GVHD and relapse prophylaxis after...
At the 2023 ASH Annual Meeting, Shernan G Holtan, MD, shares data from a trial of post-transplant cyclophosphamide plus sirolimus combined with VIC-1911, a selective oral AURKA inhibitor, for patients with GVHD and relapse prophylaxis after...
At the 2023 ASH Annual Meeting,...
12/21/2023
Oncology
Ryan Lynch, MD, Fred Hutch Cancer Center
Videos
Evaluating Early Complete Responses of Mosunetuzumab Monotherapy for Patients With Previously Untreated Follicular Lymphoma and MZL
12/21/2023
Ryan Lynch, MD
At the 65th ASH Annual Meeting, Ryan C Lynch, MD, presented data on the high complete response rates of mosunetuzumab in previously untreated patients with follicular lymphoma and marginal zone lymphoma and only low-grade cytokine release...
At the 65th ASH Annual Meeting, Ryan C Lynch, MD, presented data on the high complete response rates of mosunetuzumab in previously untreated patients with follicular lymphoma and marginal zone lymphoma and only low-grade cytokine release...
At the 65th ASH Annual Meeting,...
12/21/2023
Oncology
Claire Harrison, MD, FRCP, Guy’s and St. Thomas’ NHS Foundation Trust
Conference Coverage
Ruxolitinib Therapy Demonstrates Reduced JAK2 Allele Burden and Improvement in Hematocrit Control and Symptom Burden for Patients With PV
12/21/2023
Claire Harrison, MD
At the 65th ASH Annual Meeting in San Diego, California, Claire Harrison, MD, FRCP discussed a pooled efficacy analysis that provided further evidence of the benefit of ruxolitinib treatment for patients with polycythemia vera, with or...
At the 65th ASH Annual Meeting in San Diego, California, Claire Harrison, MD, FRCP discussed a pooled efficacy analysis that provided further evidence of the benefit of ruxolitinib treatment for patients with polycythemia vera, with or...
At the 65th ASH Annual Meeting...
12/21/2023
Oncology
Pankit Vachhani, MD, O’Neal Comprehensive Cancer Center
Conference Coverage
Platelet Count Response Among Patients With Cytopenic Myelofibrosis Treated With Pacritinib
12/21/2023
Pankit Vachhani, MD
At the 65th ASH Annual Meeting in San Diego, California, Pankit Vachhani, MD, presented data that platelet count improvement occurred in a subset of patients with myelofibrosis treated with pacritinib.
At the 65th ASH Annual Meeting in San Diego, California, Pankit Vachhani, MD, presented data that platelet count improvement occurred in a subset of patients with myelofibrosis treated with pacritinib.
At the 65th ASH Annual Meeting...
12/21/2023
Oncology
Nirav Shah, MD
Conference Coverage
Bispecific Lentiviral Anti-CD20/Anti-CD19 CAR T-Cells for R/R MCL
12/21/2023
Nirav R. Shah, MD
During the 2023 ASH Annual Meeting in San Diego, Nirav N Shah, MD, discussed the efficacy of dual-targeted lentiviral anti-CD20/anti-CD19 (LV20.19) CAR T-cells with an adaptive manufacturing process among patients with relapsed/refractory...
During the 2023 ASH Annual Meeting in San Diego, Nirav N Shah, MD, discussed the efficacy of dual-targeted lentiviral anti-CD20/anti-CD19 (LV20.19) CAR T-cells with an adaptive manufacturing process among patients with relapsed/refractory...
During the 2023 ASH Annual...
12/21/2023
Oncology
Craig A Portell, MD
Conference Coverage
Bendamustine, Rituximab, and Venetoclax Shows Promise Among Previously Untreated Older Patients With MCL
12/21/2023
Craig A. Portell, MD
At the 65th ASH Annual Meeting, Craig A Portell, MD, assessed the potential benefit of bendamustine, rituximab, and venetoclax as an initial treatment among older patients with mantle cell lymphoma, noting that results and safety precautions...
At the 65th ASH Annual Meeting, Craig A Portell, MD, assessed the potential benefit of bendamustine, rituximab, and venetoclax as an initial treatment among older patients with mantle cell lymphoma, noting that results and safety precautions...
At the 65th ASH Annual Meeting,...
12/21/2023
Oncology
Swetha Kambhampati, MD
Conference Coverage
Real-World Value of Brexucabtagene Autoleucel for Patients With R/R MCL Including High-Risk Features
12/20/2023
Swetha Kambhampati, MD
At the 65th ASH Annual Meeting, Swetha Kambhampati, MD, shares data on the real-world outcomes of brexucabtagene autoleucel treatment for patients with R/R mantle cell lymphoma, including high-risk subgroups.
At the 65th ASH Annual Meeting, Swetha Kambhampati, MD, shares data on the real-world outcomes of brexucabtagene autoleucel treatment for patients with R/R mantle cell lymphoma, including high-risk subgroups.
At the 65th ASH Annual Meeting,...
12/20/2023
Oncology
Emanuele Zucca, MD
Conference Coverage
Rituximab Plus Lenalidomide Yields Favorable Outcomes Compared to Standard Regimen for Patients With Follicular Lymphoma
12/20/2023
Emanuele Zucca, MD
At the 65th ASH Annual Meeting, Emanuele Zucca, MD, discussed long-term results from an updated analysis of the SAKK 35/10 trial, which indicated that rituximab plus lenalidomide therapy demonstrated durable efficacy among patients with...
At the 65th ASH Annual Meeting, Emanuele Zucca, MD, discussed long-term results from an updated analysis of the SAKK 35/10 trial, which indicated that rituximab plus lenalidomide therapy demonstrated durable efficacy among patients with...
At the 65th ASH Annual Meeting,...
12/20/2023
Oncology
Daniel Wolff, MD, University Hospital Regensburg
Conference Coverage
AGAVE-201 Trial Finds Axatilimab Yields Durable Responses for R/R Chronic GVHD Treatment
12/18/2023
Daniel Wolff, MD
At the 2023 ASH Annual Meeting in San Diego, Daniel Wolff, MD, presented phase 2 data on axatilimab treatment of patients with heavily pretreated R/R chronic GVHD, which yielded robust clinical activity and durable responses within 3 dose...
At the 2023 ASH Annual Meeting in San Diego, Daniel Wolff, MD, presented phase 2 data on axatilimab treatment of patients with heavily pretreated R/R chronic GVHD, which yielded robust clinical activity and durable responses within 3 dose...
At the 2023 ASH Annual Meeting...
12/18/2023
Oncology
Sylvain Garciaz, MD
Conference Coverage
Long-Term Survival Rates and Discontinuation of Venetoclax/Azacitidine for Responding Patients With AML
12/15/2023
Sylvain Garciaz, MD
At the 65th ASH Annual Meeting, Sylvain Garciaz, MD, shared insights on the potential benefit of stopping venetoclax and/or azacytidine treatment for responding patients with acute myeloid leukemia.
At the 65th ASH Annual Meeting, Sylvain Garciaz, MD, shared insights on the potential benefit of stopping venetoclax and/or azacytidine treatment for responding patients with acute myeloid leukemia.
At the 65th ASH Annual Meeting,...
12/15/2023
Oncology
Ibrahim Aldoss, MD
Conference Coverage
Augment-101 Study Shows Revumenib Yields High Overall Response Rate for Patients With Heavily Pretreated KMT2Ar Acute Leukemia
12/13/2023
Ibrahim Aldoss, MD
At the 65th ASH Annual Meeting, Ibrahim Aldoss, MD, shared phase 2 results on the value of revumenib monotherapy among patients with heavily pretreated, relapsed/refractory KMT2Ar acute leukemia.
At the 65th ASH Annual Meeting, Ibrahim Aldoss, MD, shared phase 2 results on the value of revumenib monotherapy among patients with heavily pretreated, relapsed/refractory KMT2Ar acute leukemia.
At the 65th ASH Annual Meeting,...
12/13/2023
Oncology
Oluwatobi Odetola, MD,
Conference Coverage
Promising Efficacy of Frontline Nivolumab in Combination With R-CHOP for Patients With High-Risk DLBCL
12/12/2023
Oluwatobi Odetola, MD
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual...
12/12/2023
Oncology
Ira L Zackon, MD
Conference Coverage
Evaluating Effects of Racial Disparities on the Treatment of Patients With Chronic Lymphocytic Leukemia
12/12/2023
Ira Zackon, MD
At the 65th ASH Annual Meeting, Ira L Zackon, MD, presented real-world data from a large community oncology setting on the racial disparities observed in chronic lymphocytic leukemia treatment.
At the 65th ASH Annual Meeting, Ira L Zackon, MD, presented real-world data from a large community oncology setting on the racial disparities observed in chronic lymphocytic leukemia treatment.
At the 65th ASH Annual Meeting,...
12/12/2023
Oncology
Peihua Lu, MD
Conference Coverage
Naturally Selected CD7 CAR-T Cell Therapy Shows Promise for CD7-Positive AML Treatment
12/12/2023
Peihua Lu, MD
At the 65th ASH Annual Meeting, Peihua Lu, MD, highlights the promising efficacy and safety outcomes of NS7CAR T-cell therapy as a potential bridging therapy for patients with CD7-positive acute myeloid leukemia.
At the 65th ASH Annual Meeting, Peihua Lu, MD, highlights the promising efficacy and safety outcomes of NS7CAR T-cell therapy as a potential bridging therapy for patients with CD7-positive acute myeloid leukemia.
At the 65th ASH Annual Meeting,...
12/12/2023
Oncology
Martin Hutchings, MD, PhD, Rigshospitalet, Copenhagen
Videos
Glofitamab Plus Polatuzumab Vedotin Shows Frequent, Durable Responses and Manageable Safety Among Patients With R/R DLBCL
12/12/2023
Martin Hutchings
At the 65th ASH Annual Meeting, Martin Hutchings, MD, discussed updated data on the combination of glofitamab plus polatuzumab vedotin, which yielded high response rates and manageable safety among heavily pretreated patients with diffuse...
At the 65th ASH Annual Meeting, Martin Hutchings, MD, discussed updated data on the combination of glofitamab plus polatuzumab vedotin, which yielded high response rates and manageable safety among heavily pretreated patients with diffuse...
At the 65th ASH Annual Meeting,...
12/12/2023
Oncology
Narendranath Epperla, MD, MS
Conference Coverage
Analyzing Outcomes of Tafasitamab for the Treatment of R/R DLBCL Among Racial and Ethnic Minorities
12/11/2023
Narendranath Epperla, MD, MS
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting,...
12/11/2023
Oncology
Jeff Sharman, MD
Conference Coverage
Efficacy of Acalabrutinib With or Without Obinutuzumab Among Patients With Treatment-Naive CLL
12/11/2023
Jeff P. Sharman
At the 65th ASH Annual Meeting, Jeff Sharman, MD, presented findings from a 6-year follow-up of the ELEVATE-TN trial, which indicated that acalabrutinib with or without obinutuzumab continued to yield promising efficacy outcomes among...
At the 65th ASH Annual Meeting, Jeff Sharman, MD, presented findings from a 6-year follow-up of the ELEVATE-TN trial, which indicated that acalabrutinib with or without obinutuzumab continued to yield promising efficacy outcomes among...
At the 65th ASH Annual Meeting,...
12/11/2023
Oncology
Jennifer Brown, MD
Conference Coverage
Extended Follow-up of ALPINE Study Confirms Zanubrutinib Yields Progression-Free Survival Benefit vs Ibrutinib for R/R CLL/SLL
12/11/2023
Jennifer R. Brown, MD, PhD
At the 65th ASH Annual Meeting, Jennifer R Brown, MD, PhD, presented follow-up data which found that zanubrutinib continued to be a more efficacious treatment than ibrutinib for patients with R/R chronic lymphocytic leukemia/small lymphocytic...
At the 65th ASH Annual Meeting, Jennifer R Brown, MD, PhD, presented follow-up data which found that zanubrutinib continued to be a more efficacious treatment than ibrutinib for patients with R/R chronic lymphocytic leukemia/small lymphocytic...
At the 65th ASH Annual Meeting,...
12/11/2023
Oncology
Adrian Wiestner, MD
Conference Coverage
Analyzing Long-Term Outcomes of Ibrutinib Therapy for Patients With Chronic Lymphocytic Leukemia
12/11/2023
Adrian Wiestner, MD
At the 65th ASH Annual Meeting, Adrian Wiestner, MD, presented long-term follow-up data on a phase 2 study assessing the efficacy, safety, and depth of response of ibrutinib therapy for patients with CLL.
At the 65th ASH Annual Meeting, Adrian Wiestner, MD, presented long-term follow-up data on a phase 2 study assessing the efficacy, safety, and depth of response of ibrutinib therapy for patients with CLL.
At the 65th ASH Annual Meeting,...
12/11/2023
Oncology
Conference Coverage
R-CHOP Plus Tazemetostat Therapy Feasible Among Older Patients With Newly Diagnosed DLBCL
12/11/2023
Amber Denham
Efficacy results of the phase 2 TAZ R-CHOP study demonstrate that R-CHOP plus tazemetostat is a feasible treatment option among older patients with newly diagnosed diffuse large B-cell lymphoma.
Efficacy results of the phase 2 TAZ R-CHOP study demonstrate that R-CHOP plus tazemetostat is a feasible treatment option among older patients with newly diagnosed diffuse large B-cell lymphoma.
Efficacy results of the phase 2...
12/11/2023
Oncology
Conference Coverage
Odronextamab Monotherapy Shows Promising Antitumor Activity Among Patients With R/R DLBCL Post CAR T-Cell Therapy
12/11/2023
Amber Denham
Odronextamab monotherapy demonstrated encouraging antitumor activity and generally manageable safety among heavily pretreated patients with DLBCL who have progressed after CAR T-cell therapy, according to a phase 1 study.
Odronextamab monotherapy demonstrated encouraging antitumor activity and generally manageable safety among heavily pretreated patients with DLBCL who have progressed after CAR T-cell therapy, according to a phase 1 study.
Odronextamab monotherapy...
12/11/2023
Oncology
Conference Coverage
Glofitamab Plus Polatuzumab Vedotin Demonstrates Durable Responses Among Pretreated Patients With DLBCL, Including HGBCL
12/11/2023
Amber Denham
Glofitamab plus polatuzumab vedotin demonstrated high response rates and durable responses among heavily pre-treated patients with DLBCL, including patients with HGBCL and with prior CAR T-cell therapy, according to updated phase 1b/2 study...
Glofitamab plus polatuzumab vedotin demonstrated high response rates and durable responses among heavily pre-treated patients with DLBCL, including patients with HGBCL and with prior CAR T-cell therapy, according to updated phase 1b/2 study...
Glofitamab plus polatuzumab...
12/11/2023
Oncology
Paolo Ghia, MD, PhD
Conference Coverage
Importance of Assessing Minimal Residual Disease for R/R CLL Treatment
12/10/2023
Paolo Ghia
At the 65th ASH Annual Meeting, Paolo Ghia, MD, PhD, discusses the importance of assessing minimal residual disease when treating patients with relapsed/refractory chronic lymphocytic leukemia, particularly those with high-risk disease.
At the 65th ASH Annual Meeting, Paolo Ghia, MD, PhD, discusses the importance of assessing minimal residual disease when treating patients with relapsed/refractory chronic lymphocytic leukemia, particularly those with high-risk disease.
At the 65th ASH Annual Meeting,...
12/10/2023
Oncology
Charalambos Andreadis, MD 
Conference Coverage
Ibrutinib With Standard Conditioning and as Consolidation Therapy Following AutoHCT Well-Tolerated Among Patients With DLBCL
12/10/2023
Charalambos Andreadis, MD
At the 65th ASH Annual Meeting, Charalambos Andreadis, MD, presented on a phase 3 trial evaluating the efficacy of the addition of ibrutinib to autoHCT as conditioning and as consolidation therapy for patients with R/R ABC diffuse large...
At the 65th ASH Annual Meeting, Charalambos Andreadis, MD, presented on a phase 3 trial evaluating the efficacy of the addition of ibrutinib to autoHCT as conditioning and as consolidation therapy for patients with R/R ABC diffuse large...
At the 65th ASH Annual Meeting,...
12/10/2023
Oncology
Paolo Ghia, MD, PhD
Conference Coverage
Frontline Ibrutinib Plus Venetoclax Treatment Demonstrates Lasting Efficacy for Patients With CLL/SLL
12/10/2023
Paolo Ghia
At the 65th ASH Annual Meeting, Paolo Ghia, MD, PhD, highlights findings from up to 5 years of follow-up of the CAPTIVATE study, which demonstrates the durable efficacy of ibrutinib plus venetoclax as a first-line treatment among patients...
At the 65th ASH Annual Meeting, Paolo Ghia, MD, PhD, highlights findings from up to 5 years of follow-up of the CAPTIVATE study, which demonstrates the durable efficacy of ibrutinib plus venetoclax as a first-line treatment among patients...
At the 65th ASH Annual Meeting,...
12/10/2023
Oncology
Narendranath Epperla, MD, MS
Conference Coverage
Assessing the Optimal Ki-67 Cut-Off for Outcome Prediction Among Patients With Newly Diagnosed Mantle Cell Lymphoma
12/10/2023
Narendranath Epperla, MD, MS
At the 65th ASH Annual Meeting, Narendranath Epperla, MD, MS, shared insights on an optimal Ki-67 cut-off for patients with newly diagnosed mantle cell lymphoma, which was found to be prognostic for progression-free survival, but not overall...
At the 65th ASH Annual Meeting, Narendranath Epperla, MD, MS, shared insights on an optimal Ki-67 cut-off for patients with newly diagnosed mantle cell lymphoma, which was found to be prognostic for progression-free survival, but not overall...
At the 65th ASH Annual Meeting,...
12/10/2023
Oncology
Tycel Phillips, MD
Conference Coverage
Analyzing Response Rate and Line of Therapy Correlation Among Patients With R/R Follicular Lymphoma
12/10/2023
Tycel Phillips
At the 65th ASH Annual Meeting, Tycel Phillips, MD, discusses the relationship between the line of treatment, treatment site, and response rates among patients with follicular lymphoma with a poor prognosis, according to findings from a...
At the 65th ASH Annual Meeting, Tycel Phillips, MD, discusses the relationship between the line of treatment, treatment site, and response rates among patients with follicular lymphoma with a poor prognosis, according to findings from a...
At the 65th ASH Annual Meeting,...
12/10/2023
Oncology
Conference Coverage
Ibrutinib With and Following AutoHCT Well-Tolerated Among Patients With R/R Activated-B-Cell Subtype DLBCL
12/10/2023
Jordan Kadish
The addition of ibrutinib with and following autoHCT showed tolerability and may improve progression-free survival among patients with relapsed/refractory activated B-cell subtype diffuse large B-cell lymphoma, according to a primary analysis...
The addition of ibrutinib with and following autoHCT showed tolerability and may improve progression-free survival among patients with relapsed/refractory activated B-cell subtype diffuse large B-cell lymphoma, according to a primary analysis...
The addition of ibrutinib with...
12/10/2023
Oncology
Conference Coverage
Fedratinib Demonstrates Promising Efficacy in MDS/MPN and Chronic Neutrophilic Leukemia
12/09/2023
Janelle Bradley
Data from a phase 2 trial show fedratinib demonstrates promising clinical activity in patients with MDS/MPN and chronic neutrophilic leukemia.
Data from a phase 2 trial show fedratinib demonstrates promising clinical activity in patients with MDS/MPN and chronic neutrophilic leukemia.
Data from a phase 2 trial show...
12/09/2023
Oncology
Conference Coverage
Phase 3 IMerge Study Confirms Clinical Efficacy of Imetelstat in Lower-Risk MDS Across Risk Categories
12/09/2023
Janelle Bradley
Imetelstat improves red blood cell transfusion independence rates vs placebo in patients with lower-risk MDS relapsed/refractory to erythropoiesis-stimulating agents across different subgroups, according to data from the IMerge phase 3 study.
Imetelstat improves red blood cell transfusion independence rates vs placebo in patients with lower-risk MDS relapsed/refractory to erythropoiesis-stimulating agents across different subgroups, according to data from the IMerge phase 3 study.
Imetelstat improves red blood...
12/09/2023
Oncology
Conference Coverage
The Potential of Pelabresib Plus Ruxolitinib For Treating Patients With Myelofibrosis: The MANIFEST-2 Study
12/08/2023
Grace Taylor, MS, MA
A study by Raajit K. Rampal, MD, PhD, and colleagues investigates the effects of pelabresib + ruxolitinib in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.
A study by Raajit K. Rampal, MD, PhD, and colleagues investigates the effects of pelabresib + ruxolitinib in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.
A study by Raajit K. Rampal, MD,...
12/08/2023
Journal of Clinical Pathways
Conference Coverage
Ropeginterferon Alfa-2b Yielded Higher Hematologic and Molecular Response Rates Among Patients With Low-Risk vs High-Risk Polycythemia Vera
02/27/2023
Jordan Kadish
A phase 3 study found that implementation of ropeginterferon alfa-2b yielded significantly higher hematologic and molecular response rates among patients with polycythemia vera compared with hydroxyurea or other available treatments.
A phase 3 study found that implementation of ropeginterferon alfa-2b yielded significantly higher hematologic and molecular response rates among patients with polycythemia vera compared with hydroxyurea or other available treatments.
A phase 3 study found that...
02/27/2023
Oncology
News
Increased Likelihood of Blood Clots in Patients With Non-Proliferative CBC Thrombosis Myeloproliferative Neoplasms
02/27/2023
Jordan Kadish
A study found that patients with non-proliferative CBC thrombosis MPNs and driver mutations with non-splanchnic involvement have an increased risk for recurrent blood clots and progression of the disorder than those with splanchnic...
A study found that patients with non-proliferative CBC thrombosis MPNs and driver mutations with non-splanchnic involvement have an increased risk for recurrent blood clots and progression of the disorder than those with splanchnic...
A study found that patients with...
02/27/2023
Oncology
News
Iberdomide and Anti-CD20 Monoclonal Antibody Therapy May Benefit Patients with R/R Lymphoma
02/15/2023
Jordan Kadish
A phase 1/2 open-label study found that the combination of iberdomide monotherapy and anti-CD20 monoclonal antibody therapy for patients with R/R lymphoma yielded safe and effective results.
A phase 1/2 open-label study found that the combination of iberdomide monotherapy and anti-CD20 monoclonal antibody therapy for patients with R/R lymphoma yielded safe and effective results.
A phase 1/2 open-label study...
02/15/2023
Oncology
News
Odronextamab Demonstrated High Complete Response Rates in Patients With R/R Follicular Lymphoma
02/15/2023
Jordan Kadish
A pivotal phase 2 study found that the implementation of odronextamab for patients with relapsed/refractory follicular lymphoma grade 1 to 3a resulted in high complete response rates.
A pivotal phase 2 study found that the implementation of odronextamab for patients with relapsed/refractory follicular lymphoma grade 1 to 3a resulted in high complete response rates.
A pivotal phase 2 study found...
02/15/2023
Oncology
News
Luxeptinib Demonstrates Positive Antitumor Activity in Patients With Relapsed/Refractory B-Cell Malignancies
02/15/2023
Jordan Kadish
A phase 1a/b study found that luxeptinib resulted in positive antitumor activity post-ibrutinib relapse and did not lead to greater pharmacokinetics exposure in patients with R/R B-cell malignancies.
A phase 1a/b study found that luxeptinib resulted in positive antitumor activity post-ibrutinib relapse and did not lead to greater pharmacokinetics exposure in patients with R/R B-cell malignancies.
A phase 1a/b study found that...
02/15/2023
Oncology
News
Ruxolitinib or Fedratinib Combined With BMS-986158 Yielded Robust Sustained Viral Response in Patients With Myelofibrosis
02/14/2023
Jordan Kadish
A phase 1/2 dose escalation study found that a combination of BMS-986158 and ruxolitinib or fedratinib for patients with intermediate to high-risk myelofibrosis resulted in robust SVR, with deepened responses following continued treatment.
A phase 1/2 dose escalation study found that a combination of BMS-986158 and ruxolitinib or fedratinib for patients with intermediate to high-risk myelofibrosis resulted in robust SVR, with deepened responses following continued treatment.
A phase 1/2 dose escalation...
02/14/2023
Oncology
News
Lintuzumab-Ac225 With Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML
02/10/2023
Jordan Kadish
A phase 1 study found that the combination of Actimab-A (Lintuzumab-Ac225) and CLAG-M for patients with R/R AML with adverse features yielded a high response rate and MRD negativity.
A phase 1 study found that the combination of Actimab-A (Lintuzumab-Ac225) and CLAG-M for patients with R/R AML with adverse features yielded a high response rate and MRD negativity.
A phase 1 study found that the...
02/10/2023
Oncology
News
Subcutaneous Epcoritamab Combined With R-Dhax/C Yielded High ORR and CMR Rates in Patients With R/R DLBCL
02/10/2023
Jordan Kadish
An updated phase 1/2 dose escalation study found that a combination of subcutaneous epcoritamab and R-Dhax/C luxeptinib for patients with R/R diffuse b-cell lymphoma resulted in high ORR and CMR rates.
An updated phase 1/2 dose escalation study found that a combination of subcutaneous epcoritamab and R-Dhax/C luxeptinib for patients with R/R diffuse b-cell lymphoma resulted in high ORR and CMR rates.
An updated phase 1/2 dose...
02/10/2023
Oncology
News
ASTX727, Gilteritinib and Venetoclax Yielded High Remission Rates in Patients With R/R FLT3­ Mutated AML Unfit for Chemotherapy
02/10/2023
Jordan Kadish
A phase 1/2 study found that the combination of ASTX727, gilteritinib, and venetoclax yielded high remission rates for patients with R/R FLT3-mutated AML or who are unable to receive chemotherapy.
A phase 1/2 study found that the combination of ASTX727, gilteritinib, and venetoclax yielded high remission rates for patients with R/R FLT3-mutated AML or who are unable to receive chemotherapy.
A phase 1/2 study found that the...
02/10/2023
Oncology
News
Zanubrutinib Yields Superior PFS and ORR Compared to Ibrutinib for Patients With R/R CLL/SLL
02/09/2023
Jordan Kadish
A final analysis of the ALPINE randomized phase 3 study found that zanubritinib for patients with R/R CLL/SLL resulted in superior progression-free survival and overall remission rate compared with ibrutinib.
A final analysis of the ALPINE randomized phase 3 study found that zanubritinib for patients with R/R CLL/SLL resulted in superior progression-free survival and overall remission rate compared with ibrutinib.
A final analysis of the ALPINE...
02/09/2023
Oncology
News
Venetoclax With FLAG-IDA Yielded High Remission and Transition to Transplant Rates in Patients With R/R Acute Myeloid Leukemia
02/09/2023
Jordan Kadish
An updated phase 2b study found that the combination of venetoclax and FLAG-IDA therapy for patients with R/R AML resulted in deep remission and a high rate of transition to transplant.
An updated phase 2b study found that the combination of venetoclax and FLAG-IDA therapy for patients with R/R AML resulted in deep remission and a high rate of transition to transplant.
An updated phase 2b study found...
02/09/2023
Oncology
News
Inotuzumab Ozogamicin Induction Yielded High Remission Rates in Older Adults With De Novo Acute B-Lymphoblastic Leukemia
02/08/2023
Jordan Kadish
Inotuzumab ozogamicin induction therapy for adults with de novo acute B-lymphoblastic leukemia resulted in high remission rates, according to a phase 2 study.
Inotuzumab ozogamicin induction therapy for adults with de novo acute B-lymphoblastic leukemia resulted in high remission rates, according to a phase 2 study.
Inotuzumab ozogamicin induction...
02/08/2023
Oncology
News
Blinatumomab During Consolidation May Benefit Patients With High-Risk Ph-Negative BCP Acute Lymphoblastic Leukemia
02/08/2023
Jordan Kadish
Results from the GRAALL-2014/B 2-cohort comparison study presented at the 2022 ASH Annual Meeting & Exposition found blinatumomab during consolidation demonstrated a significant reduction of the risk of relapse among patients with high-risk...
Results from the GRAALL-2014/B 2-cohort comparison study presented at the 2022 ASH Annual Meeting & Exposition found blinatumomab during consolidation demonstrated a significant reduction of the risk of relapse among patients with high-risk...
Results from the GRAALL-2014/B...
02/08/2023
Oncology
Emma Searle, MD
Videos
Teclistamab Combined With Subcutaneous Daratumumab and Lenalidomide in Patients With Multiple Myeloma
02/05/2023
Emma Searle, MD, discusses treatment with teclistamab combined with subcutaneous daratumumab and lenalidomide for patients with multiple myeloma.
Emma Searle, MD, discusses treatment with teclistamab combined with subcutaneous daratumumab and lenalidomide for patients with multiple myeloma.
Emma Searle, MD, discusses...
02/05/2023
Oncology
Shaji K. Kumar, MD
Videos
Daratumumab Plus Lenalidomide and Dexamethasone Demonstrates Survival Benefits for Transplant-Ineligible Patients With Newly Diagnosed MM
02/05/2023
Shaji K. Kumar, MD, discusses the PFS and OS benefit seen with daratumumab added to lenalidomide and dexamethasone vs lenalidomide and dexamethasone alone in transplant-ineligible patients with newly diagnosed multiple myeloma.
Shaji K. Kumar, MD, discusses the PFS and OS benefit seen with daratumumab added to lenalidomide and dexamethasone vs lenalidomide and dexamethasone alone in transplant-ineligible patients with newly diagnosed multiple myeloma.
Shaji K. Kumar, MD, discusses...
02/05/2023
Oncology
Kevin H M Kuo, MD
Videos
Mitapivat Improves Markers of Erythropoietic Activity in Adults With Alpha- or Beta-Non-Transfusion-Dependent Thalassemia
02/05/2023
Kevin H.M. Kuo, MD, discusses the use of mitapivat to improve erythropoiesis in patients with alpha- or beta-non-transfusion-dependent thalassemia.
Kevin H.M. Kuo, MD, discusses the use of mitapivat to improve erythropoiesis in patients with alpha- or beta-non-transfusion-dependent thalassemia.
Kevin H.M. Kuo, MD, discusses...
02/05/2023
Oncology
Talha Munir, MD
Videos
Early MRD Clearance With Ibrutinib Plus Venetoclax Yields Sustained Clinical and MRD Responses in CLL
01/26/2023
Talha Munir, MD, discusses findings from an exploratory analysis of the phase 2 CLARITY trial, which showed that early MRD clearance with ibrutinib plus venetoclax yields sustained clinical and MRD responses in relapsed/refractory CLL.
Talha Munir, MD, discusses findings from an exploratory analysis of the phase 2 CLARITY trial, which showed that early MRD clearance with ibrutinib plus venetoclax yields sustained clinical and MRD responses in relapsed/refractory CLL.
Talha Munir, MD, discusses...
01/26/2023
Oncology
Muhammad Bilal Abid, MD
Videos
AlloHSCT Outcomes From Younger Matched Unrelated Donors vs Older Sibling Donors for AML
01/25/2023
Muhammad Bilal Abid, MD, discusses findings from a retrospective cohort study that compared outcomes of patients with AML who underwent alloHSCT with younger matched unrelated donors vs older matched sibling donors, showing a reduced risk of...
Muhammad Bilal Abid, MD, discusses findings from a retrospective cohort study that compared outcomes of patients with AML who underwent alloHSCT with younger matched unrelated donors vs older matched sibling donors, showing a reduced risk of...
Muhammad Bilal Abid, MD,...
01/25/2023
Oncology
Mark Litzow, MD
Videos
Blinatumomab Added to Consolidation Chemotherapy Improves OS in Newly Diagnosed ALL in MRD-Negative Remission
01/19/2023
Mark Litzow, MD, presents findings from a phase 3 trial showing the addition of blinatumomab to consolidation chemotherapy improves overall survival in patients with newly diagnosed B-lineage ALL.
Mark Litzow, MD, presents findings from a phase 3 trial showing the addition of blinatumomab to consolidation chemotherapy improves overall survival in patients with newly diagnosed B-lineage ALL.
Mark Litzow, MD, presents...
01/19/2023
Oncology
Srdan Verstovsek, MD
Videos
Momelotinib Demonstrates Consistent Long-Term Safety in Patients With Myelofibrosis
01/19/2023
Srdan Verstovsek, MD, discusses the long-term safety of momelotinib in patients with high- and intermediate-risk myelofibrosis, using data from 3 randomized controlled trials: SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM.
Srdan Verstovsek, MD, discusses the long-term safety of momelotinib in patients with high- and intermediate-risk myelofibrosis, using data from 3 randomized controlled trials: SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM.
Srdan Verstovsek, MD, discusses...
01/19/2023
Oncology
Nicholas Short, MD
Videos
Ponatinib Plus Blinatumomab Safe, Effective for Newly Diagnosed Philadelphia Chromosome-Positive ALL
01/19/2023
Nicholas Short, MD, presents findings from an analysis exploring simultaneous ponatinib and blinatumomab treatment for patients with newly diagnosed Philadelphia chromosome-positive ALL.
Nicholas Short, MD, presents findings from an analysis exploring simultaneous ponatinib and blinatumomab treatment for patients with newly diagnosed Philadelphia chromosome-positive ALL.
Nicholas Short, MD, presents...
01/19/2023
Oncology
Lucia Masarova, MD
Videos
Pegylated Interferon for Essential Thrombocythemia and Polycythemia Vera: Long-Term Durability of Responses and Disease Control
01/18/2023
Lucia Masarova, MD discusses findings from a phase 2 study showing long-term durability of responses and disease control with pegylated interferon in patients with essential thrombocythemia and polycythemia vera after 15 years.
Lucia Masarova, MD discusses findings from a phase 2 study showing long-term durability of responses and disease control with pegylated interferon in patients with essential thrombocythemia and polycythemia vera after 15 years.
Lucia Masarova, MD discusses...
01/18/2023
Oncology
Talha Munir, MD
Videos
Ibrutinib Plus Venetoclax Induces High Rates of MRD Negativity in IGHV-Unmutated CLL
01/16/2023
Talha Munir, MD, discusses findings from an updated interim analysis of the FLAIR study at the 2022 ASH Annual Meeting & Exposition in New Orleans, LA.
Talha Munir, MD, discusses findings from an updated interim analysis of the FLAIR study at the 2022 ASH Annual Meeting & Exposition in New Orleans, LA.
Talha Munir, MD, discusses...
01/16/2023
Oncology
Jan Burger, MD
Videos
First-Line Ibrutinib Plus Venetoclax for Patients With CLL: Video Roundtable
12/21/2022
Jan Burger, MD, PhD; Nitin Jain, MD; and Alessandra Ferrajoli, MD, discuss 4-year follow-up data from a phase 2 trial exploring combined ibrutinib and venetoclax for the first-line treatment of patients with CLL.
Jan Burger, MD, PhD; Nitin Jain, MD; and Alessandra Ferrajoli, MD, discuss 4-year follow-up data from a phase 2 trial exploring combined ibrutinib and venetoclax for the first-line treatment of patients with CLL.
Jan Burger, MD, PhD; Nitin Jain,...
12/21/2022
Oncology
Martin Dreyling, MD
Videos
Adding Ibrutinib to Induction or Maintenance With or Without AutoHSCT Shows Strong Efficacy, Acceptable Toxicity in MCL
12/21/2022
Martin Dreyling, MD, discusses data from the Triangle trial showing strong efficacy and acceptable safety with the addition of ibrutinib to induction or maintenance treatment with or without autoHSCT in younger patients with MCL.
Martin Dreyling, MD, discusses data from the Triangle trial showing strong efficacy and acceptable safety with the addition of ibrutinib to induction or maintenance treatment with or without autoHSCT in younger patients with MCL.
Martin Dreyling, MD, discusses...
12/21/2022
Oncology
Conference Coverage
Double Induction With Daunorubicin Shows No OS Benefit Over Single Induction in Newly Diagnosed AML
12/20/2022
Double induction with daunorubicin did not lead to an OS benefit over single induction in patients with newly diagnosed AML, according to a phase 3 trial presented at the 2022 ASH Annual Meeting & Exposition.
Double induction with daunorubicin did not lead to an OS benefit over single induction in patients with newly diagnosed AML, according to a phase 3 trial presented at the 2022 ASH Annual Meeting & Exposition.
Double induction with...
12/20/2022
Oncology
Srdan Verstovsek, MD
Videos
Ruxolitinib in Patients With Myelofibrosis Who Had Anemia or Thrombocytopenia: Real-World Outcomes
12/20/2022
Srdan Verstovsek, MD, presents data on real-world outcomes of the use of ruxolitinib in patients with myelofibrosis who had anemia or thrombocytopenia at the ASH 2022 Meeting in New Orleans, LA.
Srdan Verstovsek, MD, presents data on real-world outcomes of the use of ruxolitinib in patients with myelofibrosis who had anemia or thrombocytopenia at the ASH 2022 Meeting in New Orleans, LA.
Srdan Verstovsek, MD, presents...
12/20/2022
Oncology
Francesco Passamonti, MD
Videos
Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis
12/19/2022
Francesco Passamonti, MD, presents findings from a study on the combination of navitoclax and ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis at the 2022 ASH Annual Meeting & Exposition.
Francesco Passamonti, MD, presents findings from a study on the combination of navitoclax and ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis at the 2022 ASH Annual Meeting & Exposition.
Francesco Passamonti, MD,...
12/19/2022
Oncology
Conference Coverage
Epcoritamab Plus Rituximab and Lenalidomide Yields High Complete Metabolic Response Rate in Follicular Lymphoma
12/16/2022
Janelle Bradley
In patients with relapsed or refractory follicular lymphoma, epcoritamab combined with rituximab and lenalidomide demonstrated manageable safety and a high complete metabolic response rate, according to findings from a phase 1/2 study.
In patients with relapsed or refractory follicular lymphoma, epcoritamab combined with rituximab and lenalidomide demonstrated manageable safety and a high complete metabolic response rate, according to findings from a phase 1/2 study.
In patients with relapsed or...
12/16/2022
Oncology
Conference Coverage
Epcoritamab With Rituximab Plus Lenalidomide Demonstrates Promising Efficacy as First-Line Therapy for Patients With Follicular Lymphoma
12/16/2022
Epcoritamab combined with rituximab plus lenalidomide regimen showed encouraging efficacy as a first-line treatment for follicular lymphoma, according to data presented at the 2022 American Society of Hematology Annual Meeting and Exposition.
Epcoritamab combined with rituximab plus lenalidomide regimen showed encouraging efficacy as a first-line treatment for follicular lymphoma, according to data presented at the 2022 American Society of Hematology Annual Meeting and Exposition.
Epcoritamab combined with...
12/16/2022
Oncology
Conference Coverage
Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine for Treatment of Patients With R/R Follicular Lymphoma
12/16/2022
Usage of regimens of lenalidomide-rituximab or lenalidomide-rituximab-bendamustine were associated with less severe toxicity than expected in patients with R/R FL, according to analysis of a phase 2 trial.
Usage of regimens of lenalidomide-rituximab or lenalidomide-rituximab-bendamustine were associated with less severe toxicity than expected in patients with R/R FL, according to analysis of a phase 2 trial.
Usage of regimens of...
12/16/2022
Oncology
Ryan Jacobs, MD
Videos
Fixed-Duration Ibrutinib Plus Venetoclax Continues to Provide Deep, Durable Responses in CLL
12/16/2022
Ryan Jacobs, MD, discusses 5-year follow-up results from the CAPTIVATE study, which explored long-term outcomes after undetectable MRD with fixed-duration ibrutinib plus venetoclax in patients with CLL.
Ryan Jacobs, MD, discusses 5-year follow-up results from the CAPTIVATE study, which explored long-term outcomes after undetectable MRD with fixed-duration ibrutinib plus venetoclax in patients with CLL.
Ryan Jacobs, MD, discusses...
12/16/2022
Oncology
Anna Halpern, MD
Videos
Sorafenib Added to CLAG-M Produces High Rates of Complete Remission With MRD Negativity in AML and Myeloid Neoplasms
12/14/2022
Anna Halpern, MD, presents study findings showing the addition of sorafenib to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone (CLAG-M) produces high rates of complete remission with MRD negativity in newly diagnosed AML and...
Anna Halpern, MD, presents study findings showing the addition of sorafenib to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone (CLAG-M) produces high rates of complete remission with MRD negativity in newly diagnosed AML and...
Anna Halpern, MD, presents study...
12/14/2022
Oncology
Ryan Jacobs, MD
Videos
BTK Inhibitor Class Switching in the First-Line Treatment of CLL and SLL: Real-World Outcomes
12/13/2022
Ryan Jacobs, MD, discusses findings from a real-world analysis exploring BTK inhibitor-class switching in the first-line treatment of CLL and SLL, suggesting approximately 40% of patients who switch from ibrutinib to acalabrutinib experience...
Ryan Jacobs, MD, discusses findings from a real-world analysis exploring BTK inhibitor-class switching in the first-line treatment of CLL and SLL, suggesting approximately 40% of patients who switch from ibrutinib to acalabrutinib experience...
Ryan Jacobs, MD, discusses...
12/13/2022
Oncology
Conference Coverage
Rituximab Monotherapy Prolongs Time to Next Treatment in Low Tumor Burden Follicular Lymphoma
12/12/2022
Janelle Bradley
Long-term findings from the phase 3 Watch & Wait trial show that after a median follow-up of 12.3 years, rituximab is highly effective at delaying time to next treatment in patients with low tumor burden follicular lymphoma.
Long-term findings from the phase 3 Watch & Wait trial show that after a median follow-up of 12.3 years, rituximab is highly effective at delaying time to next treatment in patients with low tumor burden follicular lymphoma.
Long-term findings from the...
12/12/2022
Oncology
Abdulraheem Yacoub, MD
Videos
Efficacy and Safety of Parsaclisib Add-on to Ruxolitinib in Patients With Myelofibrosis
12/12/2022
At the 2022 ASH Annual Meeting and Exposition, Abdulraheem Yacoub, MD, presented final results from a phase 2 study on the efficacy and safety of adding parsaclisib to ruxolitinib therapy in patients with myelofibrosis.
At the 2022 ASH Annual Meeting and Exposition, Abdulraheem Yacoub, MD, presented final results from a phase 2 study on the efficacy and safety of adding parsaclisib to ruxolitinib therapy in patients with myelofibrosis.
At the 2022 ASH Annual Meeting...
12/12/2022
Oncology
Conference Coverage
Mosunetuzumab Monotherapy Continues to Demonstrate Efficacy, Safety for Elderly/Unfit Patients With DLBCL
12/12/2022
Allison Casey
For patients with DLBCL unable to tolerate first-line chemoimmunotherapy, mosunetuzumab monotherapy continues to demonstrate promising efficacy with durable response with manageable safety with longer follow-up.
For patients with DLBCL unable to tolerate first-line chemoimmunotherapy, mosunetuzumab monotherapy continues to demonstrate promising efficacy with durable response with manageable safety with longer follow-up.
For patients with DLBCL unable...
12/12/2022
Oncology
Conference Coverage
Odronextamab Exhibits Clinically Meaningful Efficacy and Manageable Safety in Relapsed/Refractory DLBCL
12/12/2022
Allison Casey
Findings from a phase 2 trial show that odronextamab demonstrates clinically meaningful efficacy, durable complete responses, and tolerable safety in patients with relapsed/refractory DLBCL.
Findings from a phase 2 trial show that odronextamab demonstrates clinically meaningful efficacy, durable complete responses, and tolerable safety in patients with relapsed/refractory DLBCL.
Findings from a phase 2 trial...
12/12/2022
Oncology
Ajari Chari, MD
Videos
Talquetamab Demonstrates Robust Efficacy, Manageable Safety in Patients With Heavily Pretreated R/R Multiple Myeloma
12/12/2022
At the 2022 ASH Annual Meeting and Exposition in New Orleans, LA, Ajai Chari, MD, discusses talquetamab efficacy and safety for patients with heavily pretreated relapsed/refractory multiple myeloma.
At the 2022 ASH Annual Meeting and Exposition in New Orleans, LA, Ajai Chari, MD, discusses talquetamab efficacy and safety for patients with heavily pretreated relapsed/refractory multiple myeloma.
At the 2022 ASH Annual Meeting...
12/12/2022
Oncology
Conference Coverage
Novel Agents Preferable to Standard Chemotherapy for Salvage Treatment in LBCL Progressing After CAR-T Therapy
12/11/2022
Janelle Bradley
Salvage treatment with polatuzumab-containing and bispecific antibody-based regimens is preferable to standard chemotherapy for patients with relapsed/refractory LBCL, according to study findings.
Salvage treatment with polatuzumab-containing and bispecific antibody-based regimens is preferable to standard chemotherapy for patients with relapsed/refractory LBCL, according to study findings.
Salvage treatment with...
12/11/2022
Oncology
Conference Coverage
Second-Line Polatuzumab Vedotin Plus RICE Yields High Response Rates in Relapsed/Refractory DLBCL
12/11/2022
Janelle Bradley
Second-line treatment with polatuzumab vedotin combined with rituximab, ifosfamide, carboplatin, and etoposide (RICE) yields encouraging responses in patients with relapsed/refractory DLBCL, according to a phase 2 study.
Second-line treatment with polatuzumab vedotin combined with rituximab, ifosfamide, carboplatin, and etoposide (RICE) yields encouraging responses in patients with relapsed/refractory DLBCL, according to a phase 2 study.
Second-line treatment with...
12/11/2022
Oncology
Conference Coverage
Tolerability and Efficacy of Azacitidine Plus Venetoclax Maintenance for Patients With AML
12/11/2022
Gina Tomaine
Low-dose azacitidine plus venetoclax demonstrates tolerability and feasibility as maintenance therapy for patients with AML, according to findings from a phase 2 trial with over 13 months of follow-up.
Low-dose azacitidine plus venetoclax demonstrates tolerability and feasibility as maintenance therapy for patients with AML, according to findings from a phase 2 trial with over 13 months of follow-up.
Low-dose azacitidine plus...
12/11/2022
Oncology
Conference Coverage
Venetoclax Plus Azacitidine Sustains OS Benefit for Patients With AML Ineligible for Intensive Chemotherapy
12/11/2022
Gina Tomaine
Long-term follow-up results from the phase 3 VIALE-A trial show sustained OS benefit with venetoclax plus azacitidine vs placebo plus azacitidine for patients with AML ineligible for intensive chemotherapy.
Long-term follow-up results from the phase 3 VIALE-A trial show sustained OS benefit with venetoclax plus azacitidine vs placebo plus azacitidine for patients with AML ineligible for intensive chemotherapy.
Long-term follow-up results from...
12/11/2022
Oncology
Dr Aroldi
Videos
Dr Aroldi Overviews CD24 ‘Don’t Eat Me’ Signal as a Potential Immunotherapeutic Target for MCL
03/29/2022
Andrea Aroldi, MD, overviews the CD24 ‘don’t eat me’ signal immune checkpoint blockade as a potential immunotherapeutic target for MCL, presented at ASH 2021.
Andrea Aroldi, MD, overviews the CD24 ‘don’t eat me’ signal immune checkpoint blockade as a potential immunotherapeutic target for MCL, presented at ASH 2021.
Andrea Aroldi, MD, overviews the...
03/29/2022
Oncology
Dr Uy
Videos
Dr Uy Reviews Low-Dose CPX-351 Plus Venetoclax for AML
03/09/2022
Geoffrey L. Uy, MD, reviews the safety and efficacy results from a phase 1b study on lower-dose CPX-351 plus venetoclax as a first-line treatment for patients with AML who are unfit for intensive chemotherapy, presented at ASH 2021.
Geoffrey L. Uy, MD, reviews the safety and efficacy results from a phase 1b study on lower-dose CPX-351 plus venetoclax as a first-line treatment for patients with AML who are unfit for intensive chemotherapy, presented at ASH 2021.
Geoffrey L. Uy, MD, reviews the...
03/09/2022
Oncology
Dr Constantine Tam
Videos
Dr Tam Overviews Zanubrutinib Versus Bendamustine-Rituximab in CLL/SLL
02/24/2022
Constantine Tam, MD, overviews results from the phase 3 SEQUOIA study on zanubrutinib versus bendamustine-rituximab in patients with treatment-naïve CLL/SLL, presented at ASH 2021.
Constantine Tam, MD, overviews results from the phase 3 SEQUOIA study on zanubrutinib versus bendamustine-rituximab in patients with treatment-naïve CLL/SLL, presented at ASH 2021.
Constantine Tam, MD, overviews...
02/24/2022
Oncology
Dr Madiha Iqbal
Videos
Dr Iqbal Highlights Calcineurin Inhibitor Free GVHD Prophylaxis for Patients Undergoing Allo-HCT
02/22/2022
Madiha Iqbal, MD, MBBS, discusses calcineurin inhibitor free GVHD prophylaxis for patients undergoing matched-related and matched-unrelated donor allogeneic HCT.
Madiha Iqbal, MD, MBBS, discusses calcineurin inhibitor free GVHD prophylaxis for patients undergoing matched-related and matched-unrelated donor allogeneic HCT.
Madiha Iqbal, MD, MBBS,...
02/22/2022
Oncology
Dr M
Videos
Dr McKinney on the Efficacy, Safety of Parsaclisib for R/R FL
02/15/2022
Matthew McKinney, MD, overviews the phase 2 CITADEL-203 study on parsaclisib in patients with R/R FL, presented at ASH 2021.
Matthew McKinney, MD, overviews the phase 2 CITADEL-203 study on parsaclisib in patients with R/R FL, presented at ASH 2021.
Matthew McKinney, MD, overviews...
02/15/2022
Oncology
Dr W
Videos
Dr Westin on Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and With Chemo for DLBCL
02/14/2022
Jason Westin, MD, discusses a phase 2 study on lenalidomide, tafasitamab, rituximab, and acalabrutinib alone or in combination with chemotherapy in patients with newly diagnosed DLBCL, presented at ASH 2021.
Jason Westin, MD, discusses a phase 2 study on lenalidomide, tafasitamab, rituximab, and acalabrutinib alone or in combination with chemotherapy in patients with newly diagnosed DLBCL, presented at ASH 2021.
Jason Westin, MD, discusses a...
02/14/2022
Oncology
Dr S
Videos
Dr Shah Highlights a First in-Human Study of YTB323 for Patients With R/R DLBCL
02/11/2022
Nirav Shah, MD, highlights a first in-human study of YTB323 for the treatment of patients with R/R DLBCL, presented at ASH 2021.
Nirav Shah, MD, highlights a first in-human study of YTB323 for the treatment of patients with R/R DLBCL, presented at ASH 2021.
Nirav Shah, MD, highlights a...
02/11/2022
Oncology
Anita Kumar, MD
Videos
Dr Kumar Highlights Safety, Efficacy of Obinutuzumab-Based Triplet Regimen for TP35-Mutant MCL
02/04/2022
Anita Kumar, MD, highlights preliminary safety and efficacy data from a phase 2 study on zanubrutinib, obinutuzumab, and venetoclax for untreated patients with MCL expressing a TP53 mutation.
Anita Kumar, MD, highlights preliminary safety and efficacy data from a phase 2 study on zanubrutinib, obinutuzumab, and venetoclax for untreated patients with MCL expressing a TP53 mutation.
Anita Kumar, MD, highlights...
02/04/2022
Oncology
Question mark
Quiz
Quiz: Will the S1918 Trial Impact the Standard of Care in DLBCL?
01/28/2022
True or false: The S1918 study has the potential to change the standard of care for patients with DLBCL.
True or false: The S1918 study has the potential to change the standard of care for patients with DLBCL.
True or false: The S1918 study...
01/28/2022
Oncology
Dr Everett Meyer
Videos
Orca-T Demonstrates Reduced Instances of GVHD for Hematologic Malignancies
01/24/2022
Dr Meyer on how Orca-T, an investigational cell therapy, led to high GVHD- and relapse-free survival following myeloablative conditioning for hematologic malignancies, presented at ASH 2021.
Dr Meyer on how Orca-T, an investigational cell therapy, led to high GVHD- and relapse-free survival following myeloablative conditioning for hematologic malignancies, presented at ASH 2021.
Dr Meyer on how Orca-T, an...
01/24/2022
Oncology
Question marks
Quiz
Quiz: Sotatercept for Anemic Patients With MPN-Associated MF
01/20/2022
True or false: A phase 2 study found sotatercept to be unsafe and ineffective for anemic patients with MPN-associated MF.
True or false: A phase 2 study found sotatercept to be unsafe and ineffective for anemic patients with MPN-associated MF.
True or false: A phase 2 study...
01/20/2022
Oncology
News
Sotatercept is Safe, Effective for MPN-Associated MF Anemia
01/20/2022
Treatment with sotatercept was found to be safe and effective for anemic patients with MPN-associated MF, according to phase 2 data presented at the 2021 ASH Annual Meeting.
Treatment with sotatercept was found to be safe and effective for anemic patients with MPN-associated MF, according to phase 2 data presented at the 2021 ASH Annual Meeting.
Treatment with sotatercept was...
01/20/2022
Oncology
a computer
Quiz
Quiz: Is This Monotherapy Safe, Well-Tolerated in Newly Diagnosed AML?
01/20/2022
According to data from a phase 2b study, which of the following therapies is generally safe and effective as a first-line therapy for AML patients who are unfit for intensive chemotherapy?
According to data from a phase 2b study, which of the following therapies is generally safe and effective as a first-line therapy for AML patients who are unfit for intensive chemotherapy?
According to data from a phase...
01/20/2022
Oncology
News
Aspacytarabine is Safe, Well-Tolerated for Patients With Newly Diagnosed AML
01/20/2022
Data from a phase 2b study on aspacytarabine, a prodrug of cytarabine, as a single agent for induction and consolidation therapy for patients with newly diagnosed AML who are unfit for standard induction chemotherapy, were presented at the...
Data from a phase 2b study on aspacytarabine, a prodrug of cytarabine, as a single agent for induction and consolidation therapy for patients with newly diagnosed AML who are unfit for standard induction chemotherapy, were presented at the...
Data from a phase 2b study on...
01/20/2022
Oncology
Dr Phillips
Videos
Glofitamab Step-Up Dosing Induces High Response Rates in MCL
01/19/2022
Tycel Phillips, MD, highlights how glofitamab step-up dosing induces high response rates in patients with R/R MCL that didn't respond to BTKi therapy. These data were presented at ASH 2021.
Tycel Phillips, MD, highlights how glofitamab step-up dosing induces high response rates in patients with R/R MCL that didn't respond to BTKi therapy. These data were presented at ASH 2021.
Tycel Phillips, MD, highlights...
01/19/2022
Oncology
Dr Jamy
Videos
Dr Jamy Highlights HMAs Plus Venetoclax for Patients With R/R AML
01/18/2022
Omer Hassan Jamy, MD, highlights a retrospective study on HMAs plus venetoclax versus intensive chemotherapy for patients with R/R AML. These data were presented at the 2021 ASH Annual Meeting.
Omer Hassan Jamy, MD, highlights a retrospective study on HMAs plus venetoclax versus intensive chemotherapy for patients with R/R AML. These data were presented at the 2021 ASH Annual Meeting.
Omer Hassan Jamy, MD, highlights...
01/18/2022
Oncology
Dr Holtan
Videos
Human Chorionic Gonadotropin/Epidermal Growth Factor as Treatment for aGVHD
01/13/2022
Shernan Holtan, MD, provides overview of a phase 2 study on human chorionic gonadotropin and epidermal growth factor as treatment for patients with aGVHD. These data were presented at ASH 2021.
Shernan Holtan, MD, provides overview of a phase 2 study on human chorionic gonadotropin and epidermal growth factor as treatment for patients with aGVHD. These data were presented at ASH 2021.
Shernan Holtan, MD, provides...
01/13/2022
Oncology
Dr Cowan
Videos
Dr Cowan Reviews the Benefit of Fully Human BCMA CAR-T Cells Plus GSI in R/R MM
01/13/2022
Andrew Cowan, MD, University of Washington, Fred Hutchinson Cancer Research Center, discusses the safety and efficacy of fully human BCMA CAR T Cells in combination with a Gamma Secretase Inhibitor to increase BCMA surface expression in...
Andrew Cowan, MD, University of Washington, Fred Hutchinson Cancer Research Center, discusses the safety and efficacy of fully human BCMA CAR T Cells in combination with a Gamma Secretase Inhibitor to increase BCMA surface expression in...
Andrew Cowan, MD, University of...
01/13/2022
Oncology
Dr Ghosh
Videos
Dr Ghosh Overviews Glofitamab Plus R-CHOP for R/R NHL, Including FL, DLBCL
01/13/2022
Nilanjan Ghosh, MD, highlights preliminary results from a dose-escalation and safety run-in phase 1b study of glofitamab plus R-CHOP for patients with R/R NHL and previously untreated DLBCL, presented at ASH 2021.
Nilanjan Ghosh, MD, highlights preliminary results from a dose-escalation and safety run-in phase 1b study of glofitamab plus R-CHOP for patients with R/R NHL and previously untreated DLBCL, presented at ASH 2021.
Nilanjan Ghosh, MD, highlights...
01/13/2022
Oncology
Dr Shadman
Videos
Dr Shadman Discusses Safety and Efficacy of Third Generation CD20 Targeted CAR-T for R/R B-NHL, CLL
01/10/2022
Mayzar Shadman, MD, MPH, discusses the safety and efficacy of a third-generation CD20-targeted CAR-T therapy for relapsed/refractory B-NHL and CLL, presented at ASH 2021.
Mayzar Shadman, MD, MPH, discusses the safety and efficacy of a third-generation CD20-targeted CAR-T therapy for relapsed/refractory B-NHL and CLL, presented at ASH 2021.
Mayzar Shadman, MD, MPH,...
01/10/2022
Oncology
Dr Shadman
Videos
Dr Shadman Reviews Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant, R/R B-Cell Malignancies
01/10/2022
Mayzar Shadman, MD, MPH, Seattle Cancer Care Alliance, highlights phase 2 Study of zanubrutinib in BTK Inhibitor-Intolerant patients with relapsed/refractory B-Cell malignancies, presented at the 2021 ASH Annual Meeting.
Mayzar Shadman, MD, MPH, Seattle Cancer Care Alliance, highlights phase 2 Study of zanubrutinib in BTK Inhibitor-Intolerant patients with relapsed/refractory B-Cell malignancies, presented at the 2021 ASH Annual Meeting.
Mayzar Shadman, MD, MPH, Seattle...
01/10/2022
Oncology
Dr Laubach
Videos
Dr Laubach Reviews Phase 2 GRIFFIN Study Results in Newly Diagnosed MM
01/10/2022
Jacob Laubach, MD, MPP, Dana-Farber Cancer Institute, discusses new results from the Phase 2 GRIFFIN study of daratumumab as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the ASH 2021 Annual Meeting.
Jacob Laubach, MD, MPP, Dana-Farber Cancer Institute, discusses new results from the Phase 2 GRIFFIN study of daratumumab as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the ASH 2021 Annual Meeting.
Jacob Laubach, MD, MPP,...
01/10/2022
Oncology
?
Test Your Knowledge
Quiz: Does This Monotherapy Induce High CR/CRi Rates in AML?
01/10/2022
True or false: Gilteritinib monotherapy induces a high CR/CRi rate in older newly-diagnosed patients with FLT3-mutated AML.
True or false: Gilteritinib monotherapy induces a high CR/CRi rate in older newly-diagnosed patients with FLT3-mutated AML.
True or false: Gilteritinib...
01/10/2022
Oncology
News
Gilteritinib Monotherapy Induces High Rate of Complete Response in FLT3-Mutated AML
01/10/2022
Data from the phase 2/1b sub-study of the Beat AML Master Trial were presented at the 2021 ASH Annual Meeting and assessed the efficacy of gilteritinib monotherapy with the addition of decitabine in non-responders in older newly diagnosed...
Data from the phase 2/1b sub-study of the Beat AML Master Trial were presented at the 2021 ASH Annual Meeting and assessed the efficacy of gilteritinib monotherapy with the addition of decitabine in non-responders in older newly diagnosed...
Data from the phase 2/1b...
01/10/2022
Oncology
News
Comparing R-MiniCHOP With or Without Azacitidine in Patients With Lymphomas, Including DLBCL
01/10/2022
A randomized study of R-miniCHOP with or without oral azacitidine in patients with newly diagnosed DLBCL, grade 3B FL, transformed lymphoma, and high-grade B-cell lymphomas with MTC and BCL2 and/or BCL6 rearrangements, was presented at the...
A randomized study of R-miniCHOP with or without oral azacitidine in patients with newly diagnosed DLBCL, grade 3B FL, transformed lymphoma, and high-grade B-cell lymphomas with MTC and BCL2 and/or BCL6 rearrangements, was presented at the...
A randomized study of R-miniCHOP...
01/10/2022
Oncology
idea
Test Your Knowledge
Quiz: Tisagenlecleucel Therapy in Patients With High-Risk R/R FL
01/06/2022
True or false: Tisagenlecleucel induces high response rates in adult patients with high-risk R/R FL.
True or false: Tisagenlecleucel induces high response rates in adult patients with high-risk R/R FL.
True or false: Tisagenlecleucel...
01/06/2022
Oncology
News
Tisagenlecleucel Therapy Produces High Response Rates in Patients With High-Risk R/R FL
01/06/2022
Efficacy data of tisagenlecleucel in adult patients with high-risk R/R FL were presented at the 2021 ASH Annual Meeting to update results from the overall population at a median follow-up of 17 months and report a subgroup analysis of...
Efficacy data of tisagenlecleucel in adult patients with high-risk R/R FL were presented at the 2021 ASH Annual Meeting to update results from the overall population at a median follow-up of 17 months and report a subgroup analysis of...
Efficacy data of...
01/06/2022
Oncology
News
Frontline Therapy With RCVP has Similar Outcomes to Bendamustine-Rituximab in Patients With Treatment-Naïve WM
01/05/2022
Data from a real-world population-based analysis of frontline therapy with bendamustine-rituximab in patients with TN WM were presented at the 2021 ASH Annual Meeting to evaluate outcomes in TN-WM patients comparing BR with the combination of...
Data from a real-world population-based analysis of frontline therapy with bendamustine-rituximab in patients with TN WM were presented at the 2021 ASH Annual Meeting to evaluate outcomes in TN-WM patients comparing BR with the combination of...
Data from a real-world...
01/05/2022
Oncology
News
EFS is a Surrogate Endpoint for Long-Term OS in Patients With Refractory LBCL
01/04/2022
Data from a pivotal study of axicabtagene ciloleucel, an autologous anti-CD19 CAR T-cell therapy approved for the treatment of patients with R/R LBCL with ≥ 2 prior systemic therapies, was presented at the 2021 ASH Annual Meeting to highlight...
Data from a pivotal study of axicabtagene ciloleucel, an autologous anti-CD19 CAR T-cell therapy approved for the treatment of patients with R/R LBCL with ≥ 2 prior systemic therapies, was presented at the 2021 ASH Annual Meeting to highlight...
Data from a pivotal study of...
01/04/2022
Oncology
News
Acalabrutinib Plus AZD9150 is Safe and Effective in Patients With R/R DLBCL
01/04/2022
Data of the combination of acalabrutinib and AZD9150 in patients with R/R DLBCL from a phase 1 study were presented at the 2021 ASH Annual Meeting.
Data of the combination of acalabrutinib and AZD9150 in patients with R/R DLBCL from a phase 1 study were presented at the 2021 ASH Annual Meeting.
Data of the combination of...
01/04/2022
Oncology
News
Phase 1b Trial Shows Safety of CD19-7x19 CAR-T Cells in Combination With Anti-PD-1 Antibody for R/R DLBCL
01/04/2022
Data of CD19-7x19 CAR-T cells plus anti-PD-1 antibody from a groundbreaking clinical trial were presented at the 2021 ASH Annual Meeting to highlight the safety and efficacy of this new strategy.
Data of CD19-7x19 CAR-T cells plus anti-PD-1 antibody from a groundbreaking clinical trial were presented at the 2021 ASH Annual Meeting to highlight the safety and efficacy of this new strategy.
Data of CD19-7x19 CAR-T cells...
01/04/2022
Oncology
idea
Test Your Knowledge
Quiz: SWOG Trials Highlight Extranodal Presentation in Limited Stage DLBCL
12/22/2021
Fill in the blank: Patients with LS DLBCL treated on 3 SWOG studies had ______ PFS and OS, regardless of extranodal versus nodal presentation.
Fill in the blank: Patients with LS DLBCL treated on 3 SWOG studies had ______ PFS and OS, regardless of extranodal versus nodal presentation.
Fill in the blank: Patients with...
12/22/2021
Oncology
medical
Test Your Knowledge
Quiz: What is the First FDA Approved Therapy for WM?
12/22/2021
True or false: Ibrutinib, a BTK inhibitor, is not the first FDA approved therapy for WM.
True or false: Ibrutinib, a BTK inhibitor, is not the first FDA approved therapy for WM.
True or false: Ibrutinib, a BTK...
12/22/2021
Oncology
Q mark
Test Your Knowledge
Quiz: Is ASCT a Feasible Treatment Option for Patients With WM?
12/22/2021
True or false: ASCT is a feasible treatment option for patients with relapsed WM.
True or false: ASCT is a feasible treatment option for patients with relapsed WM.
True or false: ASCT is a...
12/22/2021
Oncology
News
Extranodal Presentation is Not a Prognostic Marker in Limited Stage DLBCL
12/22/2021
Data analyses from the 3 sequential SWOG trials were presented at the 2021 ASH Annual Meeting to highlight extranodal presentation in limited stage DLBCL.
Data analyses from the 3 sequential SWOG trials were presented at the 2021 ASH Annual Meeting to highlight extranodal presentation in limited stage DLBCL.
Data analyses from the 3...
12/22/2021
Oncology
News
Dose Reductions of Ibrutinib Result from Intolerable Side Effects for WM
12/22/2021
Dose reduction data of the BTK-inhibitor ibrutinib, the first FDA approved therapy for WM, were presented at the 2021 ASH Annual Meeting.
Dose reduction data of the BTK-inhibitor ibrutinib, the first FDA approved therapy for WM, were presented at the 2021 ASH Annual Meeting.
Dose reduction data of the...
12/22/2021
Oncology
News
ASCT is a Feasible Treatment Option for Patients With WM
12/22/2021
Data from a real-world analysis on the role of ASCT in patients with WM was presented at the 2021 ASH Annual Meeting to review response outcomes, survival outcomes, and relapsed risk factors in patients with WM who underwent ASCT.
Data from a real-world analysis on the role of ASCT in patients with WM was presented at the 2021 ASH Annual Meeting to review response outcomes, survival outcomes, and relapsed risk factors in patients with WM who underwent ASCT.
Data from a real-world analysis...
12/22/2021
Oncology
Dr Burke
Videos
Dr Burke Highlights POLARIX Study on Pola-R-CHP vs R-CHOP for Patients With DLBCL
12/22/2021
John Burke, MD, discusses the phase 3 POLARIX study on pola-R-CHP versus R-CHOP for patients with previously untreated DLBCL. These data were presented at the 2021 ASH Annual Meeting.
John Burke, MD, discusses the phase 3 POLARIX study on pola-R-CHP versus R-CHOP for patients with previously untreated DLBCL. These data were presented at the 2021 ASH Annual Meeting.
John Burke, MD, discusses the...
12/22/2021
Oncology
Dr Burke
Videos
Dr Burke Discusses Umbralisib and Ublituximab Plus Bendamustine for Patients With R/R DLBCL
12/22/2021
John Burke, MD, discusses the efficacy and safety of umbralisib, ublituximab, and bendamustine for patients with R/R DLBCL. These data were presented at the 2021 ASH Annual Meeting.
John Burke, MD, discusses the efficacy and safety of umbralisib, ublituximab, and bendamustine for patients with R/R DLBCL. These data were presented at the 2021 ASH Annual Meeting.
John Burke, MD, discusses the...
12/22/2021
Oncology
News
cITP Associated With Familial Autoimmune Dysregulation
12/21/2021
A retrospective analysis suggests there is an association between patients with chronic ITP and a family history of autoimmune disorders or dysregulation.
A retrospective analysis suggests there is an association between patients with chronic ITP and a family history of autoimmune disorders or dysregulation.
A retrospective analysis...
12/21/2021
Oncology
medical
Test Your Knowledge
Quiz: Does Cirmtuzumab Plus Ibrutinib Demonstrate Clinical Benefit in MCL, CLL?
12/20/2021
True or false: Results from a phase 1b and 2 study found cirmtuzumab plus ibrutinib was not well tolerated in patients with R/R MCL or CLL.
True or false: Results from a phase 1b and 2 study found cirmtuzumab plus ibrutinib was not well tolerated in patients with R/R MCL or CLL.
True or false: Results from a...
12/20/2021
Oncology
News
Cirmtuzumab Plus Ibrutinib Demonstrates Clinical Benefit in MCL, CLL
12/20/2021
Phase 1b and 2 results of cirmtuzumab plus ibrutinib in patients with MCL or CLL were shared at the 2021 ASH Annual Meeting.
Phase 1b and 2 results of cirmtuzumab plus ibrutinib in patients with MCL or CLL were shared at the 2021 ASH Annual Meeting.
Phase 1b and 2 results of...
12/20/2021
Oncology
phone
Test Your Knowledge
Quiz: Does This Combo Therapy Show Safety in DLBCL?
12/17/2021
True or false: A phase 2 study of naratuximab emtansine found it has limited safety and efficacy for patients with DLBCL and other B-cell NHLs.
True or false: A phase 2 study of naratuximab emtansine found it has limited safety and efficacy for patients with DLBCL and other B-cell NHLs.
True or false: A phase 2 study...
12/17/2021
Oncology
?
Test Your Knowledge
Quiz: Are DOACs Associated With High Bleeding Rates in MPNs?
12/17/2021
True or false: DOAC’s are associated with high bleeding rates in patients with MPNs.
True or false: DOAC’s are associated with high bleeding rates in patients with MPNs.
True or false: DOAC’s are...
12/17/2021
Oncology
Computer
Test Your Knowledge
Quiz: Does This Inhibitor Therapy Yield Safety in Portal Hypertension MPNs?
12/16/2021
True or false: JAK inhibitor therapy is safe and effective in patients with MPNs complicated by PT without underlying ST.
True or false: JAK inhibitor therapy is safe and effective in patients with MPNs complicated by PT without underlying ST.
True or false: JAK inhibitor...
12/16/2021
Oncology
Dr G
Videos
Ibrutinib Plus Venetoclax Yields Deep Responses in Patients With CLL
12/16/2021
Paolo Ghia, MD, PhD, discusses 2-year follow-up results from the phase 2 CAPTIVATE study on first-line ibrutinib plus venetoclax for the treatment of patients with CLL. These data were presented at the 2021 ASH Annual Meeting.
Paolo Ghia, MD, PhD, discusses 2-year follow-up results from the phase 2 CAPTIVATE study on first-line ibrutinib plus venetoclax for the treatment of patients with CLL. These data were presented at the 2021 ASH Annual Meeting.
Paolo Ghia, MD, PhD, discusses...
12/16/2021
Oncology
dr k
Videos
Dr Kannan Highlights Subasumstat Plus Rituximab for CD20+ R/R NHL, Including DLBCL
12/16/2021
Karuppiah Kannan, PhD, highlights subasumstat in combination with rituximab for CD20+ R/R NHL, including DLBCL, and more. These data were presented at the 2021 ASH Annual Meeting.
Karuppiah Kannan, PhD, highlights subasumstat in combination with rituximab for CD20+ R/R NHL, including DLBCL, and more. These data were presented at the 2021 ASH Annual Meeting.
Karuppiah Kannan, PhD,...
12/16/2021
Oncology
Dr Treon
Videos
Dr Treon Highlights Mavorixafor Plus Ibrutinib for Patients With WM
12/16/2021
Steven P. Treon, MD, MA, PhD, discusses preliminary clinical data from a phase 1b study of mavorixafor in combination with ibrutinib for patients with WM with MYDD88 and CXCR4 mutations. These data were presented at the 2021 ASH Annual...
Steven P. Treon, MD, MA, PhD, discusses preliminary clinical data from a phase 1b study of mavorixafor in combination with ibrutinib for patients with WM with MYDD88 and CXCR4 mutations. These data were presented at the 2021 ASH Annual...
Steven P. Treon, MD, MA, PhD,...
12/16/2021
Oncology
John Mascarenhas, MD
Podcasts
Dr Mascarenhas Discusses AVID200 for Patients With Myelofibrosis
12/15/2021
John Mascarenhas, MD, provides insight on the treatment of myelofibrosis patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118), presented at the 2021 Annual ASH Meeting.
John Mascarenhas, MD, provides insight on the treatment of myelofibrosis patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118), presented at the 2021 Annual ASH Meeting.
John Mascarenhas, MD, provides...
12/15/2021
Oncology
dr C
Videos
Loncastuximab Teserine Plus Ibrutinib Shows Encouraging Anti-Tumor Activity in Patients With R/R DLBCL
12/15/2021
Carmelo Carlo-Stella, MD, discusses a phase 2 study on loncastuximab tesirine plus ibrutinib for patients with advanced DLBCL. These data were presented at the 2021 ASH Annual Meeting.
Carmelo Carlo-Stella, MD, discusses a phase 2 study on loncastuximab tesirine plus ibrutinib for patients with advanced DLBCL. These data were presented at the 2021 ASH Annual Meeting.
Carmelo Carlo-Stella, MD,...
12/15/2021
Oncology
Dr Wildgust
Podcasts
Dr Wildgust Reviews CASSIOPEIA Phase 3 Results in First-Line MM
12/15/2021
Mark Wildgust, PhD, highlights results from the Phase 3 CASSIOPEIA study of daratumumab as maintenance therapy in first-line MM treatment after stem cell transplant, presented at the 2021 Annual ASH Meeting.
Mark Wildgust, PhD, highlights results from the Phase 3 CASSIOPEIA study of daratumumab as maintenance therapy in first-line MM treatment after stem cell transplant, presented at the 2021 Annual ASH Meeting.
Mark Wildgust, PhD, highlights...
12/15/2021
Oncology
Dr Visco
Videos
Carlo Visco, MD, Discusses Rituximab, Bendamustine, and Cytarabine Plus Venetoclax for MCL
12/15/2021
Carlo Visco, MD, discusses rituximab, bendamustine, and cytarabine followed by venetoclax for high-risk elderly patients with MCL. These data were presented at the 2021 ASH Annual Meeting.
Carlo Visco, MD, discusses rituximab, bendamustine, and cytarabine followed by venetoclax for high-risk elderly patients with MCL. These data were presented at the 2021 ASH Annual Meeting.
Carlo Visco, MD, discusses...
12/15/2021
Oncology
Dr Wildgust
Podcasts
Dr Wildgust Discusses Racial Disparities in Treatment Patterns, Outcomes in MM
12/14/2021
Mark Wildgust, PhD, reviews real-world evidence examining potential healthcare disparities- highlighting patient characteristics, treatment patterns and outcomes for Black and White patients with multiple myeloma who initiated treatment with...
Mark Wildgust, PhD, reviews real-world evidence examining potential healthcare disparities- highlighting patient characteristics, treatment patterns and outcomes for Black and White patients with multiple myeloma who initiated treatment with...
Mark Wildgust, PhD, reviews...
12/14/2021
Oncology
Dr Cassaday
Dr Cassady Reviews Phase 4 Study Results of Inotuzumab Ozagamicin in R/R ALL
12/13/2021
Ryan Cassady, MD, SCCA, discusses the safety and efficacy of low-dose inotuzumab ozagamicin in patients with relapsed or refractory ALL, presented at the 2021 ASH Annual Meeting.
Ryan Cassady, MD, SCCA, discusses the safety and efficacy of low-dose inotuzumab ozagamicin in patients with relapsed or refractory ALL, presented at the 2021 ASH Annual Meeting.
Ryan Cassady, MD, SCCA,...
12/13/2021
Oncology
Dr Fonseca
Videos
Dr Fonseca Highlights Phase 2 GRIFFIN Study Results for Newly Diagnosed MM
12/13/2021
Rafael Fonseca, MD, Mayo Clinic, discusses new results from the Phase 2 GRIFFIN study of daratumumab, as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the 2021 ASH Annual Meeting.
Rafael Fonseca, MD, Mayo Clinic, discusses new results from the Phase 2 GRIFFIN study of daratumumab, as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the 2021 ASH Annual Meeting.
Rafael Fonseca, MD, Mayo Clinic,...
12/13/2021
Oncology
News
Naratuximab Emtansine Plus Rituximab Shows Safety in Patients With DLBCL and Other B-NHLs
12/08/2021
A phase 2 study of naratuximab emtansine plus rituximab found it has promising safety and efficacy for patients with DLBCL and other B-NHLs; these data were presented at the 2021 Annual ASH Meeting.
A phase 2 study of naratuximab emtansine plus rituximab found it has promising safety and efficacy for patients with DLBCL and other B-NHLs; these data were presented at the 2021 Annual ASH Meeting.
A phase 2 study of naratuximab...
12/08/2021
Oncology
Typing Q
Test Your Knowledge
Quiz: Is Entospletinib Plus Decitabine Associated With Poor CR and OS Rates?
12/07/2021
True or false: Results of the phase 2 sub-study for the Beat AML Master Trial found low CR and short OS rates associated with entospletinib plus decitabine in patients with AML.
True or false: Results of the phase 2 sub-study for the Beat AML Master Trial found low CR and short OS rates associated with entospletinib plus decitabine in patients with AML.
True or false: Results of the...
12/07/2021
Oncology
Q
Test Your Knowledge
Quiz: Is CIT Superior to These Venetoclax Combos in CLL?
12/06/2021
True or false: Results of the phase 3 GAIA CLL13 trial showed CIT produced superior rates of uMRD to venetoclax plus obinutuzumab and venetoclax plus obinutuzumab with ibrutinib for patients with CLL.
True or false: Results of the phase 3 GAIA CLL13 trial showed CIT produced superior rates of uMRD to venetoclax plus obinutuzumab and venetoclax plus obinutuzumab with ibrutinib for patients with CLL.
True or false: Results of the...
12/06/2021
Oncology
ee
Test Your Knowledge
Quiz: ASCT for the Treatment of Patients With Relapsed WM
12/03/2021
Is ASCT a feasible treatment option for patients with relapsed WM?
Is ASCT a feasible treatment option for patients with relapsed WM?
Is ASCT a feasible treatment...
12/03/2021
Oncology
News
ASCT Produces Deeper Responses Following Salvage Therapy in Relapsed WM
12/03/2021
According to a retrospective cohort analysis, ASCT is a feasible treatment option for patients with relapsed WM. These data were presented at the 2021 ASH Annual Meeting.
According to a retrospective cohort analysis, ASCT is a feasible treatment option for patients with relapsed WM. These data were presented at the 2021 ASH Annual Meeting.
According to a retrospective...
12/03/2021
Oncology
Franco
Conference Insider
Improved EFS With Blinatumomab vs Chemo for High-Risk First Relapse of BCP-ALL
12/03/2021
Study findings being presented at the ASH Annual Meeting suggest blinatumomab as a new standard-of-care consolidation therapy before alloHSCT in young patients with high-risk first-relapse BCP-ALL.
Study findings being presented at the ASH Annual Meeting suggest blinatumomab as a new standard-of-care consolidation therapy before alloHSCT in young patients with high-risk first-relapse BCP-ALL.
Study findings being presented...
12/03/2021
Oncology
q
Test Your Knowledge
Quiz: Efficacy and Safety of Parsaclisib in Patients With R/R FL
12/02/2021
According to data from a phase 2 study, parsaclisib was found to have an unfavorable safety profile for patients with R/R FL.
According to data from a phase 2 study, parsaclisib was found to have an unfavorable safety profile for patients with R/R FL.
According to data from a phase 2...
12/02/2021
Oncology
News
Parsaclisib Safe, Tolerable in Patients With R/R FL
12/02/2021
Parsaclisib was found to be safe and tolerable in patients with R/R FL, according to data from a phase 2 study which was presented at the 2021 Annual ASH Meeting.
Parsaclisib was found to be safe and tolerable in patients with R/R FL, according to data from a phase 2 study which was presented at the 2021 Annual ASH Meeting.
Parsaclisib was found to be safe...
12/02/2021
Oncology
pgr
Conference Coverage
Safety and Tolerability Analysis of Melflufen plus Dexamethasone in Patients with Relapsed/Refractory MM
12/01/2021
Melfulen plus dexamethasone shows consistent safety and tolerability when compared to pomalidomide and dexamethasone.
Melfulen plus dexamethasone shows consistent safety and tolerability when compared to pomalidomide and dexamethasone.
Melfulen plus dexamethasone...
12/01/2021
Oncology
idea
Test Your Knowledge
Quiz: Novel IMGN632-Based Triplet for Patients With R/R AML
12/01/2021
Does IMGN632 plus azacitidine and venetoclax yield anti-leukemia activity in patients with R/R AML?
Does IMGN632 plus azacitidine and venetoclax yield anti-leukemia activity in patients with R/R AML?
Does IMGN632 plus azacitidine...
12/01/2021
Oncology
News
Novel IMGN632-Based Triplet Yields Anti-Leukemia Activity for R/R AML
12/01/2021
Data from a phase 1b/2 study on IMGN632 in combination with azacitidine and venetoclax for patients with R/R AML were presented at the 2021 ASH Annual Meeting.
Data from a phase 1b/2 study on IMGN632 in combination with azacitidine and venetoclax for patients with R/R AML were presented at the 2021 ASH Annual Meeting.
Data from a phase 1b/2 study on...
12/01/2021
Oncology
Conference Insider
Combination Daratumumab and Dexamethasone Shows Promising Efficacy in Patients with RRMM and Severe Renal Impairment
12/01/2021
Daratumumab, in combination with dexamethasone, demonstrated promising efficacy with manageable safety in patients with RRMM and severe renal impairment or on dialysis.
Daratumumab, in combination with dexamethasone, demonstrated promising efficacy with manageable safety in patients with RRMM and severe renal impairment or on dialysis.
Daratumumab, in combination with...
12/01/2021
Oncology
mm
Conference Coverage
Ixazomib and Daratumumab Demonstrate Tolerable Safety for Elderly Patients with Relapsed/Refractory MM
12/01/2021
When given to elderly and frail patients with relapsed/refractory MM, combination ixazomib and daratumumab, without dexamethasone, showed favorable safety.
When given to elderly and frail patients with relapsed/refractory MM, combination ixazomib and daratumumab, without dexamethasone, showed favorable safety.
When given to elderly and frail...
12/01/2021
Oncology
quiz
Test Your Knowledge
Quiz: Enrollment Characteristics and Outcomes of US Patients With ALL
12/01/2021
A prospective Phase II clinical trial, known as ______, conducted by the U.S. Intergroup, demonstrated the feasibility of delivering a pediatric-inspired ALL regimen to newly diagnosed AYA ALL patients and found this approach to be superior...
A prospective Phase II clinical trial, known as ______, conducted by the U.S. Intergroup, demonstrated the feasibility of delivering a pediatric-inspired ALL regimen to newly diagnosed AYA ALL patients and found this approach to be superior...
A prospective Phase II clinical...
12/01/2021
Oncology
Conference Insider
Asciminib, DAS + Prednisone Combo Found Feasible in BCR-ABL1+ ALL
12/01/2021
Investigators sought to discover if ABL blockade with catalytic domain and allosteric inhibitors would be discovered as tolerable and effective in adult patients with BCR-ABL1+ ALL, to be presented at the 2021 Annual ASH Meeting.
Investigators sought to discover if ABL blockade with catalytic domain and allosteric inhibitors would be discovered as tolerable and effective in adult patients with BCR-ABL1+ ALL, to be presented at the 2021 Annual ASH Meeting.
Investigators sought to discover...
12/01/2021
Oncology
Test Your Knowledge
Quiz: Real-World Outcomes for R/R B-Cell ALL Treated with Tisagenlecleucel
12/01/2021
True or False: Updated registry data from ASH for pediatric and young adult patients with R/R ALL treated with tisagenlecleucel revealed that patients aged ≥18y had a greater disease burden and were more heavily pre-treated at baseline than...
True or False: Updated registry data from ASH for pediatric and young adult patients with R/R ALL treated with tisagenlecleucel revealed that patients aged ≥18y had a greater disease burden and were more heavily pre-treated at baseline than...
True or False: Updated registry...
12/01/2021
Oncology
mm
Conference Coverage
Ruxolitinib with Steroids Shows Promise in Patients with Relapsed/Refractory MM
11/30/2021
Ruxolitinib in combination with steroids is a promising treatment option for heavily pretreated patients with relapsed/refractory MM.
Ruxolitinib in combination with steroids is a promising treatment option for heavily pretreated patients with relapsed/refractory MM.
Ruxolitinib in combination with...
11/30/2021
Oncology
?
Test Your Knowledge
Quiz: Abatacept for Steroid-Refractory cGVHD
11/30/2021
True or false: Abatacept is associated with a 10 percent ORR in steroid-refractory cGVHD.
True or false: Abatacept is associated with a 10 percent ORR in steroid-refractory cGVHD.
True or false: Abatacept is...
11/30/2021
Oncology
q
Test Your Knowledge
Quiz: Does Orelabrutinib Show Safety in Patients With R/R WM?
11/30/2021
True or false: A phase 2 study found orelabrutinib had substantial efficacy in treating patients with R/R WM.
True or false: A phase 2 study found orelabrutinib had substantial efficacy in treating patients with R/R WM.
True or false: A phase 2 study...
11/30/2021
Oncology
News
Orelabrutinib Shows Favorable Safety and Tolerability in Patients With R/R WM
11/30/2021
A phase 2 study found orelabrutinib has substantial efficacy in treating patients with R/R WM; these data were presented at the 2021 ASH Annual Meeting.
A phase 2 study found orelabrutinib has substantial efficacy in treating patients with R/R WM; these data were presented at the 2021 ASH Annual Meeting.
A phase 2 study found...
11/30/2021
Oncology
mm
Conference Coverage
Venetoclax Plus Daratumumab and Dexamethasone Yields Tolerable Safety in Patients with Relapsed/Refractory MM
11/29/2021
Preliminary results from a phase 1/2 trial showed that venetoclax plus daratumumab and dexamethasone demonstrates a tolerable safety profile in patients with relapsed/refractory MM.
Preliminary results from a phase 1/2 trial showed that venetoclax plus daratumumab and dexamethasone demonstrates a tolerable safety profile in patients with relapsed/refractory MM.
Preliminary results from a phase...
11/29/2021
Oncology
Conference Coverage
Adding Venetoclax to Bortezomib and Dexamethasone Improves PFS in Patients with Relapsed/Refractory MM
11/28/2021
Results from the BELLINI trial showed adding venetoclax to bortezomib and dexamethasone showed improved PFS but increased mortality in patients with relapsed/refractory MM.
Results from the BELLINI trial showed adding venetoclax to bortezomib and dexamethasone showed improved PFS but increased mortality in patients with relapsed/refractory MM.
Results from the BELLINI trial...
11/28/2021
Oncology
Conference Coverage
Ixazomib plus Pomalidomide and Dexamethasone Shows Promise in R/R MM
11/23/2021
Adding ixazomib to pomalidomide and dexamethasone treatment was found to be well-tolerated and a promising treatment option for patients with relapsed and refractory multiple myeloma.
Adding ixazomib to pomalidomide and dexamethasone treatment was found to be well-tolerated and a promising treatment option for patients with relapsed and refractory multiple myeloma.
Adding ixazomib to pomalidomide...
11/23/2021
Oncology
News
Aspacytarabine Yields Reduced Toxicity as a First-Line Regimen in AML
11/23/2021
Aspacytarabine demonstrated reduced toxicity and efficacy as a cytotoxic first-line therapy for the treatment of patients with AML. All data were shown at the 2021 ASH Annual Meeting.
Aspacytarabine demonstrated reduced toxicity and efficacy as a cytotoxic first-line therapy for the treatment of patients with AML. All data were shown at the 2021 ASH Annual Meeting.
Aspacytarabine demonstrated...
11/23/2021
Oncology
News
Entospletinib Plus Decitabine Found to Cause Poor Responses in AML
11/23/2021
Entospletinib and decitabine were found to cause poor response and survival rates in newly diagnosed patients with AML. All data were shared at the 2021 ASH Annual Meeting.
Entospletinib and decitabine were found to cause poor response and survival rates in newly diagnosed patients with AML. All data were shared at the 2021 ASH Annual Meeting.
Entospletinib and decitabine...
11/23/2021
Oncology
q
Test Your Knowledge
Quiz: BRUIN Study on Pirtobrutinib in Patients With MCL
11/23/2021
True or false: Updated results from the BRUIN study found that pirtobrutinib has promising efficacy in heavily pretreated, poor-prognosis patients with MCL following multiple prior lines of therapy, including a covalent BTK inhibitor.
True or false: Updated results from the BRUIN study found that pirtobrutinib has promising efficacy in heavily pretreated, poor-prognosis patients with MCL following multiple prior lines of therapy, including a covalent BTK inhibitor.
True or false: Updated results...
11/23/2021
Oncology
News
Pirtobrutinib Shows Promising Efficacy in Heavily Pretreated MCL
11/23/2021
Updated results from the BRUIN study found that pirtobrutinib has promising efficacy in heavily pretreated, poor-prognosis patients with MCL following multiple prior lines of therapy, including a covalent BTK inhibitor; these data were...
Updated results from the BRUIN study found that pirtobrutinib has promising efficacy in heavily pretreated, poor-prognosis patients with MCL following multiple prior lines of therapy, including a covalent BTK inhibitor; these data were...
Updated results from the BRUIN...
11/23/2021
Oncology
qqq
Test Your Knowledge
Quiz: Umbralisib Plus Ublituximab for Patients With TN, PT CLL
11/22/2021
True or false: the phase 3 UNITY-CLL study found umbralisib plus ublituximab has a tolerable safety profile and prolonged PFS compared to CIT in patients with both TN and PT CLL.
True or false: the phase 3 UNITY-CLL study found umbralisib plus ublituximab has a tolerable safety profile and prolonged PFS compared to CIT in patients with both TN and PT CLL.
True or false: the phase 3...
11/22/2021
Oncology
News
Umbralisib Plus Ublituximab Yields Longer PFS in Patients With TN, PT CLL
11/22/2021
The phase 3 UNITY-CLL study found umbralisib plus ublituximab has a tolerable safety profile and prolonged PFS compared to CIT in patients with both TN and PT CLL; these data were presented at the 2021 ASH Annual Meeting.
The phase 3 UNITY-CLL study found umbralisib plus ublituximab has a tolerable safety profile and prolonged PFS compared to CIT in patients with both TN and PT CLL; these data were presented at the 2021 ASH Annual Meeting.
The phase 3 UNITY-CLL study...
11/22/2021
Oncology
News
Anti-CD40 Antibody Iomab-B Succeeds in Engraftment During Phase 3 Trial in AML
11/22/2021
The SIERRA trial highlights successful engraftment rates for patients with AML who crossed over from standard of care therapies.
The SIERRA trial highlights successful engraftment rates for patients with AML who crossed over from standard of care therapies.
The SIERRA trial highlights...
11/22/2021
Oncology
News
AI-Based Tool Developed to Assess Proliferation Centers in CLL and Sub-Groups
11/22/2021
An AI-based tool designed to assess proliferation centers in CLL, aCLL, and RT was showcased at the 2021 ASH Annual Meeting.
An AI-based tool designed to assess proliferation centers in CLL, aCLL, and RT was showcased at the 2021 ASH Annual Meeting.
An AI-based tool designed to...
11/22/2021
Oncology
News
GAIA Trial Shows Venetoclax Combo as Superior in CLL
11/22/2021
Co-primary analysis results of the phase 3 GAIA trial were presented at the 2021 ASH Annual Meeting to demonstrate high response rates with venetoclax treatment combinations in CLL.
Co-primary analysis results of the phase 3 GAIA trial were presented at the 2021 ASH Annual Meeting to demonstrate high response rates with venetoclax treatment combinations in CLL.
Co-primary analysis results of...
11/22/2021
Oncology
News
Ibrutinib Plus Venetoclax Achieve Deep Responses and High uMRD Rates in CLL
11/19/2021
Findings of the phase 2 CAPTIVATE study confirmed deep responses and potential in patients with CLL; these data were presented at the 2021 ASH Annual Meeting.
Findings of the phase 2 CAPTIVATE study confirmed deep responses and potential in patients with CLL; these data were presented at the 2021 ASH Annual Meeting.
Findings of the phase 2...
11/19/2021
Oncology
News
FLAIR Trial Demonstrates Superiority of Ibrutinib Plus Rituximab in CLL
11/19/2021
Results of the phase 3, ongoing FLAIR trial were presented at the 2021 ASH Annual Meeting to demonstrate the superiority of ibrutinib plus rituximab in CLL.
Results of the phase 3, ongoing FLAIR trial were presented at the 2021 ASH Annual Meeting to demonstrate the superiority of ibrutinib plus rituximab in CLL.
Results of the phase 3, ongoing...
11/19/2021
Oncology
Test Your Knowledge
Quiz: Is This Triplet Combo Effective for R/R WM?
11/17/2021
True or false: When used a second-line therapy, bendamustine, rituximab, and bortezomib, is not an effective treatment for patients with R/R WM.
True or false: When used a second-line therapy, bendamustine, rituximab, and bortezomib, is not an effective treatment for patients with R/R WM.
True or false: When used a...
11/17/2021
Oncology
News
Triplet Therapy Found Effective, Well-Tolerated in R/R WM
11/17/2021
A phase 2 trial found that bendamustine, rituximab, and bortezomib, used a second-line therapy, is an effective and well-tolerated salvage treatment for patients with R/R WM; these data were presented at the 2021 ASH Annual Meeting.
A phase 2 trial found that bendamustine, rituximab, and bortezomib, used a second-line therapy, is an effective and well-tolerated salvage treatment for patients with R/R WM; these data were presented at the 2021 ASH Annual Meeting.
A phase 2 trial found that...
11/17/2021
Oncology
qqq
Test Your Knowledge
Quiz: Is Orelabrutinib Effective for Patients With R/R CLL/SLL?
11/17/2021
True or false: A phase 2 study confirmed that orelabrutinib is effective for patients with R/R CLL/SLL.
True or false: A phase 2 study confirmed that orelabrutinib is effective for patients with R/R CLL/SLL.
True or false: A phase 2 study...
11/17/2021
Oncology
News
Orelabrutinib Monotherapy Found Effective For Patients With R/R CLL/SLL
11/17/2021
Findings from an updated study have further confirmed that orelabrutinib is effective in patients with R/R CLL/SLL; these data were presented at the 2021 ASH Annual Meeting.
Findings from an updated study have further confirmed that orelabrutinib is effective in patients with R/R CLL/SLL; these data were presented at the 2021 ASH Annual Meeting.
Findings from an updated study...
11/17/2021
Oncology
News
Entospletinib Plus Obinutuzumab Brings Favorable Outcomes in R/R CLL
11/16/2021
Findings of an investigation on the efficacy of entospletinib in combination with obinutuzumab for R/R CLL were presented at the 2021 ASH Annual Meeting.
Findings of an investigation on the efficacy of entospletinib in combination with obinutuzumab for R/R CLL were presented at the 2021 ASH Annual Meeting.
Findings of an investigation on...
11/16/2021
Oncology
News
Phase 3 SEQUOIA Trial Reveals PFS Benefit With Zanubrutinib in CLL
11/16/2021
Results of the phase 3 SEQUOIA trial were presented at the 2021 ASH Annual Meeting to highlight statistically significant improvements in PFS with zanubrutinib in CLL/SLL.
Results of the phase 3 SEQUOIA trial were presented at the 2021 ASH Annual Meeting to highlight statistically significant improvements in PFS with zanubrutinib in CLL/SLL.
Results of the phase 3 SEQUOIA...
11/16/2021
Oncology
News
Phase 3 and 2 Trials Highlight Feasibility of Pacritinib in MF
11/16/2021
Compassionate-use data of pacritinib after multiple trials for advanced MF were presented at the 2021 ASH Annual Meeting.
Compassionate-use data of pacritinib after multiple trials for advanced MF were presented at the 2021 ASH Annual Meeting.
Compassionate-use data of...
11/16/2021
Oncology
News
JAK and P13K Inhibitors Found Beneficial for Patients with MF, Low Platelet Counts
11/15/2021
Novel data from a subgroup analysis from a phase 2 trial of parsaclisib in patients with MF found JAK inhibitors and P13K inhibitors can be beneficial for those with low platelet counts; all data were featured at the 2021 ASH Meeting.
Novel data from a subgroup analysis from a phase 2 trial of parsaclisib in patients with MF found JAK inhibitors and P13K inhibitors can be beneficial for those with low platelet counts; all data were featured at the 2021 ASH Meeting.
Novel data from a subgroup...
11/15/2021
Oncology
News
FREEDOM Trial Finds Fedratinib Well Tolerated in MF; Offers Strategies To Mitigate GI AEs
11/15/2021
The phase 3b FREEDOM trial found fedratinib to be well tolerated in patients with MF previously treated with ruxolitinib, with the addition of prospective strategies to mitigate GI AEs. All data were presented at the 2021 ASH Meeting.
The phase 3b FREEDOM trial found fedratinib to be well tolerated in patients with MF previously treated with ruxolitinib, with the addition of prospective strategies to mitigate GI AEs. All data were presented at the 2021 ASH Meeting.
The phase 3b FREEDOM trial found...
11/15/2021
Oncology
writing
Test Your Knowledge
Quiz: Is This Acalabrutinib Combo Safe for Patients With R/R DLBCL?
11/15/2021
True or false: Acalabrutinib plus AXD9150 is safe and tolerable for patients with R/R DLBCL, but has limited efficacy.
True or false: Acalabrutinib plus AXD9150 is safe and tolerable for patients with R/R DLBCL, but has limited efficacy.
True or false: Acalabrutinib...
11/15/2021
Oncology
News
BTK, STAT3 Targeting Is Safe in R/R DLBCL, But Has Limited Efficacy
11/15/2021
A phase 1b study found acalabrutinib, plus AZD9150 is safe and tolerable for patients with R/R DLBCL, but has limited efficacy; these findings were presented at the 2021 ASH Annual Meeting.
A phase 1b study found acalabrutinib, plus AZD9150 is safe and tolerable for patients with R/R DLBCL, but has limited efficacy; these findings were presented at the 2021 ASH Annual Meeting.
A phase 1b study found...
11/15/2021
Oncology
qqq
Test Your Knowledge
Quiz: Does Tafasitamab Show Tolerability in DLBCL?
11/11/2021
True or false: Tafasitamab with or without lenalidomide and R-CHOP are both tolerable regimens for patients with DLBCL.
True or false: Tafasitamab with or without lenalidomide and R-CHOP are both tolerable regimens for patients with DLBCL.
True or false: Tafasitamab with...
11/11/2021
Oncology
Conference Insider
Tafasitamab With or Without Lenalidomide and R-CHOP Tolerable for Patients With DLBCL
11/11/2021
A phase 1B study shared at the 2021 Annual ASH Meeting reported on the safety and tolerability of tafasitamab in newly diagnosed DLBCL.
A phase 1B study shared at the 2021 Annual ASH Meeting reported on the safety and tolerability of tafasitamab in newly diagnosed DLBCL.
A phase 1B study shared at the...
11/11/2021
Oncology
quiz
Test Your Knowledge
Quiz: What Monotherapy Shows Safety in R/R MCL?
11/11/2021
Which of the following monotherapies showed rapid and durable responses, an acceptable safety profile, and was generally well tolerated in BTK inhibitor-naïve patients with R/R MCL?
Which of the following monotherapies showed rapid and durable responses, an acceptable safety profile, and was generally well tolerated in BTK inhibitor-naïve patients with R/R MCL?
Which of the following...
11/11/2021
Oncology
News
Parsaclisib Monotherapy Well Tolerated in Patients With R/R MCL
11/11/2021
Parsaclisib monotherapy showed rapid and durable response, an acceptable safety profile, and was generally well tolerated in BTK inhibitor-naïve patients with R/R MCL; these data were presented at the 2021 ASH Annual Meeting.
Parsaclisib monotherapy showed rapid and durable response, an acceptable safety profile, and was generally well tolerated in BTK inhibitor-naïve patients with R/R MCL; these data were presented at the 2021 ASH Annual Meeting.
Parsaclisib monotherapy showed...
11/11/2021
Oncology
qq
Test Your Knowledge
Quiz: Which Mutation Was Identified as High-Risk Bleeding Factor in MPN?
11/11/2021
Which of the following mutations was identified as a high-risk bleeding factor in MPN?
Which of the following mutations was identified as a high-risk bleeding factor in MPN?
Which of the following mutations...
11/11/2021
Oncology
qqqq
Test Your Knowledge
Quiz: Which Treatment Shows Continued Efficacy in TN and R/R WM?
11/10/2021
Which treatment demonstrated sustained efficacy in TN and R/R WM after a 2-year follow-up period?
Which treatment demonstrated sustained efficacy in TN and R/R WM after a 2-year follow-up period?
Which treatment demonstrated...
11/10/2021
Oncology
News
Tirabrutinib Shows Continued Efficacy in TN, R/R WM
11/10/2021
A report on 2 years of follow-up data from a phase 2 study found tirabrutinib continued to show efficacy in patients with TN or R/R WM; these findings were presented at the 2021 Annual ASH Meeting.
A report on 2 years of follow-up data from a phase 2 study found tirabrutinib continued to show efficacy in patients with TN or R/R WM; these findings were presented at the 2021 Annual ASH Meeting.
A report on 2 years of follow-up...
11/10/2021
Oncology
qq
Test Your Knowledge
Quiz: What Combo Regimen Shows a Promising Safety Profile in DLBCL?
11/09/2021
Which of the following combinations showed a promising safety profile in patients with DLBCL and other B-NHLs?
Which of the following combinations showed a promising safety profile in patients with DLBCL and other B-NHLs?
Which of the following...
11/09/2021
Oncology
qq
Test Your Knowledge
Quiz: Is Glofitamab Plus R-CHOP Tolerable for Patients With NHL, DLBCL?
11/08/2021
True or false: Glofitamab plus R-CHOP has tolerable safety in R/R NHL and previously untreated DLBCL?
True or false: Glofitamab plus R-CHOP has tolerable safety in R/R NHL and previously untreated DLBCL?
True or false: Glofitamab plus...
11/08/2021
Oncology
News
Glofitamab Plus R-CHOP Induces High Response Rates in NHL, DLBCL
11/08/2021
Findings from a phase 1b study found glofitamab plus R-CHOP induces high response rates with minimal CRS in patients with R/R NHL and previously untreated DLBCL. These data were presented at the 2021 ASH Annual Meeting.
Findings from a phase 1b study found glofitamab plus R-CHOP induces high response rates with minimal CRS in patients with R/R NHL and previously untreated DLBCL. These data were presented at the 2021 ASH Annual Meeting.
Findings from a phase 1b study...
11/08/2021
Oncology
Debates and Roundtables
Advancements in the Management of Patients With T-Cell Lymphoma
01/05/2021
In the third part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss notable advancements in the standard treatment of T-cell lymphoma.
In the third part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss notable advancements in the standard treatment of T-cell lymphoma.
In the third part of this...
01/05/2021
Oncology
Debates and Roundtables
The Clinical Significance of the ECHELON-2 Trial
01/05/2021
In the second part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss the background, findings, and importance of the ECHELON-2 clinical trial.
In the second part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss the background, findings, and importance of the ECHELON-2 clinical trial.
In the second part of this...
01/05/2021
Oncology
Debates and Roundtables
Challenges in the Treatment of T-Cell Lymphoma
01/05/2021
In the first part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss the challenges of treating patients with T-cell lymphoma.
In the first part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss the challenges of treating patients with T-cell lymphoma.
In the first part of this...
01/05/2021
Oncology
News
Guadecitabine Maintenance Therapy Shows Promise in High Risk MDS/AML Patients
01/01/2021
Guadecitabine, when given as maintenance therapy following allo-SCT, showed promising relapse-free survival rates with manageable safety in high-risk MDS/AML patients.
Guadecitabine, when given as maintenance therapy following allo-SCT, showed promising relapse-free survival rates with manageable safety in high-risk MDS/AML patients.
Guadecitabine, when given as...
01/01/2021
Oncology
Videos
Kevin Boyd, PhD, on the Safety, Efficacy of Belantamab Mafodotin With B-Vd for R/R MM
12/29/2020
Dr Boyd highlights details of the phase 3 DREAMM-7 trial, examining the efficacy and safety of belantamab mafodotin with bortezomib and dexamethasone for relapsed/refractory MM.
Dr Boyd highlights details of the phase 3 DREAMM-7 trial, examining the efficacy and safety of belantamab mafodotin with bortezomib and dexamethasone for relapsed/refractory MM.
Dr Boyd highlights details of...
12/29/2020
Oncology
jk
Conference Insider
Researchers Establish Recommended Phase 3 Dose of CAEL-101 for AL Amyloidosis
12/22/2020
Study findings presented at ASH 2020 propose a recommended dose of CAEL-101 for use in combination with CyBorD in phase 3 clinical trials of patients with AL amyloidosis.
Study findings presented at ASH 2020 propose a recommended dose of CAEL-101 for use in combination with CyBorD in phase 3 clinical trials of patients with AL amyloidosis.
Study findings presented at ASH...
12/22/2020
Oncology
Podcasts
Dr Burger Discusses Outcomes Following RESONATE-2 and iLLUMINATE Studies
12/17/2020
Jan A. Burger, MD, PhD, MD Anderson Cancer Center, discusses "Outcomes of First-Line Ibrutinib in Patients with CLL/SLL and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and...
Jan A. Burger, MD, PhD, MD Anderson Cancer Center, discusses "Outcomes of First-Line Ibrutinib in Patients with CLL/SLL and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and...
Jan A. Burger, MD, PhD, MD...
12/17/2020
Oncology
matthias
Conference Insider
Induction With Inotuzumab Ozogamicin Feasible for Patients With ALL
12/16/2020
Induction therapy with inotuzumab ozogamicin followed by conventional chemotherapy has shown promise in older patients with ALL.
Induction therapy with inotuzumab ozogamicin followed by conventional chemotherapy has shown promise in older patients with ALL.
Induction therapy with...
12/16/2020
Oncology
Interview
Real-World Outcomes of First-Line Ibrutinib vs CIT for CLL
12/16/2020
Lori Leslie, MD, discusses clinical outcomes among real-world patients with CLL given first-line therapy with ibrutinib or chemoimmunotherapy (CIT).
Lori Leslie, MD, discusses clinical outcomes among real-world patients with CLL given first-line therapy with ibrutinib or chemoimmunotherapy (CIT).
Lori Leslie, MD, discusses...
12/16/2020
Oncology
Videos
Julie Kanter, MD, Talks QoL Outcomes After Lentiglobin Gene Therapy for Sickle Cell Disease
12/15/2020
Dr Kanter discusses lentiglobin gene therapy for sickle cell disease, QoL data from ASH 2020, and how measuring outcomes for these patients can be improved.
Dr Kanter discusses lentiglobin gene therapy for sickle cell disease, QoL data from ASH 2020, and how measuring outcomes for these patients can be improved.
Dr Kanter discusses lentiglobin...
12/15/2020
Oncology
Conference Insider
Long-Lasting Remission With Dual Targeting CAR-T Therapy for R/R DLBCL
12/15/2020
Patients with relapsed/refractory DLBCL given AUTO3 (a CD19/22 dual targeting CAR-T therapy) plus pembrolizumab had durable responses.
Patients with relapsed/refractory DLBCL given AUTO3 (a CD19/22 dual targeting CAR-T therapy) plus pembrolizumab had durable responses.
Patients with...
12/15/2020
Oncology
News
ViPOR Yields Complete Response in Patients with R/R B-Cell NHL
12/15/2020
In a study of patients with relapsed/refractory B-Cell NHL, the ViPOR regimen led to complete responses, with no unexpected toxicities.
In a study of patients with relapsed/refractory B-Cell NHL, the ViPOR regimen led to complete responses, with no unexpected toxicities.
In a study of patients with...
12/15/2020
Oncology
aw
Conference Insider
Exploring Dosing Regimens of Sabatolimab Therapy for MDS/AML
12/14/2020
Study findings support further exploration of specific dosing regimens of sabatolimab in patients with intermediate- to very high-risk MDS/AML.
Study findings support further exploration of specific dosing regimens of sabatolimab in patients with intermediate- to very high-risk MDS/AML.
Study findings support further...
12/14/2020
Oncology
blood
Conference Insider
Inotuzumab Ozogamicin Yields Anti-Leukemia Activity in Young Patients With R/R ALL
12/11/2020
Single-agent inotuzumab ozogamicin demonstrated anti-leukemia activity in heavily pre-treated young patients with CD22+ relapsed/refractory ALL.
Single-agent inotuzumab ozogamicin demonstrated anti-leukemia activity in heavily pre-treated young patients with CD22+ relapsed/refractory ALL.
Single-agent inotuzumab...
12/11/2020
Oncology
Podcasts
Andreas Hochhaus, MD, Talks About the ASCEMBL Trial, Eliminating LSCs in CML
12/11/2020
In this podcast, Dr Hochhaus discusses the significance of the ASCEMBL trial, and proposes the question of how to eliminate persisting leukemic stem cells (LSCs) in CML.
In this podcast, Dr Hochhaus discusses the significance of the ASCEMBL trial, and proposes the question of how to eliminate persisting leukemic stem cells (LSCs) in CML.
In this podcast, Dr Hochhaus...
12/11/2020
Oncology
cc
Conference Insider
Initial Data Suggest P-BCMA-101 CAR-T Cells Safe for R/R MM
12/11/2020
Available clinical data presented at the ASH Annual meeting finds P-BCMA-101 CAR-T therapy, targeting BCMA, can produce significant efficacy with low toxicity in patients with relapsed/refractory multiple myeloma.
Available clinical data presented at the ASH Annual meeting finds P-BCMA-101 CAR-T therapy, targeting BCMA, can produce significant efficacy with low toxicity in patients with relapsed/refractory multiple myeloma.
Available clinical data...
12/11/2020
Oncology
Conference Insider
Paul Richardson, MD, Discusses Belantamab Mafodotin for Relapsed/Refractory MM
12/10/2020
Dr Richardson discusses belantamab mafodotin for targeting BCMA pathways in relapsed/refractory MM, and the DREAMM-5 trial of 4 novel combo therapies for this disease.
Dr Richardson discusses belantamab mafodotin for targeting BCMA pathways in relapsed/refractory MM, and the DREAMM-5 trial of 4 novel combo therapies for this disease.
Dr Richardson discusses...
12/10/2020
Oncology
Conference Insider
Avelumab Plus R-CHOP Effective for Newly Diagnosed DLBCL
12/10/2020
Avelumab plus R-CHOP yielded high rates of complete response with manageable toxicity in a cohort of patients with newly diagnosed DLBCL.
Avelumab plus R-CHOP yielded high rates of complete response with manageable toxicity in a cohort of patients with newly diagnosed DLBCL.
Avelumab plus R-CHOP yielded...
12/10/2020
Oncology
Videos
Anthony Mato, MD, Talks Real-World Biomarker Testing for CLL, SLL
12/09/2020
Dr Mato discusses real-world prognostic biomarker testing, treatment patterns and dosing among patients with CLL/SLL.
Dr Mato discusses real-world prognostic biomarker testing, treatment patterns and dosing among patients with CLL/SLL.
Dr Mato discusses real-world...
12/09/2020
Oncology
Videos
Prophylactic Tocilizumab Before Anti-CD19 CAR-T Therapy for R/R Lymphoma
12/09/2020
Paolo Caimi, MD, discusses findings from a study examining the use of prophylactic tocilizumab prior to anti-CD19 CAR-T therapy for relapsed/refractory lymphoma.
Paolo Caimi, MD, discusses findings from a study examining the use of prophylactic tocilizumab prior to anti-CD19 CAR-T therapy for relapsed/refractory lymphoma.
Paolo Caimi, MD, discusses...
12/09/2020
Oncology
Videos
Dr Tam Discusses Ibrutinib Therapy Plus Venetoclax for R/R MCL
12/07/2020
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, discusses highlights from, "Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study", presented...
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, discusses highlights from, "Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study", presented...
Constantine Tam, MBBS (Hons),...
12/07/2020
Oncology
Videos
Othman Al-Sawaf, MD, Discusses Results From the Phase 3 CLL14 Trial
12/07/2020
Othman Al-Sawaf, MD, University Hospital of Cologne, Germany, discusses highlights from the phase 3 CLL14 trial, which looked at venetoclax plus obinutuzumab therapy for chronic lymphocytic leukemia (CLL). These data were presented at the...
Othman Al-Sawaf, MD, University Hospital of Cologne, Germany, discusses highlights from the phase 3 CLL14 trial, which looked at venetoclax plus obinutuzumab therapy for chronic lymphocytic leukemia (CLL). These data were presented at the...
Othman Al-Sawaf, MD, University...
12/07/2020
Oncology
Videos
Michael Wang, MD, Talks LOXO-305 for MCL, WM
12/07/2020
In this video, Dr Wang discusses the use of LOXO-305, a highly selective BTK inhibitor, in patients with pretreated MCL, WM, and other NHLs.
In this video, Dr Wang discusses the use of LOXO-305, a highly selective BTK inhibitor, in patients with pretreated MCL, WM, and other NHLs.
In this video, Dr Wang discusses...
12/07/2020
Oncology
Conference Insider
Mosunetuzumab Safe, Effective for Elderly Patients With DLBCL
12/07/2020
Single-agent mosunetuzumab shows efficacy, remarkable safety, as a chemo-free option for previously untreated elderly/unfit patients with DLBCL.
Single-agent mosunetuzumab shows efficacy, remarkable safety, as a chemo-free option for previously untreated elderly/unfit patients with DLBCL.
Single-agent mosunetuzumab shows...
12/07/2020
Oncology
Videos
John Allan, MD, Talks Long-Term Efficacy of First-Line Ibrutinib for TP53-Mutated CLL
12/07/2020
In this video, John Allan, MD, Weill Cornell Medicine, discusses long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukemia with 4 years of follow-up in patients with TP53 aberrations.
In this video, John Allan, MD, Weill Cornell Medicine, discusses long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukemia with 4 years of follow-up in patients with TP53 aberrations.
In this video, John Allan, MD,...
12/07/2020
Oncology
Conference Insider
R-CHOP, Rituximab Maintenance Therapy Extend PFS in Patients With Newly Diagnosed FL
12/05/2020
Rituximab maintenance therapy significantly prolonged PFS in patients with newly diagnosed FL given R-CHOP versus rituximab plus bendamustine, according to data presented at ASH 2020.
Rituximab maintenance therapy significantly prolonged PFS in patients with newly diagnosed FL given R-CHOP versus rituximab plus bendamustine, according to data presented at ASH 2020.
Rituximab maintenance therapy...
12/05/2020
Oncology
Videos
Ajai Chari, MD, Talks Talquetamab for Relapsed/Refractory MM
12/05/2020
In this video, Dr Chari discusses the findings of a phase 1 trial examining the use of talquetamab in heavily pretreated patients with relapsed/refractory MM.
In this video, Dr Chari discusses the findings of a phase 1 trial examining the use of talquetamab in heavily pretreated patients with relapsed/refractory MM.
In this video, Dr Chari...
12/05/2020
Oncology
jr
Conference Insider
Venetoclax Plus Navitoclax and Chemo Effective for Lymphoblastic Lymphoma, ALL
12/03/2020
Venetoclax combined with navitoclax and chemo showed manageable safety and promising efficacy in heavily pretreated patients with ALL and lymphoblastic lymphoma.
Venetoclax combined with navitoclax and chemo showed manageable safety and promising efficacy in heavily pretreated patients with ALL and lymphoblastic lymphoma.
Venetoclax combined with...
12/03/2020
Oncology
medical
Conference Insider
Polatuzumab Vedotin Plus Venetoclax, Rituximab Shows Promise in R/R DLBCL
12/03/2020
Polatuzumab vedotin plus venetoclax with rituximab shows promise in the treatment of patients with R/R DLBCL, according to phase 1b/2 study findings.
Polatuzumab vedotin plus venetoclax with rituximab shows promise in the treatment of patients with R/R DLBCL, according to phase 1b/2 study findings.
Polatuzumab vedotin plus...
12/03/2020
Oncology
News
Ruxolitinib Plus Azacitidine Tolerable for Advanced Phase MPN, Post-MPN AML
12/02/2020
Ruxolitinib combined with azacitidine was a well-tolerated therapy option for patients with advanced phase MPN and post-MPN AML.
Ruxolitinib combined with azacitidine was a well-tolerated therapy option for patients with advanced phase MPN and post-MPN AML.
Ruxolitinib combined with...
12/02/2020
Oncology
Conference Insider
Triplet Therapy Superior to Doublet for Patients With Lenalidomide-Refractory MM
12/02/2020
Data being presented at the virtual 62nd ASH Annual Meeting and Exposition show that triplet therapy is superior to doublet therapy for the treatment of lenalidomide-refractory MM.
Data being presented at the virtual 62nd ASH Annual Meeting and Exposition show that triplet therapy is superior to doublet therapy for the treatment of lenalidomide-refractory MM.
Data being presented at the...
12/02/2020
Oncology
sh
Conference Insider
Frailty Tied to Increased 1-Year Mortality in Patients with Newly Diagnosed DLBCL
12/02/2020
According to data being presented at the virtual ASH Annual Meeting and Exposition, fragility in patients with DLBCL is significantly associated with 1-year mortality.
According to data being presented at the virtual ASH Annual Meeting and Exposition, fragility in patients with DLBCL is significantly associated with 1-year mortality.
According to data being...
12/02/2020
Oncology
Podcasts
Andreas Hochhaus, MD, on Asciminib vs Bosutinib for Pretreated CML-CP
11/30/2020
Dr Hochhaus discusses the use of asciminib versus bosutinib for the treatment of patients with CML-CP previously given ≥2 TKIs.
Dr Hochhaus discusses the use of asciminib versus bosutinib for the treatment of patients with CML-CP previously given ≥2 TKIs.
Dr Hochhaus discusses the use of...
11/30/2020
Oncology
Podcasts
Acalabrutinib Alone or in Combination With Obinutuzumab Improves PFS in Treatment-Naïve CLL
02/02/2020
Jeff Sharman, MD, discusses results from the ELEVATE TN trial, which led to the FDA approval of acalabrutinib for the management of patients with treatment-naïve CLL.
Jeff Sharman, MD, discusses results from the ELEVATE TN trial, which led to the FDA approval of acalabrutinib for the management of patients with treatment-naïve CLL.
Jeff Sharman, MD, discusses...
02/02/2020
Oncology
Interview
Time to Relapse Can Predict Outcomes in Patients With MCL
01/28/2020
David Bond, MD, Ohio State University Comprehensive Cancer Center, discusses study data suggesting that time to relapse can be used to predict outcomes in MCL.
David Bond, MD, Ohio State University Comprehensive Cancer Center, discusses study data suggesting that time to relapse can be used to predict outcomes in MCL.
David Bond, MD, Ohio State...
01/28/2020
Oncology
Interview
Front-Line Ibrutinib-Rituximab Combo Therapy Shows High Efficacy in MCL
01/24/2020
Eva Giné, MD, discusses results of the IMCL-2015 trial, evaluating ibrutinib in combination with rituximab for the treatment of MCL.
Eva Giné, MD, discusses results of the IMCL-2015 trial, evaluating ibrutinib in combination with rituximab for the treatment of MCL.
Eva Giné, MD, discusses results...
01/24/2020
Oncology
Debates and Roundtables
Key Updates on Brentuximab Vedotin for Classical Hodgkin Lymphoma
01/21/2020
Experts sat down with Oncology Learning Network to discuss key updates on the use of brentuximab vedotin in patients with classical Hodgkin lymphoma.
Experts sat down with Oncology Learning Network to discuss key updates on the use of brentuximab vedotin in patients with classical Hodgkin lymphoma.
Experts sat down with Oncology...
01/21/2020
Oncology
Podcasts
Pacritinib Promising for Patients With Myelofibrosis and Severe Thrombocytopenia
01/21/2020
John Mascarenhas, MD, discusses a retrospective analysis of 2 clinical trials evaluating pacritnib for myelofibrosis and severe thrombocytopenia.
John Mascarenhas, MD, discusses a retrospective analysis of 2 clinical trials evaluating pacritnib for myelofibrosis and severe thrombocytopenia.
John Mascarenhas, MD, discusses...
01/21/2020
Oncology
Videos
Obinutuzumab Plus Lenalidomide Effective for High Tumor Burden FL
01/17/2020
Loretta Nastoupil, MD, discusses results from a study exploring obinutuzumab therapy plus lenalidomide in patients with untreated, high tumor burden FL.
Loretta Nastoupil, MD, discusses results from a study exploring obinutuzumab therapy plus lenalidomide in patients with untreated, high tumor burden FL.
Loretta Nastoupil, MD, discusses...
01/17/2020
Oncology
DB
Videos
TBI vs CT-Based Myeloablative Conditioning in Patients With ALL Undergoing Haplo-HCT
01/12/2020
Bhagirathbhai Dholaria, MBBS, compares total body irradiation- vs CT-based myeloablative conditioning in patients with ALL undergoing haplo-HCT.
Bhagirathbhai Dholaria, MBBS, compares total body irradiation- vs CT-based myeloablative conditioning in patients with ALL undergoing haplo-HCT.
Bhagirathbhai Dholaria, MBBS,...
01/12/2020
Oncology
News
Adding Aspirin to Direct Oral Anticoagulant Therapy Does Not Improve Patient Outcomes
12/30/2019
Adding aspirin to direct oral anticoagulants in patients with VTE or non-valvular atrial fibrillation resulted in more bleeding events without significant improvement in thrombosis.
Adding aspirin to direct oral anticoagulants in patients with VTE or non-valvular atrial fibrillation resulted in more bleeding events without significant improvement in thrombosis.
Adding aspirin to direct oral...
12/30/2019
Oncology
News
LMWID and Ferumoxytol Well-Tolerated as Treatment for Adult Iron Deficiency Anemia
12/30/2019
Treatment of iron deficiency with low molecular weight iron dextran (LMWID) or ferumoxytol was well-tolerated and led to minimal adverse events, study findings have shown.
Treatment of iron deficiency with low molecular weight iron dextran (LMWID) or ferumoxytol was well-tolerated and led to minimal adverse events, study findings have shown.
Treatment of iron deficiency...
12/30/2019
Oncology
News
Luspatercept Demonstrates Long-Term Safety and Efficacy for Anemia in Patients With MDS
12/27/2019
Long-term analyses of the MEDALIST study show sustained responses with durable clinical benefit in patients with MDS receiving luspatercept for anemia, superior to that of patients receiving placebo.
Long-term analyses of the MEDALIST study show sustained responses with durable clinical benefit in patients with MDS receiving luspatercept for anemia, superior to that of patients receiving placebo.
Long-term analyses of the...
12/27/2019
Oncology
News
Luspatercept Active in Patients with Myelofibrosis-Associated Anemia
12/27/2019
Initial results from an ongoing study suggest clinically significant activity of luspatercept for the treatment of myelofibrosis-associated anemia.
Initial results from an ongoing study suggest clinically significant activity of luspatercept for the treatment of myelofibrosis-associated anemia.
Initial results from an ongoing...
12/27/2019
Oncology
News
Perioperative Eltrombopag May Trump IVIG in Patients With ITP Undergoing Surgery
12/20/2019
Eltrombopag may be superior to IVIG for the achievement of platelet count targets in patients with ITP undergoing major and minor surgery, according data presented at ASH 2019.
Eltrombopag may be superior to IVIG for the achievement of platelet count targets in patients with ITP undergoing major and minor surgery, according data presented at ASH 2019.
Eltrombopag may be superior to...
12/20/2019
Oncology
News
Nilotinib Therapy Plus Peg-IFN Feasible, Effective for BCR-ABL1–Positive CML
12/20/2019
Research presented at ASH 2019 demonstrated the feasibility of adding Peg-IFN to up upfront nilotinib in patients with BCR-ABL1–positive CML.
Research presented at ASH 2019 demonstrated the feasibility of adding Peg-IFN to up upfront nilotinib in patients with BCR-ABL1–positive CML.
Research presented at ASH 2019...
12/20/2019
Oncology
News
Enasidenib Plus Azacitidine Improves Responses in Newly Diagnosed AML With IDH2 Mutations
12/19/2019
Enasidenib added to azacitadine is associated with significantly improved responses and significant mIDH2 VAF reductions compared with azacitadine monotherapy in patients with newly diagnosed AML With IDH2 mutations.
Enasidenib added to azacitadine is associated with significantly improved responses and significant mIDH2 VAF reductions compared with azacitadine monotherapy in patients with newly diagnosed AML With IDH2 mutations.
Enasidenib added to azacitadine...
12/19/2019
Oncology
News
Ruxolitinib Plus Pomalidomide Feasible for Treatment of MF With Anemia
12/18/2019
Combining ruxolitinib therapy with pomalidomide is feasible for the treatment of patients with poor-risk MF and anemia, updated study findings show.
Combining ruxolitinib therapy with pomalidomide is feasible for the treatment of patients with poor-risk MF and anemia, updated study findings show.
Combining ruxolitinib therapy...
12/18/2019
Oncology
Videos
Navitoclax Plus Ruxolitinib Yields Encouraging Responses in Myelofibrosis
12/16/2019
Jacqueline Garcia, MD, discusses results from a phase 2 study of navitoclax in combination with ruxolitinib for patients with primary or secondary myelofibrosis.
Jacqueline Garcia, MD, discusses results from a phase 2 study of navitoclax in combination with ruxolitinib for patients with primary or secondary myelofibrosis.
Jacqueline Garcia, MD, discusses...
12/16/2019
Oncology
Videos
Amer Zeidan, MBBS, MHS, Discusses Efficacy of Azacitdine Plus Durvalumab for AML, MDS
12/15/2019
Dr Zeidan discusses results from a study of azacitidine plus durvalumab in older patients with AML and high-risk MDS unfit for intensive chemo.
Dr Zeidan discusses results from a study of azacitidine plus durvalumab in older patients with AML and high-risk MDS unfit for intensive chemo.
Dr Zeidan discusses results from...
12/15/2019
Oncology
Videos
Next-Generation Sequencing and Flow Cytometry Feasible for MRD Assessment in MCL
12/14/2019
Mitchell Smith, MD, PhD, discusses MRD assessment results from the ECOG1411 trial of patients with MCL.
Mitchell Smith, MD, PhD, discusses MRD assessment results from the ECOG1411 trial of patients with MCL.
Mitchell Smith, MD, PhD,...
12/14/2019
Oncology
News
Data Support Monitoring Patients After Treatment for Iron Deficiency Anemia
12/12/2019
According to data being presented at ASH 2019, patients with iron deficiency anemia should be monitored for serum phosphate after being treated with ferric carboxymaltose.
According to data being presented at ASH 2019, patients with iron deficiency anemia should be monitored for serum phosphate after being treated with ferric carboxymaltose.
According to data being...
12/12/2019
Oncology
News
Zanubrutinib Yields High Overall Response Rate in Patients With CLL/SLL
12/09/2019
According to updated data presented at ASH 2019, the next-generation BTK inhibitor zanubrutinib yields a high overall and durable response rate in patients with CLL/SLL.
According to updated data presented at ASH 2019, the next-generation BTK inhibitor zanubrutinib yields a high overall and durable response rate in patients with CLL/SLL.
According to updated data...
12/09/2019
Oncology
News
Cerdulatinib Active in Patients With Relapsed/Refractory PTCL and CTCL
12/08/2019
Cerdulatinib demonstrated activity in patients with relapsed/refractory peripheral and cutaneous T-cell lymphomas, according to data being presented at ASH 2019.
Cerdulatinib demonstrated activity in patients with relapsed/refractory peripheral and cutaneous T-cell lymphomas, according to data being presented at ASH 2019.
Cerdulatinib demonstrated...
12/08/2019
Oncology
News
MRD Testing to Identify High-Risk MCL Cases That Could Benefit From Alternate Therapies
12/08/2019
Study findings being presented at ASH 2019 posit that interim MRD testing at cycle 3 can help identify high-risk patients with MCL who may benefit from alternative therapies.
Study findings being presented at ASH 2019 posit that interim MRD testing at cycle 3 can help identify high-risk patients with MCL who may benefit from alternative therapies.
Study findings being presented...
12/08/2019
Oncology
News
Maintenance Decitabine Impacts DFS and OS After Intensive Therapy in Older Adults With AML
12/08/2019
Relapse is the most common cause of treatment failure following intensive induction and consolidation (CONS) therapy in older adults with acute myeloid leukemia (AML).
Relapse is the most common cause of treatment failure following intensive induction and consolidation (CONS) therapy in older adults with acute myeloid leukemia (AML).
Relapse is the most common cause...
12/08/2019
Oncology
News
Researchers Identify Significant Risk Factors for Treatment Response to CD-19 CAR-T Therapy in ALL
12/08/2019
Results from an analysis presented at the 2019 ASH Annual Meeting reveal significant risk factors for worse treatment response after CD-19 CAR T-cell therapy in relapsed/refractory B-ALL.
Results from an analysis presented at the 2019 ASH Annual Meeting reveal significant risk factors for worse treatment response after CD-19 CAR T-cell therapy in relapsed/refractory B-ALL.
Results from an analysis...
12/08/2019
Oncology
News
Vosaroxin and Cytarabine Yield Less Toxicity Than Standard AML Therapy
12/08/2019
Findings presented at ASH 2019 demonstrate that vosaroxin and infusional cytarabine are a safe treatment regimen for newly diagnosed patients with AML.
Findings presented at ASH 2019 demonstrate that vosaroxin and infusional cytarabine are a safe treatment regimen for newly diagnosed patients with AML.
Findings presented at ASH 2019...
12/08/2019
Oncology
News
Acalabrutinib With or Without Obinutuzumab Improved PFS Over Obinutuzumab Plus Chlorambucil in Treatment-Naïve CLL
12/08/2019
Acalabrutinib has demonstrated durable responses as a single agent or combined with obinutuzumab in treatment-naïve (TN) chronic lymphocytic leukemia (CLL).
Acalabrutinib has demonstrated durable responses as a single agent or combined with obinutuzumab in treatment-naïve (TN) chronic lymphocytic leukemia (CLL).
Acalabrutinib has demonstrated...
12/08/2019
Oncology
News
Bevacizumab Highly Effective for Chronic Bleeding in Hereditary Hemorrhagic Telangiectasia
12/06/2019
Findings from a retrospective study being presented at the 2019 ASH Annual Meeting support the use of bevacizumab to treat chronic bleeding and anemia in patients with hereditary hemorrhagic telangiectasia.
Findings from a retrospective study being presented at the 2019 ASH Annual Meeting support the use of bevacizumab to treat chronic bleeding and anemia in patients with hereditary hemorrhagic telangiectasia.
Findings from a retrospective...
12/06/2019
Oncology
News
Front-Line Ibrutinib–Rituximab Combo Highly Effective in Indolent Clinical MCL Forms
12/06/2019
Data being presented at the 2019 ASH Annual Meeting show front-line ibrutinib therapy plus rituximab as having a high efficacy rate in patients with indolent clinical forms of MCL.
Data being presented at the 2019 ASH Annual Meeting show front-line ibrutinib therapy plus rituximab as having a high efficacy rate in patients with indolent clinical forms of MCL.
Data being presented at the 2019...
12/06/2019
Oncology
News
Fostamatinib as Second-Line Therapy Yields Increased Response Rates in ITP
12/06/2019
Fostamatinib administered as second-line therapy in patients with immune thrombocytopenic purpura (ITP) and those with persistent ITP may lead to higher response rates than if the drug is used in later lines of therapy or for later-stage ITP.
Fostamatinib administered as second-line therapy in patients with immune thrombocytopenic purpura (ITP) and those with persistent ITP may lead to higher response rates than if the drug is used in later lines of therapy or for later-stage ITP.
Fostamatinib administered as...
12/06/2019
Oncology
News
Perioperative Iron Plus BOC Improves Outcomes in Patients Undergoing Gynecologic Procedures
12/06/2019
Study results being presented at ASH 2019 suggest that combining perioperative iron with blood optimization compound (BOC) can lead to improved patient outcomes.
Study results being presented at ASH 2019 suggest that combining perioperative iron with blood optimization compound (BOC) can lead to improved patient outcomes.
Study results being presented at...
12/06/2019
Oncology
Podcasts
Adam D. Cohen, MD, Discusses Therapy Options for Multiple Myeloma
04/10/2019
Adam D. Cohen, MD, shares his thoughts on several abstracts on therapy options for MM presented at the ASH Annual Meeting.
Adam D. Cohen, MD, shares his thoughts on several abstracts on therapy options for MM presented at the ASH Annual Meeting.
Adam D. Cohen, MD, shares his...
04/10/2019
Oncology
Podcasts
Quadruplet Therapy Yields Promising Results in Newly Diagnosed MM
12/26/2018
Shaji Kumar, MD, discusses the significance of a trial presented at ASH that involved an MM therapy comprising ixazomib, lenalidomide, dexamethasone, and daratumumab.
Shaji Kumar, MD, discusses the significance of a trial presented at ASH that involved an MM therapy comprising ixazomib, lenalidomide, dexamethasone, and daratumumab.
Shaji Kumar, MD, discusses the...
12/26/2018
Oncology
Podcasts
The Use of CAR-T Therapy for B-Cell Lymphomas Outside of Clinical Trials
12/25/2018
Jonathon Cohen, MD, discussed a trial presented at the ASH Annual Meeting on real world results of axicabtagene ciloleucel in B-cell lymphomas.
Jonathon Cohen, MD, discussed a trial presented at the ASH Annual Meeting on real world results of axicabtagene ciloleucel in B-cell lymphomas.
Jonathon Cohen, MD, discussed a...
12/25/2018
Oncology
Debates and Roundtables
Expert Roundtable: Lessons From ASH for Optimizing CLL Treatment
12/21/2018
Jeff Sharman, MD, Anthony Mato, MD, MSCE, and Chaitra Ujjani, MD, discussed the findings of an interim analysis from the prospective informCLL real-world registry and how to optimize CLL treatment in real-world practice.
Jeff Sharman, MD, Anthony Mato, MD, MSCE, and Chaitra Ujjani, MD, discussed the findings of an interim analysis from the prospective informCLL real-world registry and how to optimize CLL treatment in real-world practice.
Jeff Sharman, MD, Anthony Mato,...
12/21/2018
Oncology
Podcasts
Early Results Show Promise With Venetoclax-Idasanutlin Combo for Relapsed/Refractory AML
12/20/2018
Gail Roboz, MD, discusses a recent trial involving the combination of venetoclax plus idasanutlin for patients with relapsed or refractory AML.
Gail Roboz, MD, discusses a recent trial involving the combination of venetoclax plus idasanutlin for patients with relapsed or refractory AML.
Gail Roboz, MD, discusses a...
12/20/2018
Oncology
Podcasts
Extended Decitabine Dosing Schedule Provides No Benefit Over Shorter Regimen in Newly Diagnosed AML
12/20/2018
Guillermo Garcia‑Manero, MD, discussed the clinical significance and potential implications of using a 5- versus 10-day decitabine dose schedule in patients with newly diagnosed AML.
Guillermo Garcia‑Manero, MD, discussed the clinical significance and potential implications of using a 5- versus 10-day decitabine dose schedule in patients with newly diagnosed AML.
Guillermo Garcia‑Manero, MD,...
12/20/2018
Oncology
Venetoclax Well-Tolerated in Previously Treated Waldenström Macroglobulinemia
12/18/2018
Patients with symptomatic, previously treated WM responded well to therapy with venetoclax, according results from a recent phase 2 clinical trial.
Patients with symptomatic, previously treated WM responded well to therapy with venetoclax, according results from a recent phase 2 clinical trial.
Patients with symptomatic,...
12/18/2018
Oncology
Podcasts
Gemtuzumab Ozogamicin a Safe, Tolerable Option for Patients With Relapsed/Refractory AML
12/15/2018
Pamela S. Becker, MD, PhD, discussed the clinical significance and potential implications of a study examining the use of Use of gemtuzumab ozogamicin in patients with relapsed or refractory AML.
Pamela S. Becker, MD, PhD, discussed the clinical significance and potential implications of a study examining the use of Use of gemtuzumab ozogamicin in patients with relapsed or refractory AML.
Pamela S. Becker, MD, PhD,...
12/15/2018
Oncology
Practice-Changing Results With Ibrutinib–Rituximab Combo in Young Patients With CLL
12/14/2018
Survival outcomes of ibrutinib–rituximab therapy in young, treatment-naïve patients with CLL outshined rates seen with the gold standard of care regimen.
Survival outcomes of ibrutinib–rituximab therapy in young, treatment-naïve patients with CLL outshined rates seen with the gold standard of care regimen.
Survival outcomes of...
12/14/2018
Oncology
Multi-Class Drug Combo Shows Promise in Newly Diagnosed MM
12/13/2018
A combination regimen comprised of multiple drug classes has produced rapid and deep responses in patients with newly diagnosed multiple myeloma.
A combination regimen comprised of multiple drug classes has produced rapid and deep responses in patients with newly diagnosed multiple myeloma.
A combination regimen comprised...
12/13/2018
Oncology
Combo Therapy for Smoldering MM Yields Promising Results
12/13/2018
Therapy with elotuzumab plus lenalidomide and dexamethasone was tolerable and led to high response rates in patients with high-risk smoldering multiple myeloma.
Therapy with elotuzumab plus lenalidomide and dexamethasone was tolerable and led to high response rates in patients with high-risk smoldering multiple myeloma.
Therapy with elotuzumab plus...
12/13/2018
Oncology
Real-World Results Support Axi-Cel Use in B-Cell Lymphomas Outside of Clinical Trials
12/12/2018
Results from a real-world trial show that axicabtagene ciloleucel can be used outside of clinical trial settings, although outcomes may differ.
Results from a real-world trial show that axicabtagene ciloleucel can be used outside of clinical trial settings, although outcomes may differ.
Results from a real-world trial...
12/12/2018
Oncology
News
Acalabrutinib Demonstrates Efficacy and Safety in Relapsed/Refractory MCL
12/12/2018
Long-term response to acalabrutinib remained consistent with high efficacy and manageable safety in patients with relapsed or refractory MCL, according to results from a follow-up study.
Long-term response to acalabrutinib remained consistent with high efficacy and manageable safety in patients with relapsed or refractory MCL, according to results from a follow-up study.
Long-term response to...
12/12/2018
Oncology
Ibrutinib–Rituximab Combo Effective, Safe for Waldenström Macroglobulinemia
12/12/2018
The combination of ibrutinib and rituximab consistently outshined rituximab alone in the treatment of patients with WM, according to follow-up results from the iNNOVATE trial.
The combination of ibrutinib and rituximab consistently outshined rituximab alone in the treatment of patients with WM, according to follow-up results from the iNNOVATE trial.
The combination of ibrutinib and...
12/12/2018
Oncology
Ruxolitinib Improves Therapy Response With Less Toxicity in Early Primary MF
12/11/2018
Patients with early primary myelofibrosis are likely to have better responses and lower toxicities from ruxolitinib treatment, according to a recent study presented at ASH 2018.
Patients with early primary myelofibrosis are likely to have better responses and lower toxicities from ruxolitinib treatment, according to a recent study presented at ASH 2018.
Patients with early primary...
12/11/2018
Oncology
Bortezomib Maintenance or Consolidation Posttransplant Improves Survival in MCL
12/11/2018
Induction chemotherapy followed by bortezomib maintenance or consolidation was efficacious and tolerable for patients with mantle cell lymphoma who underwent autologous stem cell transplant.
Induction chemotherapy followed by bortezomib maintenance or consolidation was efficacious and tolerable for patients with mantle cell lymphoma who underwent autologous stem cell transplant.
Induction chemotherapy followed...
12/11/2018
Oncology
Crenolanib–Chemo Combo Improves Outcomes in Newly Diagnosed, FLT3-Mutated AML
12/11/2018
A combination therapy including crenolanib improved outcomes in patients with newly diagnosed AML positive for FLT3 and other co-occurring driver mutations.
A combination therapy including crenolanib improved outcomes in patients with newly diagnosed AML positive for FLT3 and other co-occurring driver mutations.
A combination therapy including...
12/11/2018
Oncology
Circulating Tumor DNA May Predict Outcomes in Mantle Cell Lymphoma
12/07/2018
Dynamic changes in circulating tumor DNA that occur very early during therapy may predict outcomes for patients with mantle cell lymphoma.
Dynamic changes in circulating tumor DNA that occur very early during therapy may predict outcomes for patients with mantle cell lymphoma.
Dynamic changes in circulating...
12/07/2018
Oncology
News
Lenalidomide Plus Rituximab Improves PFS Among Patients with FL and MZL
12/06/2018
Lenalidomide plus rituximab improves progression-free survival by 54% compared to single-agent rituximab for patients with relapsed or refractory indolent non-Hodgkin lymphoma.
Lenalidomide plus rituximab improves progression-free survival by 54% compared to single-agent rituximab for patients with relapsed or refractory indolent non-Hodgkin lymphoma.
Lenalidomide plus rituximab...
12/06/2018
Oncology
Targeted Therapy Promising for Certain Patients With Relapsed/Refractory AML
12/06/2018
Gemtuzumab ozogamicin is safe for patients with AML, but combinations of the drug may be better suited for certain patients with relapsed or refractory disease.
Gemtuzumab ozogamicin is safe for patients with AML, but combinations of the drug may be better suited for certain patients with relapsed or refractory disease.
Gemtuzumab ozogamicin is safe...
12/06/2018
Oncology
News
Anti-CD19 CAR-T Therapy Safe, Effective in Large B-Cell Lymphoma
12/05/2018
A follow-up analysis of the ZUMA-1 trial reported 51% of patients receiving axicabtagene ciloleucel were still alive 2 years after treatment.
A follow-up analysis of the ZUMA-1 trial reported 51% of patients receiving axicabtagene ciloleucel were still alive 2 years after treatment.
A follow-up analysis of the...
12/05/2018
Oncology
Incorporation of Immune Checkpoint Inhibitors Promising for MDS
12/05/2018
Immune checkpoint inhibitors demonstrate significant activity in myelodysplastic syndrome with an acceptable toxicity profile, according to a recent study presented at ASH 2018.
Immune checkpoint inhibitors demonstrate significant activity in myelodysplastic syndrome with an acceptable toxicity profile, according to a recent study presented at ASH 2018.
Immune checkpoint inhibitors...
12/05/2018
Oncology
2-Year PFS Can Predict Outcomes in Patients With Marginal Zone Lymphomas
12/02/2018
Researchers have confirmed the prognostic role of 2-year PFS in patients with MZLs, according to a study presented at ASH 2018.
Researchers have confirmed the prognostic role of 2-year PFS in patients with MZLs, according to a study presented at ASH 2018.
Researchers have confirmed the...
12/02/2018
Oncology
News
Triplet Therapy Yields Promising Results in Untreated FL and MZL
12/02/2018
Treatment-naïve patients with FL and MZL tolerated and responded well to ibrutinib plus rituximab and lenalidomide, according to a recent phase 2 trial presented at ASH 2018.
Treatment-naïve patients with FL and MZL tolerated and responded well to ibrutinib plus rituximab and lenalidomide, according to a recent phase 2 trial presented at ASH 2018.
Treatment-naïve patients with FL...
12/02/2018
Oncology
AML Outcomes With Decitabine Not Dependent on Dosing Schedule
12/02/2018
Older patients with newly diagnosed AML had similar outcomes regardless of whether they received decitabine in a 5- or 10-day schedule, a recent study has shown.
Older patients with newly diagnosed AML had similar outcomes regardless of whether they received decitabine in a 5- or 10-day schedule, a recent study has shown.
Older patients with newly...
12/02/2018
Oncology
News
Combination Regimen Safe, Effective for Advanced Untreated Follicular Lymphoma
11/30/2018
Lenalidomide combined with obinutuzumab is highly effective for advanced, previously untreated follicular lymphoma while retaining a manageable safety profile, according to study data presented at ASH 2018.
Lenalidomide combined with obinutuzumab is highly effective for advanced, previously untreated follicular lymphoma while retaining a manageable safety profile, according to study data presented at ASH 2018.
Lenalidomide combined with...
11/30/2018
Oncology
Ofatumumab Promising in Elderly Patients With Relapsed/Refractory Splenic MZL
11/30/2018
Preliminary results from an ongoing clinical trial presented at ASH 2018 suggest that elderly patients with splenic MZL respond more favorably to ofatumumab than to rituximab.
Preliminary results from an ongoing clinical trial presented at ASH 2018 suggest that elderly patients with splenic MZL respond more favorably to ofatumumab than to rituximab.
Preliminary results from an...
11/30/2018
Oncology
Ibrutinib–Obinutuzumab Combination a Promising First-Line Therapy Option for CLL and SLL
11/30/2018
Results from a recent trial highlight the promising potential of obinutuzumab plus ibrutinib as a promising new first-line treatment option for patients with CLL or SLL.
Results from a recent trial highlight the promising potential of obinutuzumab plus ibrutinib as a promising new first-line treatment option for patients with CLL or SLL.
Results from a recent trial...
11/30/2018
Oncology
Optimal Induction Chemo Identified for Transplant-Eligible MCL
11/30/2018
Induction therapy with rituximab/bendamustine and rituximab/cytarabine followed by ASCT resulted in high rates of durable remissions for patients with MCL, according to study data presented at ASH 2018.
Induction therapy with rituximab/bendamustine and rituximab/cytarabine followed by ASCT resulted in high rates of durable remissions for patients with MCL, according to study data presented at ASH 2018.
Induction therapy with...
11/30/2018
Oncology
News
New CAR-T Therapy Less Toxic, More Effective for MM Than Other CAR-Ts
11/29/2018
P-BCMA-101, a novel CAR-T therapy, has demonstrated significant efficacy in patients with relapsed or refractory MM.
P-BCMA-101, a novel CAR-T therapy, has demonstrated significant efficacy in patients with relapsed or refractory MM.
P-BCMA-101, a novel CAR-T...
11/29/2018
Oncology
News
CD19-Targeting CAR-T Therapy Yields Long-Term Response in DLBCL
11/26/2018
In heavily pretreated older adults with relapsed or refractory DLBCL, tisagenlecleucel yielded a high frequency of durable responses, according to study data presented at ASH 2018.
In heavily pretreated older adults with relapsed or refractory DLBCL, tisagenlecleucel yielded a high frequency of durable responses, according to study data presented at ASH 2018.
In heavily pretreated older...
11/26/2018
Oncology
Podcasts
The Past, Present, and Future of Follicular Lymphoma Treatment With John Leonard, MD
11/15/2018
In this 4-part podcast series, John Leonard, MD, discusses the ever changing treatment landscape for follicular lymphoma, and touches upon his research presented at the 2018 ASH Meeting on Hematologic Malignancies.
In this 4-part podcast series, John Leonard, MD, discusses the ever changing treatment landscape for follicular lymphoma, and touches upon his research presented at the 2018 ASH Meeting on Hematologic Malignancies.
In this 4-part podcast series,...
11/15/2018
Oncology
Podcasts
Jonathan Friedberg, MD, Discusses the Treatment Landscape for Aggressive Lymphomas
11/09/2018
In this 4-part podcast series, Dr Friedberg, who presented data at the 2018 ASH Meeting on Hematologic Malignancies, discusses the treatment landscape for aggressive lymphomas. 
In this 4-part podcast series, Dr Friedberg, who presented data at the 2018 ASH Meeting on Hematologic Malignancies, discusses the treatment landscape for aggressive lymphomas. 
In this 4-part podcast series,...
11/09/2018
Oncology
Podcasts
Gail J. Roboz, MD, Discusses Treatment Options for Patients With AML
11/01/2018
In this 3-part podcast series, Dr Roboz discusses the current available therapy options for patients with AML, expanding upon data she presented at the 2018 ASH Meeting on Hematologic Malignancies.
In this 3-part podcast series, Dr Roboz discusses the current available therapy options for patients with AML, expanding upon data she presented at the 2018 ASH Meeting on Hematologic Malignancies.
In this 3-part podcast series,...
11/01/2018
Oncology

ASH Annual Meeting

Oncology Learning Network provides up-to-date coverage of the American Society of Hematology Annual Meeting & Exposition, including interviews with leading experts; thought-provoking roundtable discussions; and news reports of scientific abstracts highlighting the latest clinical updates in hematology oncology.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use